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Abstract 
The majority of breast cancers express the oestrogen receptor and are potentially 
amenable to endocrine therapy, however the clinical effectiveness of these agents is 
limited by the phenomenon of acquired resistance which is associated with disease 
relapse and poor prognosis. It has been previously demonstrated that the CD44 
receptor is overexpressed in acquired tamoxifen resistance where it associates with 
an enhanced migratory phenotype, however little is known regarding the effects of 
CD44 splice variants in this context. This thesis aimed to explore the role of CD44 
variant isoforms in a model of ER+ breast cancer derived tamoxifen-resistance (Tam-
R cells) and expand these explorations into an additional model of acquired 
fulvestrant-resistance (Fas-R cells).  
Multiple CD44 isoforms were found to be upregulated in resistance although a 
differential expression profile was observed between Tam-R and Fas-R cells. 
Inhibition of global CD44 expression in both endocrine resistant models led to a loss 
in their migratory, proliferative and invasive capacity and attenuated their responses 
to the CD44 ligand, hyaluronan. Overexpression of CD44v6 in endocrine sensitive 
MCF-7 cells induced EGFR pathway activation leading to enhanced cellular invasion, 
and attenuated response to fulvestrant. Accordingly, CD44v6 suppression in Tam-R 
cells resulted in a loss of EGFR pathway signalling and reduced invasion. Preliminary 
clinical analysis revealed that co-expression of CD44v6 and EGFR associated with a 
trend for worsened outcome in ER+ breast cancer patients treated with tamoxifen. 
These data suggest that upregulation of CD44v6 may contribute to an aggressive 
phenotype in tamoxifen resistant cells through a mechanism involving the EGFR. 
Future use of CD44v6 and EGFR as biomarkers may have potential therapeutic value 
to predict a cohort of ER+ breast cancer patients which relapse earlier on tamoxifen 
and may thus require more aggressive treatment strategies. 
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1. Introduction 
1.1 Breast cancer and risk factors 
Breast cancer is the second most common cancer among women worldwide and the 
second leading cause of cancer death among women (DeSantis et al. 2011). Breast 
cancer incidence and mortality varies significantly globally and in general a higher 
incidence rate is found within developed countries whilst a lower incidence rate is 
observed within developing countries (Parkin and Fernandez 2006). In the UK alone, 
approximately 50, 000 women and 350 men were diagnosed with invasive breast 
cancer in 2011 (Cancer Research UK statistics 2011). However, through intensified 
detection efforts and the introduction of screening programmes, mortality rates are 
now decreasing within high risk countries. 
The majority of breast cancers are a result of sporadic mutations that result from an 
accumulation of uncorrected genetic changes in somatic genes. Therefore the large 
differences observed between incidence rates of breast cancer worldwide have 
stimulated the search to identify specific risk factors for breast cancer. Numerous 
breast cancer risk factors are now well-established and include: age (Slattery and 
Kerber 1993; Fraser and Shavlik 1997), ethnicity (Chlebowski et al. 2005), body mass 
index (Suzuki et al. 2009; Rohan et al. 2013), dietary factors (Bao et al. 2012; Link et 
al. 2013) cumulative exposure to endogenous and exogenous oestrogens and 
possibly progesterones (Clemons and Goss 2001) and family history of the disease 
(Claus et al. 1994; King et al. 2003). Further, history of benign breast cancer, 
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particularly atypial hyperplasia and dense breasts are also risk factors for breast 
cancer development (Dupont et al. 1993; Byrne et al. 1995; Marshall et al. 1997).  
1.1.1 Oestrogen exposure 
Endogenous and exogenous exposure to oestrogen in pre- and postmenopausal 
women are well-defined risk factors for breast cancer (Clemons and Goss 2001). 
Oestrogens increase cell proliferation which may decrease likelihood of DNA damage 
repair thus potentially leading to the accumulation of mutations (Preston-Martin et 
al. 1990; Pike et al. 1993a). Additional studies have suggested that oestrogens may 
also be directly genotoxic through their reactive metabolites however evidence for 
this mechanism remains limited (Liehr 2000; Yared et al. 2002).  
Of crucial importance in breast cancer etiology is the timing of exposure to risk 
factors as early and late exposure may mediate different risks (Okasha et al. 2003). 
Although oestrogen exposure early in life may increase the risk of breast cancer 
onset, conversely, the reduction of these levels later in life may rapidly decrease risk 
of disease development. Factors that increase lifetime exposure to oestrogens 
include: early menarche (Ewertz and Duffy 1988; Hsieh et al. 1990), regular ovulation 
(Henderson et al. 1985; La Vecchia et al. 1985), late menopause (Alexander and 
Roberts et al. 1987; Hsieh et al. 1990), nulliparity or late age at first birth and lack 
of/or short term breast feeding (Ewertz et al. 1990; Negri et al. 1990). Alcohol 
consumption of a minimum of one drink per day also increases endogenous 
oestrogen levels which may further contribute to disease development (Harvey et al. 
1986; Smith-Warner et al. 1998). Additionally, in postmenopausal women, obesity 
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(Hunter et al. 1993; Huang et al. 1997; Morimoto et al. 2002) and long term use of 
hormone replacement therapy (HRT) (Lauritzen and Meier 1984; Hunt et al. 1990) 
are principle determinants of oestrogen exposure and have been linked to an 
increased risk of breast cancer. Other growth factors in addition to oestrogen, 
including insulin like growth factor 1 (IGF-1) and prolactin, are also thought to also 
contribute to breast cancer risk although the mechanisms underlying these 
associations are less well-defined (Hill et al. 1976; Clevenger et al. 2003; Renehan et 
al. 2004).  
1.2 Oestrogen receptors 
Oestrogens are steroid hormones that regulate cell growth and differentiation and 
play an important role in a variety of biological functions including reproduction, 
metabolism, homeostasis and brain function (Tsai and O’Malley 1994). Oestrogen 
exerts its biological effect on target tissues through binding to oestrogen receptors 
(ER) of which there are two main types, ERα and ERβ (Walter et al. 1985; Mosselman 
et al. 1996). These receptors are members of the nuclear hormone receptor family 
which also include receptors for: androgens, thyroid hormones, progestins, 
glucocorticoids, retinoids and vitamin D (Tsai and O’Malley et al. 1994; Evans 1998). 
Numerous orphan receptors for which no ligands have been identified also belong to 
this family of receptors. ERα and ERβ are modular proteins composed of six 
functionally distinct domains referred to as A – F and depicted in Figure 1.1 (Tsai and 
O’Malley 1994). Domain A/B is located within the amino-terminal domain of the 
protein and encodes a hormone-independent transcriptional activation function 
domain (AF1). The AF1 domain regulates transcription of oestrogen-responsive 
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genes independent of ligand binding and is alternatively activated through the 
phosphorylation of serine residues located within this region, particularly in response 
to ERK/MAPK action (Schwabe et al. 1993). Domain C encodes a highly conserved 
DNA binding domain (DBD) which is comprised of two functionally distinct zinc finger 
motifs. These motifs facilitate ER dimerization and bind specifically to oestrogen 
response elements (EREs) or ERE-like sequences (small palindromic DNA sequences) 
located within the 5’ promoter region of target genes (Schwabe et al. 1993). Domain 
D is referred to as the hinge region as it separates the DBD from the ligand binding 
domain (LBD) of ER. This domain is required for binding to heat shock proteins in a 
resting state however upon activation, the flexibility conferred within the secondary 
structure of this domain is critical for ER dimerization (Kuiper et al. 1996). This region 
also contains a nuclear localisation signal which is exposed upon ligand activation 
(Kuiper et al. 1996). Domain E/F encodes the LBD and is situated at the carboxy-
terminal region of the ER. The LBD is composed of 12 α helices which fold to form a 
compact three-layered helical core. This layered structure forms a hydrophobic 
pocket cavity which facilitates ligand binding to the ER. In a resting state, helix 12 
extends away from the LBD core, however, upon ligand binding to the hydrophobic 
pocket, a conformational change is induced which leads to the repositioning of helix 
12 over the core thus sealing the hydrophobic pocket; a prerequisite action for 
transcription initiation to occur (Wurtz et al. 1996; Brzozwski et al. 1997; Singh and 
Kumar 2005). This sealing mechanism creates a hydrophobic groove on the LBD 
which is recognised and bound to by coregulatory proteins which facilitate/inhibit 
gene transcription (Savkur and Burris 2004). This domain also contains a second 
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transcriptional activation functional domain (AF2) which is critical for transactivation 
in response to ligand binding (Kumar and Chambon 1988; Green and Chambon 1991).  
 
 
 
 
 
 
Whilst both AF1 and AF2 domains are capable of initiating transcription separately, 
it is thought that maximal transcriptional activity of ER is achieved through synergistic 
action of both domains and their activities (Tzuckerman et al. 1994). However, the 
differential modes of AF1 (ligand-independent) and AF2 (ligand-dependent) 
activation leads to the association of these domains with distinct coregulatory 
proteins thus the contribution of these activating function domains to gene 
transcription is cell type specific (Paech et al. 1997). 
ERα and ERβ receptors confer a high degree of homology between their DNA binding 
domains (approximately 96%) however display only a moderate level of homology 
between their ligand binding domains (approximately 53%) and a low level of 
homology between their hinge regions (approximately 36%) (Matthews and 
Gustafsson 2003; Singh and Kumar 2005). The major functional difference between 
these receptors is with respect to their AF1 domains. Whereas ERα exhibits a high 
Figure 1.1. A schematic diagram of the human ERα and ERβ receptors adapted from Kumar et al. 
2011. Each ER contains six functional domains denoted as A – F with the starting amino acid position 
for each domain shown above. The table describes the function of each domain region.  
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level of AF1-mediated transcriptional activity, this domain shows negligible activity 
in ERβ (Hall and McDonnell 1999); this difference is suggested to be the major 
functional variation between the responses of these receptors to various ligands. 
Additional differences can be observed with respect to the expression patterns of 
these receptors. Whereas ERα is predominantly expressed in the breast, uterus and 
vagina, the majority of ERβ expression is found within tissues of the central nervous 
system, cardiovascular system, immune system, gastrointestinal system, kidneys, 
lungs and bone, with low expression levels found within the breast (Couse et al. 1997; 
Kuiper et al. 1997). These differences in expression may explain the selective action 
of oestrogens between tissues.  
Importantly, ERα and ERβ appear to take on different roles within breast cancer 
biology. Approximately two thirds of breast cancers express the ERα, which has been 
shown to be the main mediator of oestrogen-induced proliferation (Matthews and 
Gustafsson 2003). In contrast, studies suggest that ERβ may act as a tumour 
suppressor (Paruthiyil et al. 2004; Strom et al. 2004) however the prognostic value of 
ERβ remains unclear. In light of ERα representing the dominant ER subtype in breast 
cancer, this protein will subsequently be referred to as ER throughout this project. 
1.2.1 Mechanisms of ER action 
1.2.1.1 Genomic action of ER 
In the classical mechanism of ER action, oestrogen diffuses through the plasma 
membrane and associates with an ER bound to heat shock protein 90 (hsp90) in its 
resting state. The binding of oestrogen to the ER induces a conformational change 
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within the LBD causing the dissociation of hsp90 and the subsequent formation of a 
stable dimer complex (Cowley et al. 1997; Powell and Xu 2008). The oestrogen-ER 
dimer then undergoes nuclear translocation and binds to oestrogen receptor 
elements (EREs) (via the DBD) located in the promoter region of oestrogen 
responsive genes (Kumar and Chambon 1988). Once bound to DNA, the ER recruits 
coregulatory proteins (coactivators or corepressors) to the LBD which form a 
transcriptional complex leading to the activation or inhibition of gene transcription 
(Cowley et al. 1997; Kling et al. 2004). Coactivator proteins facilitate transcription 
through their intrinsic chromatin remodelling functions and through supporting 
linkage of ER to the basal transcription machinery (including activation of RNA 
polymerase II), whilst corepressors inhibit this process (McKenna and O’Malley 2001; 
Metivier et al. 2003). This mechanism is referred to as the classical mechanism of 
genomic ER action (Figure 1.2, pathway 1) and accounts for the majority of 
oestrogen-induced gene transcription.  
1.2.1.2 ERE-independent action of ER 
Evidence now exists which shows that ERs can regulate gene expression through 
various pathways separate from this classical genomic mechanism. O’lone et al. 2004 
reported that approximately one third of genes regulated by the ER do not contain 
ERE/ERE-like sequences. This finding revealed a mechanism through which ERs are 
capable of regulating gene expression without directly binding to DNA in the 
promoter regions of their target genes. This is referred to as the ERE-independent 
genomic mechanism of ER action and is facilitated through the ability of ERs (bound 
to oestrogen and dimerized) to bind and modulate the function of other classes of 
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transcription factors (through protein-protein interactions in the nucleus) which in 
turn bind to their respective response elements within the DNA (depicted in Figure 
1.2, pathway 2) (Gaub et al. 1990; Castro-Rivera et al. 2001). This phenomenon is 
referred to as ‘transcriptional cross talk’ and through this mechanism ERs are capable 
of regulating a vast array of oestrogen responsive genes that do not contain EREs 
(Gottlicher et al. 1998). 
1.2.1.3 Oestrogen-independent action of ER 
In addition to oestrogen, it is now known that the ER can be activated as a result of 
intracellular signalling molecules. For example various kinases, notably those 
downstream of EGFR and IGFR1, including MAPK (Tang et al. 2004) and protein kinase 
A (PKA) (Chen et al. 1999), can phosphorylate multiple serine residues within the 
ligand-independent AF1 domain of ER (Lannigan et al. 2003). Serine phosphorylation 
activates the ER in the absence of oestrogen and promotes ER dimerization (Chen et 
al. 1992), nuclear localisation (Lee and Bai et al. 2002), and subsequent transcription 
of oestrogen-responsive genes (Ali et al. 1993; Le Goff et al. 1994). This mechanism 
is referred to as the oestogen-independent genomic mechanism of ER action 
(depicted in Figure 1.2, pathway 3). Additionally, growth factor signalling has been 
shown to directly activate coregulatory proteins of the ER thus providing an 
alternative influence on ER-mediated transcription (Osborne and Schiff et al. 2003).  
1.2.1.4 Non-genomic ER action 
Whilst it has been shown that oestrogen can mediate its effects through ER-regulated 
gene expression, other effects known to be facilitated by oestrogen occur rapidly 
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within cells and thus cannot be accounted for by ER-induced transcription and 
subsequent RNA and protein synthesis (Watters et al. 1997; Kelly and Levin 2001; 
Jakacka et al. 2002). This mode of ER function is termed the non-genomic mechanism 
of ER action and is mediated through oestrogen activation of a proportion of ERs 
which localise to the plasma membrane (membrane-associated ER) and the 
subsequent stimulation of multiple protein kinase interactions (Norfleet et al. 1999; 
Abraham et al. 2004; Guerra et al. 2004). Various signalling molecules are activated 
through oestrogen binding to membrane-associated ERs including: cAMP (Watters 
and Dorsa 1998), MAPK (Wade and Dorsa 2003), PI3K (Alexaki et al. 2004), protein 
kinases A and C (Qiu et al. 2003) and src kinase (Pawlak et al. 2005). These activated 
molecules induce downstream signalling pathways which modulate the 
phosphorylation status of multiple non-ER transcription factors leading to initiation 
of gene transcription (Figure 1.2, pathway 4) (Watters and Dorsa 1998; Hennessy et 
al. 2005). Conversely, these signalling pathways can also phosphorylate nuclear ER 
and influence coregulatory protein binding thus regulating its own transcription (Kow 
and Pfaff 2004; Vasudevan et al. 2004) (Figure 1.2, pathway 4). This non-genomic 
mode of ER action provides a further mechanism through which ERs can regulate the 
expression of genes which both contain EREs and those which do not, thus further 
diversifying the array of ER-mediated cellular functions. 
Taken together, it is now apparent that ER regulation of gene expression is a 
multifactorial process involving both its genomic and non-genomic actions which 
may often converge at response elements in the promoters of target genes. However 
the final output of gene expression is dependent upon numerous cell-specific factors 
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including: the combination of transcription factors recruited to a specific gene 
promoter, the availability of coregulatory proteins and signal transduction elements, 
the cellular localisation of ERs and the nature of extracellular stimuli. These variable 
elements can be highly cell type specific, thus oestrogens may utilise numerous 
signalling pathways to induce distinct gene expression responses dependent upon 
the specific cellular context.  
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1.3 Molecular and clinical subtypes of breast cancer 
Breast cancer is characterised by its clinical and molecular heterogeneity. In the 
clinical setting breast cancer can be classified according to its hormone receptor (ER 
and/or PR) or human epidermal growth factor 2 receptor (HER2/ErbB2) status which 
indicates prognosis and directs for specific treatment options. Breast cancers 
displaying a positive hormone receptor status (approximately 70 – 75 % of patients 
are ER+) are more likely to respond to endocrine therapies which specifically target 
the ER (and indirectly the PR, as this is regulated by ER activity) (Cancer Genome Atlas 
Network, 2012). In tumours presenting as HER2+ (approximately 20 – 25 % of 
patients) treatments that target the HER2 receptor are used (Spector and Blackwell 
2009; Dawood et al. 2010). At present there is no available targetted therapy in 
widespread use for tumours classified as ‘triple negative’ (do not display ER, PR or 
HER2 and represent 5 – 10 % of patients). Consequently, patients presenting with 
triple negative breast cancer have the poorest prognosis (Crown et al. 2012). 
Over the past decade microarray profiling studies have further classified breast 
cancer into subtypes defined by a large number of genes and associated with 
different clinical outcomes. Each subtype displays a characteristic gene expression 
pattern thought to be partly dependent upon cellular origin. These molecular 
subtypes include: basal-like, normal-like, HER2-overexpressing, luminal A and 
luminal B (Sorlie et al. 2001; Perou et al. 2000; Sotiriou et al. 2003). The basal-like 
molecular subtype predominantly represent ER-/PR-/HER2- (triple negative) breast 
tumours whereas the HER2-overexpressing subtype represents HER2+ breast 
tumours (Creighton 2012). Normal-like, luminal A and luminal B molecular subtypes 
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all represent ER+ breast tumours however the significantly worse prognosis 
associated with diagnosis of luminal B breast cancer (highly proliferative ER+ ± 
HER2+) suggests that ER+ breast cancers may be made up of at least two distinct 
diseases with differing biology (Sorlie et al. 2001; Dawood et al. 2010). 
1.4 Endocrine therapies 
Since approximately 75 % of breast cancers diagnosed in postmenopausal women 
express the ER and/or PR they are likely to be stimulated to proliferate via the action 
of oestrogens (Anderson et al. 2002). Of these, approximately 80 % are ER+/HER2- 
(Harvey et al. 1999) and may benefit from endocrine treatment, whilst the other 20 
% are ER+/HER2+ and show a greater response to HER2 targetted therapies (Brufsky 
et al. 2005; Spector and Blackwell 2009). Several types of endocrine therapies are 
available for the treatment of ER+ (HER2-) breast cancer in postmenopausal women 
which are designed to interfere with oestrogen/ER signalling and thus subsequently 
inhibit cell growth; these agents are routinely employed in a sequential manner. 
Endocrine therapies have been proven to be invaluable agents for adjuvant therapy 
following surgery in early ER+ breast cancer patients and can lead to extended 
survival rates or even act as a curative (Jordan and Ford 2011). These agents are also 
utilised in the advanced (metastatic) stage of ER+ breast cancer where they have 
been shown to inhibit tumour growth (Joensuu et al. 2005). Further, in the 
neoadjuvant setting, endocrine therapy has been shown to be effective in tumour 
reduction thus allowing for more conservative breast surgery (Olson et al. 2009).  
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1.4.1 SERMs and tamoxifen 
Selective oestrogen receptor modulators (SERMs) are a class of endocrine 
therapeutic agents designed for the prevention and treatment of diseases including 
breast cancer and osteoporosis (Jordan 2004). Unlike oestrogens (which act as 
uniform agonists) and anti-oestrogens (which act as uniform antagonists), SERMs 
display an unusual tissue pharmacology in which they act as agonists and/or 
antagonists in a tissue-dependent manner (Wegner and Grady 1999; Muchmore 
2000). The most widely used SERM to date is tamoxifen, a non-steroidal 
triphenyethylene that exhibits antagonist action in the breast (Fisher et al. 1998). It 
has been reported that tamoxifen displays ER agonist action in the bone, liver and 
cardiovascular system and antagonist action in the brain and breast whilst mixed 
agonist and antagonist action of tamoxifen can be observed within the uterus (Fisher 
et al. 1994). Therefore, this distinct mechanism of action is ideal for the treatment of 
breast cancer where tamoxifen can function as an antagonist in the breast whilst 
simultaneously exerting the beneficial effects of oestrogen within the hearts and 
bones of patients.  
Tamoxifen competes with oestrogen for ER binding, however once bound, the bulky 
side chains of tamoxifen prevent the repositioning of helix 12 in the LBD which is 
necessary to seal the hydrophobic pocket and facilitate transcription (Brzozwski et 
al. 1997). Therefore, binding of tamoxifen to the ER prevents the recruitment of 
coactivator proteins to the LBD and inhibits AF2 driven gene transcription; however 
the activity of the AF1 domains remains unaffected (MacGregor-Shafer et al. 2000). 
In the breast, where ER activity is predominantly mediated by AF2-driven gene 
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transcription, tamoxifen functions as an antagonist (Metzger et al. 1995), however in 
the bone and uterus, where ER activity is mediated primarily through the AF1 
domain, tamoxifen exhibits agonist activity (Tzukerman et al. 1994; McDonnell et al. 
1995). Tamoxifen binding to ER can also favour the recruitment of corepressors to 
this complex which further contributes to the suppression of its agonist activity 
(Lavinsky et al. 1998; Shang and Brown 2002). Therefore it is postulated that altered 
availability/recruitment of coregulatory proteins to the tamoxifen-ER complex may 
also contribute to the specificity of tamoxifen function in different tissues (Schiff et 
al. 2003; Lonard et al. 2004; Shao et al. 2004). Interestingly, tamoxifen treatment can 
also lead to the induction of oestrogen responsive genes through association of 
tamoxifen-bound ER with cell surface signalling proteins (e.g. HER2) in the breast. 
This suggests that tamoxifen can facilitate the non-genomic activities of the ER thus 
leading to the promotion of agonist activity on a molecular level whilst functioning 
overall in these tissues as an antagonist of ER signalling (Chen et al. 1996).  
In 1999, tamoxifen became the first drug to be approved by the US Food and Drug 
Administration (FDA) for the prevention of breast cancer and until relatively recently 
was given as the first line of treatment to pre- and postmenopausal women (Michaud 
et al. 2001) and men (Giordano et al. 2005) with metastatic ER+ breast cancer and in 
the adjuvant setting after surgery. An important question still to be answered 
however is that of defining the most appropriate treatment time for patients to 
receive the most benefit from this drug. Evidence has shown that adjuvant tamoxifen 
treatment over a 5 year period can suppress breast cancer recurrence and decrease 
incidence of contralateral breast tumours by 50% (EBCTCG 2011). Moreover, 
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beneficial effects from this agent remain for 5 years following treatment cessation 
(EBCTGG 1998). However, long term tamoxifen treatment has been associated with 
an increased incidence of thromboembolism, cataracts and endometrial cancer 
within breast cancer patients (EBCTGG 1998) and healthy women (Fisher et al. 1998) 
participating in chemopreventative trials. More recently, studies have also shown 
that tamoxifen treatment alternated with an aromatase inhibitor over a 5 year period 
can lead to benefits of a more extended time frame (Rao et al. 2012; Davies 2013).  
1.4.2 Aromatase Inhibitors 
Tamoxifen treatment as a first line therapy for ER+ breast cancer patients has been 
succeeded by aromatase inhibitors (AIs): endocrine agents which inhibit the 
synthesis of oestrogen in the body (Brodie et al. 2003).  AIs have been shown to 
achieve more than 95 % inhibition of aromatase activity (an enzyme which converts 
androgens to oestrogen) and reduce circulating oestrogens to almost undetectable 
levels in postmenopausal ER+ breast cancer patients (Geisler et al. 1996). These 
endocrine agents have fewer side effects in comparison to tamoxifen. Following 
findings from the ATAC (‘Arimidex’, Tamoxifen,  Alone or in Combination) trial, the AI 
anastrozole, was found to be superior to tamoxifen as first line treatment in the 
adjuvant setting of early disease for ER+ postmenopausal women (5 year treatment) 
(Baum et al. 2003; Howell et al. 2005). Therefore tamoxifen is now used as a second-
line therapy following disease progression from AIs in hormone-dependent breast 
cancer.  
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1.4.3 SERDs and fulvestrant 
Due to the failure of tamoxifen and other SERMs to eradicate total oestrogen agonist 
activity within breast cancer patients, a search for pure anti-oestrogens with a high 
potency led to the discovery of an additional class of drugs; selective oestrogen 
receptor downregulators (SERDs). The most effective SERD discovered to date is 
fulvestrant (trade name faslodex). Fulvestrant is a steroidal 7α-alkylsulfinyl analogue 
of oestradiol and functions as a pure antagonist of the ER (Wakeling 2000). This SERD 
is structurally distinct from the non-steroidal SERMs and exhibits a higher affinity for 
the ER compared with tamoxifen (89 % versus 2.5 % of the binding affinity of 
oestradiol respectively) (Wakeling et al. 1991). In comparison to tamoxifen, 
fulvestrant exerts additional effects on the ER leading to a more effective inhibition 
of oestrogen action. Fulvestrant also competes with oestrogen for ER binding, 
however once bound, the long side chains of fulvestrant severely alter ER 
conformation such that ER dimerization is inhibited (Fawell et al. 1990; Nicholson et 
al. 1995). This interaction leads to the formation of a highly unstable complex which 
impairs ER shuttling from the cytoplasm to the nucleus thus reducing nuclear 
localisation of ER (Dauvois et al. 1993). Fulvestrant-ER complexes that may enter the 
nucleus are additionally functionally redundant as, unlike tamoxifen, fulvestrant 
binding impairs both AF1 and AF2 transcriptional activating domains. Furthermore, 
the formation of highly labile fulvestrant-ER complexes results in their rapid 
degradation from the cytoplasm (Nicholson et al. 1995). In summary, fulvestrant 
binds to, blocks and causes accelerated degradation of ERs leading to abrogation of 
ER expression, gene transcription and signalling (Osborne et al. 1995; Wakeling et al. 
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1995). Thus in contrast to alternative anti-oestrogens, fulvestrant shows full 
antagonist activity of the ER and has no known oestrogen agonist activity (Wardley 
2002). 
Despite the greater efficacy of fulvestrant to abrogate ER expression and signalling in 
breast cancer cells as compared to tamoxifen and AIs (Nicholson et al. 1995; Pink and 
Jordan 1996) this anti-hormone remains a second line therapy where these agents 
have failed. However, utilisation of therapies in this sequential manner may be 
beneficial to patients as fulvestrant has been shown to remain active within 
tamoxifen-resistant patients and does not confer cross-resistance with other anti-
oestrogens (DeFriend et al. 1994; Osborne et al. 1994). Furthermore, studies have 
suggested that HER2 status also does not preclude a response to fulvestrant; which 
is beneficial as HER2 is a limiting factor for tamoxifen treatment and may ultimately 
lead to acquired tamoxifen-resistance (Nicholson et al. 2004). To this end, in May 
2002, the U.S Food and Drug Association (FDA) approved the use of fulvestrant for 
the treatment of hormone receptor positive metastatic breast cancer in 
postmenopausal women with disease progression following endocrine therapy. 
Further, in March 2004, the European Union licenced the use of fulvestrant for the 
treatment of postmenopausal women with advanced breast cancer for disease 
relapse on or after endocrine therapy or disease progression with anti-oestrogen 
treatment. Research suggests that fulvestrant is at least as effective as the most 
widely used AI, anastrozole, in patients that have progressed from adjuvant or first-
line tamoxifen therapy (Howell et al. 2002; Osborne et al. 2002; Robertson et al. 
2003) whilst others suggest the value of fulvestrant treatment after AI failure (Ingle 
  
 
 
 
19 
 
et al. 2004;  Perey et al. 2004). However, some evidence suggests that fulvestrant 
may produce better results upon earlier administration in the treatment sequence 
(Howell et al. 2002; Steger et al. 2005). To this means, fulvestrant is now also being 
trialled in the first line clinical setting for advanced ER+ breast cancer disease with 
results revealing that fulvestrant may be at least as effective as anastrozole in this 
setting (Robertson et al. 2009). Overall, fulvestrant remains an ideal agent for 
combination treatment with other endocrine treatments and/or novel agents 
through its unique mechanism of function, good tolerability profile and lack of cross-
resistance.  
1.5 Therapeutic resistance in ER+ breast cancer 
Whilst endocrine therapies have proven successful for the treatment of ER+ breast 
cancer, de novo or acquired resistance to these therapies remains a significant 
problem. In the setting of metastatic disease, it has been reported that only 
approximately 30 % of breast tumours display objective regression with initial 
endocrine therapy with an additional 20 % exhibiting a prolonged stable disease 
(Osborne and Schiff 2003). Acquisition of endocrine resistance to these therapies 
leads to disease progression, formation of a more aggressive cancer and worsened 
prognosis for breast cancer patients and further treatment options for relapsed 
patients remains limited. For the provision of better therapeutic options for these 
patients it is imperative to understand the mechanisms through which cells develop 
resistance. In recent years several resistance mechanisms have been identified 
through which cells may overcome the growth suppressive effects of endocrine 
therapy. These mechanisms focus around three general categories: i) loss or altered 
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ER expression and/or function ii) differential availability of coregulatory proteins and 
cell-cycle regulators and iii) modulated growth factor receptor signalling, leading to 
a shift from genomic to non-genomic ER activity. However it has now become evident 
that multiple mechanisms exist which combine to orchestrate the acquisition of, and 
sustained, endocrine resistance (Massarweh et al. 2008).  
1.5.1 ER and resistance 
At present, the ER remains the most powerful biomarker for the prediction of patient 
response to endocrine therapy, thus, alterations in ER expression may affect 
endocrine sensitivity. Loss of ER expression occurs in approximately 20 % of breast 
cancer patients treated with endocrine therapy (Gutierrez et al. 2005). ER expression 
is not thought to be controlled at the genomic level, instead it is thought to be 
predominantly regulated by epigenetic modifications and post-translational 
mechanisms (Giacinti et al. 2006). Indeed, ER mutations have been shown to occur 
in less than 1 % of ER+ breast cancers (Herynk and Fuqua 2004). Further complexity 
is added through the observation that the ER undergoes post-translational 
modifications (including phosphorylation, methylation and ubiquitination) which 
alter its interactions with coregulatory proteins thus influencing transcriptional 
activity and sensitivity to various endocrine therapies (Gururaj et al. 2006).  
1.5.2 Coregulatory protein availability and cell cycle and apoptosis regulators 
The ER regulates gene expression through interactions with coregulatory proteins 
that form complexes required for the initiation of transcription (McKenna et al. 
1999). The presence of these proteins in the nucleus at rate-limiting levels can 
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significantly alter ER signalling and it has been observed that enhanced expression of 
ER coactivators and/or reduced expression of corepressors may negate the effects of 
endocrine therapy through influencing the balance of agonist versus antagonist 
activity of SERMs. Indeed, preclinical and clinical evidence suggests that enhanced 
expression of the ER coactivator AIB1/SRC3 is correlated with tamoxifen resistance 
(Osbourne and Schiff. 2003; Shou et al. 2004), whilst reduced expression of the co-
repressor protein NCoR appears to be involved in tamoxifen-refractory tumours 
(Lavinskey et al. 1998). Additionally, increased levels of transcription factors such as 
NFKß, AP1 and SP1, critical for ER-mediated signalling in the non-genomic pathway, 
have also been associated with endocrine resistance (Schiff et al. 2003; Osborne and 
Schiff 2003). Therefore, the availability and altered function of coregulatory proteins 
has been shown to directly influence ER-mediated transcription and efficacy of 
endocrine therapy. 
New evidence from preclinical and clinical studies suggests that the activity of cell 
cycle regulators and survival molecules contribute towards tumour sensitivity to 
endocrine therapies (Musgrove and Sunderland 2009). For example, overexpression 
of the cell cycle regulators MYC and cyclin D1 and E1 contribute to endocrine 
resistance through the activation of cyclin-dependent kinases that are critical for G1 
phases or through negation of the inhibitory effects of the negative cell cycle 
regulators p21 and p27 (Butt et al. 2005). Indeed, studies have revealed that 
resistance to tamoxifen has been associated with decreased expression of the 
negative cell cycle regulators p21 and p27 along with inactivation of the tumour 
suppressor RB (Perez-Tenorio et al. 2006; Chu et al. 2008). Additionally, evidence 
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suggests that downregulated expression of pro-apoptotic proteins (e.g. caspase 9) 
and upregulated expression of anti-apoptotic proteins (e.g. BCL-XL) also facilitates 
acquisition of endocrine resistance (Kumar et al. 1996) through promoting cell 
survival. The activity of these cell cycle regulators and survival molecules can be 
modulated through receptor tyrosine kinase (RTK) and transcription factor signalling 
(Zhou et al. 2007); factors also influenced by endocrine treatment.  
1.5.3 Cross-talk with receptor tyrosine kinases and their downstream signalling 
pathways 
Preclinical and clinical evidence has also shown that RTKs can contribute to endocrine 
resistance. Indeed, studies have revealed a bidirectional cross-talk mechanism 
whereby membrane ER activates RTK signalling which in turn leads to 
phosphorylation of the ER and its coregulatory proteins (Shou et al. 2004). 
Phosphorylation of serine residues in the AF1 domain of the ER, particularly serine’s 
118 and 167, activate ER in a ligand-independent manner and lead to the 
transcription of oestrogen-sensitive genes thus forming a positive feedback loop 
(Bunone et al. 1996; Joel et al. 1998). This activation of ER in the presence of 
endocrine agents may switch the transcriptional programme from genomic to non-
genomic pathway of ER action. Such signalling pathways implicated in reducing the 
efficacy of endocrine therapy include: the ErbB family of RTKs (Arpino et al. 2008), 
src (Morgan et al. 2009), ERK/MAPK (Britton et al. 2006), PI3/AKT (Campbell et al. 
2001) and receptors for insulin/IGF, FGF and VEGF (Chakraborty et al. 2010). These 
pathways lead to the activation of various transcription factors which regulate the 
transcription of multiple genes either in combination with the ER or bypassing it. The 
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RTKs, EGFR and HER2, have been heavily implicated as prominent mediators of 
endocrine resistance in ER+ breast cancer (Konecny et al. 2003; De Laurentiis et al. 
2005). Indeed, enhanced EGFR and/or HER2 expression has been found to become 
elevated in MCF-7 derived acquired tamoxifen-resistant (Tam-R) and fulvestrant-
resistant (Fas-R) in vitro cell models compared to their wild-type MCF-7 cells. Studies 
have revealed that these endocrine resistant cell models show enhanced EGFR/HER2 
heterodimerisation and activity leading to downstream activation of MAPK and 
PI3K/AKT signalling cascades which function to drive endocrine resistant cell growth 
(McClelland et al. 2001; Knowlden et al. 2003; Jordan et al. 2004; Nicholson et al. 
2007). In Tam-R cells, hyperactivated EGFR/HER2 signalling has been shown to 
activate ER and its coregulatory proteins in a ligand-independent manner (Font de 
Marc and Brown 2000; Britton et al. 2006) and EGFR/MAPK signalling in these cells 
was shown to promote AF1 phosphorylation of the ER leading to enhanced agonist 
behaviour of tamoxifen and expression of oestrogen-regulated genes (Britton et al. 
2006). Furthermore, immunohistochemical analysis of clinical breast cancer tissue 
revealed overexpression of EGFR, HER2 and MAPK in both de novo ER+ (and ER-) and 
acquired-tamoxifen resistant patients (Gee et al. 2005; Gutierrez et al. 2005). 
Additionally, in breast tumours resistant to fulvestrant, upregulation of HER2 and 
MAPK has been observed thus suggesting an involvement of this pathway in the 
acquisition of a resistant phenotype (Massarweh et al. 2006).  
To this end, the use of specific blockers or inhibitors of RTK signalling has been a 
promising therapeutic approach in endocrine resistant breast cancer. Indeed, 
gefitinib (a selective inhibitor of EGFR) has been shown to restore the effects of 
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tamoxifen in HER2 overexpressing acquired tamoxifen-resistant MCF-7 cells, whilst 
trastuzumab (monoclonal antibody that blocks HER2) has been shown to inhibit 
growth of endocrine resistant ZR-75-1 cells (Shou et al. 2004). Furthermore, co-
treatment of targetted therapies in conjunction with endocrine agents, e.g. 
tamoxifen, has also been shown to subvert the emergence of resistance in MCF-7 
cells (Gee et al. 2003; Leary et al. 2010) and targetted therapies of downstream 
signalling kinases, MAPK and PI3K/AKT, have also been shown to inhibit growth of 
endocrine resistant cells (McClelland et al. 2001; Knowlden et al. 2003; Jordan et al. 
2004).  
Taken together, it is likely that multiple factors contribute to the acquisition of 
endocrine resistance in breast cancer, however a greater understanding of the 
mechanisms which drive this process is necessary to improve treatment options for 
patients. Progress is being made in this area through the identification of biomarkers 
of resistance and search for molecular targets through which to treat resistant 
disease in patients. Over the past few decades multiple proteins have been reported 
to be involved in the acquisition of endocrine resistance in breast cancer. One such 
protein is the cell surface receptor CD44 which has been implicated in the acquisition 
of tamoxifen resistance in an ER+ breast cancer cell model (Hiscox et al. 2012) and 
extensively found to become upregulated in numerous carcinomas where it is 
thought to contribute, in some instances, to disease progression (Ma et al. 2005; 
Misra et al. 2012; Saito et al. 2013; Shi et al. 2013; Todaro et al. 2014). CD44 will be 
subsequently reviewed in this project.  
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1.6 CD44 
The CD44 protein belongs to a family of cell surface glycoproteins known as cell 
adhesion molecules (CAM) due to the strong bonds they form to specific ligands 
(Goodison et al. 1999). The CD44 family encompasses a polymorphic group of 
proteins which differ in size, glycosylation and function. Although CD44 is encoded 
by a single, highly conserved gene (Screaton et al. 1992; Rudzki and Jothy, 1997), the 
heterogeneity of CD44 proteins arise through the process of alternative splicing and 
post-translational modifications which may vary according to cell type and growth 
conditions (Jackson et al. 1992; Tolg et al. 1993). CD44 proteins are found present on 
the surface of most vertebrate cells and along with other members of the CAM 
family, are implicated in a diverse array of cellular functions including: cell to cell 
adhesions, cell to matrix adhesions, cell motility, growth, differentiation and 
signalling (Yu and Stamenkovic 1999; Mylona et al. 2006; Subramaniam et al. 2007; 
Cho et al. 2012; Montgomery et al. 2012; Bjorkland et al. 2013; Tsuneki and Mmadri 
2014). Additionally, a large proportion of CD44-mediated functions are facilitated 
through binding to its principle ligand hyaluronan (HA) (Bartolazzi et al. 1994; 
Knudson et al. 2002; Hamilton et al. 2007; Bourguignon et al. 2012). Thus, CD44 
belongs to a family of proteins linked by their shared ability to bind HA, termed 
hyaladherins.  
1.6.1 CD44 gene structure 
The human CD44 gene is located at the chromosomal locus 11p13 and is comprised 
of two groups of exons as denoted in Figure 1.3 (Goodfellow et al. 1982). The first 
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group are composed of exons 1 – 5 and 16 – 20. These constitutively expressed exons 
(termed standard exons) can be spliced together to form an isoform known as CD44 
standard (CD44 Std). The second group comprise the exons 6 – 15 (termed variant 
exons 1 – 10). These variant exons may be alternatively spliced individually, or in 
combinations, and included with the constitutively expressed standard exons at the 
insertion site between exons 5 and 16; this process allows for the formation of a vast 
array of CD44 isoforms with differing exon compositions (Dougherty et al. 1991; 
Hoffman et al. 1991; Tolg et al. 1993). Additional complexity arises through the 
alternative splicing of standard CD44 exons or use of cryptic splice sites (Screaton et 
al. 1992; Ermack et al. 1996). However, unlike mice, the human CD44 gene contains 
a stop codon in exon 6 (variant 1) within the seventeenth amino acid and thus is not 
usually included within processed transcripts (Screaton et al. 1993). 
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1.6.2 CD44 protein structure 
The CD44 protein structure is comprised of three domains; an N-terminal 
extracellular domain, a transmembrane domain and a C-terminal cytoplasmic 
domain (Figure 1.4) (Bosworth et al. 1991).  
 
 
 
 
Figure 1.4. CD44 protein structure adapted from Ponta et al. 2003. A schematic diagram to show 
the 3 structural domains of CD44 including: i) the N-terminal extracellular domain folded into a 
globular tertiary structure, which includes the stem structure containing the insertion site for 
individual or combinations of variant exons 2 – 10, ii) the highly conserved hydrophobic 
transmembrane domain and iii) the C-terminus cytoplasmic domain. The table lists the exon 
number(s), binding motifs/attachment sites and post-translation modifications attributed to each 
domain. Abbreviations represent: NH2 (amino terminus), COOH (carboxy-terminus), S-S 
(disulphide bond formed between 2 cysteine residues).  
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The extracellular domain of CD44 can be divided into two regions: conserved and 
non-conserved. The largely conserved (85 %) N-terminal domain is encoded by exons 
1 – 4 and forms a globular tertiary structure through the formation of disulphide 
bonds between three pairs of cysteine residues (Goodison et al. 1999) (Figure 1.4). 
Exon 1 encodes an N-terminal signal sequence whilst exons 2 – 3 comprise a stretch 
of 90 amino acids which contain the binding site for HA and other glycosaminoglycans 
(GAGs); this domain is termed the ‘link module’ (Aruffo et al. 1990; Culty et al. 1990; 
Naor et al. 1997). This domain also contains the conserved cysteine residues which 
form interchain disulphide bonds which are required for the stability of the domain 
and correct folding into the globular tertiary structure of this protein (Kohda et al. 
1996; Banjeri et al. 1998; Day and Sheehan 2001). The less conserved N-terminal 
region (approximately 35 – 50 %) is the membrane proximal stem domain and is 
encoded partly by exon 5 and exons 16 and 17 (Goodison et al. 1999). This stem 
structure (46 amino acids in length) separates the N-terminal domain from the 
plasma membrane. This domain contains numerous carbohydrate modifications and 
putative proteolytic cleavage sites and is thought to form a stem structure due to 
heavy glycosylation (Screaton et al. 1992; Okamoto et al. 1999). The stem structure 
may be expanded (by up to 381 amino acids in humans, or 423 amino acids in mice) 
to contain individual or combinations of variant exons through the previously 
mentioned process of alternative splicing (Jackson et al. 1992) (Figure 1.4). This 
domain also contains various binding sites for alternative CD44 ligands including: 
chondroitin sulphate (exons: 5, 15, 16 and 17) (Knutson et al. 1996; Kawashima et al. 
2000; Fujimoto et al. 2001; Murai et al. 2004), heparan sulphate (exon 8) (Bennet et 
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al. 1995; Jackson et al. 1995; Jones et al. 2000), collagen (Carter and Wayner 1988), 
laminin (Ishii et al. 1993; Hibino et al. 2004), fibronectin (Jalkanen and Jalkanen 1992) 
and osteopontin (Weber et al. 1996; Pietras et al. 2014) and is capable of forming 
complexes with various growth factors, cytokines, matrix-metalloproteinases and 
non-protein/protein integral membrane receptors (Bennet et al. 1995; Lammich et 
al. 2002; Murakami et al. 2003).  
The transmembrane region is encoded by exon 18 and comprises 23 hydrophobic 
amino acids and a cysteine residue and shows 100 % conservation between species 
(Figure 1.4) (Isacke et al. 1994); Lesley and Hyman 1998). The functional significance 
of this highly conserved transmembrane region has not yet been fully elucidated. 
However, studies have suggested a role for this domain within CD44 oligomerisation 
and incorporation into lipid rafts for the stabilisation and regulation of CD44 ligand 
associations and subsequent downstream signalling and initiation of migration 
(Neame et al. 1995; Perschl et al. 1995; Thankamony and Knudson 2006; Donatello 
et al. 2012; Babina et al. 2014). Additional studies hypothesise a role for this domain 
in efficient ligand binding (Lesley et al. 1992; Thomas et al. 1992) however this is 
disputed (Lesley et al. 2000; Gal et al. 2003; Perschl et al. 2005).  
The cytoplasmic region of CD44 is highly conserved and is encoded partially by exon 
18 (3 amino acids) and by exons 19 and 20 (Figure 1.4) (Goodison et al. 1999). 
However exon 19 is usually excluded from the majority of CD44 transcripts as 
inclusion of this exon results in a short-tail variant of CD44 through the use of an 
alternative translation stop codon (Goldstein et al. 1989; Goldstein and Butcher. 
1990; Jiang et al. 2001). Indeed, Jiang et al. 2002 revealed that inclusion of exon 19 
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in chondrocytes led to subsequent inhibition of HA endocytosis suggesting a possible 
role for this truncated isoform as a dominant negative regulator of HA internalisation. 
The cytoplasmic tail contains motifs for the cytoskeletal linker proteins ezrin, radixin, 
moesin (ERM) (Tsukita et al. 1994; Yonemura et al. 1994) and ankyrin (Bourguignon 
et al 1986; Kalomiris et a. 1988). These proteins are found to localise to membrane 
ruffles, filopodia, microvilli and cleavage furrow and are implicated within 
cytoskeletal and membrane remodelling, regulation of cell shape and migration and 
may act as a scaffold for signalling events (Bretscher et al. 1997; Hiscox and Jiang 
1999; Yonemura et al. 1999). Phosphorylation of the CD44 cytoplasmic tail by 
intracellular signalling components (including calmodulin-dependent protein kinase 
(CAMKII) and Rho-kinase (ROK)) enhance interactions between CD44 proteins and 
cytoskeletal linkers ERM and ankyrin, respectively, which regulate cell motility 
processes through facilitating indirect binding of CD44 to the actin cytoskeleton (as 
the CD44 gene itself does not encode actin binding motifs) (Zohar et al. 2000; Legg 
et al. 2002; Bourguignon et al. 2003; Donatello et al. 2012) shown in Figure 1.5. 
Furthermore the cytoplasmic tail plays an important role in subdomain localisation 
and in response to ligand binding can transduce intracellular signalling events leading 
to subsequent modulation of gene expression. As with all major classes of adhesion 
receptors, the CD44 molecule lacks intrinsic kinase activity therefore interactions 
with other proteins are required for the modulation of signalling within cells (Taher 
et al. 1996). Indeed, many intracellular signalling components have been reported to 
complex with the CD44 cytoplasmic tail including the Rho family of GTPases (and 
their exchange factors and adaptor molecules) (Oliferenko et al. 2000; Bourguignon 
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et al. 2003) and members of the src family of non-receptor tyrosine kinases 
(Llangumaran et al. 1998; Bourguignon et al. 2001). Numerous studies have shown 
that HA binding to CD44 stimulates Rho-guanine nucleotide exchange factors 
(RhoGEFs) (including p115RhoGEF and leukemia-associated RhoGEF (LARG)) which 
act as GDP/GTP exchange proteins for the Rho subfamily of GTPases, including RhoA. 
HA binding to CD44 stimulates RhoGEF/LARG mediated activation of RhoA which 
subsequently interacts with and activates downstream signalling components 
phospholipase C ɛ (PLCɛ) and ROK (Bourguignon et al. 2004; Bourguignon et al. 2006). 
Interactions between RhoA and PLCἐ promote inositol trisphophate (IP3) production 
and calcium (Ca2+) mobilisation leading to CamKII activation and subsequent 
phosphorylation of the cytoskeletal protein filamin, resulting in cellular 
migration/invasion (Bourguignon et al. 2006) (Figure 1.5). Conversely, RhoA 
activation of ROK leads to the subsequent phosphorylation of several signalling 
proteins including Na+/H+ exchanger 1 (NHE1), Grb-2 associated binder 1 (Gab-1) and 
myosin-phosphatase which contribute to enhanced cellular survival, growth, 
migration and invasion (Bourguignon et al. 2003; Bourguignon et al. 2004; 
Bourguignon et al. 2006) (depicted in Figure 1.5). Furthermore, Src has been shown 
to directly bind to the CD44 cytoplasmic tail leading to PKC activation and subsequent 
stimulation of the Ras-MEK-ERK signalling pathway resulting in enhanced cellular 
survival/growth (Bourguignon et al. 2001; Bourguignon et al. 2010) (Figure 1.5). 
Additionally, CD44 proteins are subject to proteolytic cleavage in the cytoplasmic 
domain (Okamoto et al. 2001; Lammich et al. 2002; Murakami et al. 2003). 
Extracellular domain cleavage of CD44 (by proteases) triggers subsequent 
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intracellular cleavage and the resultant fragment is translocated to the nucleus 
where it mediates the transcription of a variety of genes, including CD44 itself 
(Okamoto et al. 2001; Murakami et al. 2003).  
In summary, CD44 proteins can contribute to multiple cellular functions through i) 
co-receptor formation with integral membrane proteins, ii) binding of growth factors, 
cytokines and MMPs, iii) incorporation into lipid rafts, iv) transduction of intracellular 
signalling through interactions with proteins via the cytoplasmic tail, v) cytoskeletal 
remodelling through indirect binding to the cytoskeleton and vi) transduction of gene 
expression through proteolytic cleavage. These interactions facilitate a highly diverse 
array of CD44-mediated functions. 
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Figure 1.5. A proposed model for HA-stimulated CD44-mediated signalling during tumour 
progression, adapted from Bourguignon et al. 2009. HA binding to CD44 stimulates RhoGEF/LARG 
mediated activation of RhoA in a GTP-dependent manner which subsequently interacts with, and 
activates, downstream signalling components PLCἐ and ROK. Interactions between RhoA and PLCἐ 
promotes IP3 production and Ca2+ mobilisation leading to CamKII activation and subsequent 
phosphorylation of the cytoskeletal protein filamin, resulting in cellular migration/invasion. RhoA-
activated ROK phosphorylates several signalling proteins including: i) myosin phosphatase leading 
to actomysin mediated membrane motility, ii) NHE-1 leading to intracellular acidification and 
acidic ECM conditions resulting in cysteine proteinase-mediated matrix degradation and cellular 
migration/invasion and iii) Gab-1 leading to PI3K-AKT pathway activation and subsequently 
enhanced cell survival and growth. Furthermore, ROK phosphorylates the CD44 cytoplasmic tail 
leading to enhanced interaction with the cytoskeletal protein ankyrin resulting in cytoskeleton 
reorganisation. Phosphorylation of an alternative site in the CD44 cytoplasmic tail leads to 
interaction with the cytoskeletal linker proteins ERM also resulting in cytoskeletal reorganisation. 
The cytoplasmic domain of CD44 can also directly bind to Src leading to PKC activation and 
stimulation of the Raf-MEK-ERK signalling pathway resulting in enhanced cell survival and growth. 
Additionally, the extracellular region of CD44 can interact with numerous ligands, growth factors, 
cytokines, MMPs and integral/non-integral membrane receptors thus contributing towards the 
activation of numerous alternative cellular signalling pathways.  
 
  
 
 
 
35 
 
1.6.3 Post-translational modifications of the CD44 protein  
The calculated theoretical mass of the standard CD44 isoform (comprised of 363 
amino acids) is 37 kDa however its apparent mass (determined by gel 
electrophoresis) is approximately 80 kDa (Stamenkovic et al. 1989; Goodison et al. 
1999). Moreover, the observed mass of the largest CD44 isoform (containing all CD44 
variant exons and termed ‘epican’) can be over 200 kDa; with other CD44 variant 
isoforms falling within this size range (Goodison et al. 1999). The differences between 
the theoretical and observed mass of CD44 isoforms are due to extensive post-
translational modifications which tend to be cell specific. Such modifications of CD44 
may occur within the N-terminal domain which harbours: (i) a minimum of seven 
conserved consensus N-glycosylation sites (Bartolazzi et al. 1996;  English et al. 1998), 
(ii) chondroitin- (Knutson et al. 1996) tyrosine- (Sleeman et al. 1998) and keratin 
sulphate attachment sites  (Bennet et al. 1995) (iii) O-linked glycosylation sites (Lesley 
et al. 1995) and (v) sialic residues located on the standard extracellular region 
(Goodison et al. 1999) (shown in Figure 1.4). The splice variant exons also have the 
potential for various post-translational modifications including extra sites for N- and 
O-linked glycosylation, GAG consensus motifs and attachment sites for heparan 
sulphate on exon 8 (variant 3) and chondroitin sulphate on exon 15 (variant 10) 
(Jackson et al. 1995; Jones et al. 2000; Fujimoto et al. 2001; Murai et al. 2004) (Figure 
1.4).  
Post-translational modifications have also been shown to occur within the 
transmembrane and cytoplasmic domains of the CD44 molecule. Bourguignon et al. 
1991 revealed that CD44 can be reversibly palmitoylated at the acylation sites 
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cysteine 286 and 295 in the transmembrane and cytoplasmic domain respectively 
(Figure 1.4). The functional significance of this post-translational modification has 
been suggested to enhance the interactions between CD44 and the cytoskeletal 
protein ankyrin (Bourguignon et al. 1991) and play a role in the portioning of CD44 
into lipid rafts (Thankamony et al. 2006; Babina et al. 2014). Additionally, the 
cytoplasmic tail of CD44 contains two phosphorylation sites at serine 235 and 291 
(Neame and Isacke 1992) and 4 other potential phosphorylation sites (Figure 1.4). 
Studies have revealed a functional importance of these post-translational 
modifications in HA-stimulated migration. Indeed, Legg et al. 2002 revealed that 
protein kinase C (PKC) mediates phosphorylation switching between serine 235 and 
serine 291 on the CD44 molecule. Complete dephosphorylation of CD44 at position 
serine 235 followed by phosphorylation of serine 291 by PKC causes dissociation of 
ezrin from the molecule; these events are essential for the regulation of CD44 
interactions with ERM proteins and subsequent cytoskeleton modulation (Legg et al. 
2002).  
Clearly the CD44 molecule has the potential to be extensively modified following 
translation. The degree of glycosylation, acetylation and phosphorylation can alter 
the ligand binding characteristics of the protein and may thus account for altered 
functions observed between CD44 family members. Therefore incorporation of 
different combinations of CD44 exons into the CD44 protein can lead to the 
formation of multiple isoforms with distinct post-translational modifications, thus 
adding a further level of complexity to understanding CD44 functions.  
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1.6.4 CD44 variant expression and its pathological roles 
CD44 proteins do not exhibit uniform expression within tissues. Whereas the 
standard CD44 isoform (CD44 Std) has been shown to be ubiquitously expressed in 
the majority of vertebrate tissues (Terpe et al. 1994; Mackay et al. 1994), the larger 
CD44 variant isoforms exhibit a more restricted expression pattern and are 
predominantly located in cells of a stressed/diseased state e.g. during wound repair 
(Oksala et al. 1995; Huebener et al. 2008), inflammatory diseases (Pure and Cuff 
2001; Teder et al. 2002) and cancer cells (Gunthert et al. 1991; Foekens et al. 1999; 
Lopez et al. 2005; Louderbough et al. 2011). Further, CD44 variant expression 
changes during distinct stages of maturation (Zoller et al. 1997). Although most 
hematopoietic and epithelial cells display a CD44 variant positive phenotype during 
embryonic development and lymphocyte maturation and activation (Weber et al, 
1996), adult CD44 variant expression is confined predominantly to the skin (Haggerty 
et al. 1992; Tuhkanen et al. 1997), squamous and epithelia and ductal parts of the 
glands (Gansauge et al. 1995) and proliferating cells of epithelial tissues (Mackay et 
al. 1994). Various cell types have been identified which do not appear to express any 
of the CD44 isoforms amongst which include: hepatocytes, pancreatic acinar cells, 
adrenal glands, striated muscle, astrocytes and epithelium of the stromal intestine 
(Terpe et al. 1994; Mackay et al. 1994).  
CD44 proteins have been shown to mediate a diverse array of physiological cellular 
and tissue functions including: embryonic development (Sherman et al. 1996; 
Wainwright et al. 1996), haematopoiesis (Lewinsohn et al. 1990; Rossbach et al. 
1996), lymphocyte homing (Goldstein et al. 1989; Stamenkovic et al. 1989) and 
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migration (Bourguignon et al. 2001; Subramaniam et al. 2007; Donatello et al. 2012), 
leucocyte activation (Huet et al. 1989), effector functions and activation induced cell 
death (AICD) (McKallip et al. 2002), angiogenesis (Griffioen et al. 1997; Cao et al. 
2006) and cell adhesion (Aruffo et al. 1990; Bjorklund et al. 2013) and neoplasia 
(Gunthurt et al. 1991; Bartolazzi et al. 1994; Cho et al. 2012; Montgomery et al. 2012). 
Surprisingly, despite the well-defined role for CD44 in many physiological processes, 
CD44 null mice remain viable and develop normally showing only mild phenotypic 
abnormalities (Schmits et al. 1997; Protin et al. 1999) potentially suggesting a 
compensatory mechanism for loss of CD44. However, the effects of CD44 deletion in 
response to wound repair (Huebener et al. 2008), inflammatory diseases (Pure and 
Cuff et al. 2001; Teder et al. 2002) and tumour prone mice/tumour progression 
(Gunthurt et al. 1991; Foekens et al. 1999; Lopez et al. 2005; Louderbough et al. 2011) 
are prominent, suggesting that the main role of CD44 may be in response to 
environmental insult and disease progression.  
A large body of evidence has been gathered to support the finding of aberrant CD44 
variant expression in cancer; however this area remains largely controversial due to 
contradictory findings. Indeed, multiple studies have established a role for CD44 
variants (and in some instances upregulated expression of CD44 Std) in tumour 
progression and correlation with poor prognosis in many cancers including: breast 
carcinomas (Kalish et al. 1999; Herrera-Gayol and Jothy 1999a; Ma et al. 2005; Afify 
et al. 2009; Yae et al. 2012), colorectal carcinomas (Kuniyasa et al. 2002; Misra et al. 
2011; Saito et al. 2013), pancreatic cancer (Takada et al. 1994; Gotoda et al. 1998), 
ovarian cancer (Jaggupilli and Elkord 2012; Shi et al. 2013) and cancers of the prostate 
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(Hao et al. 2010; Ni et al. 2014; Tei et al. 2014) and brain (Marzese et al. 2014). 
However, conversely, the absence of CD44 expression (including variant proteins) 
has been shown to confer poorer prognosis in prostate cancer (Aaltomaa et al. 2001; 
Gupta et al. 2013) and neuroblastomas (Shtivelman and Bishop 1991; Favrot et al. 
1993). 
Further, in recent years, CD44 has been established as a marker of cancer stem cells 
(CSCs) (in combination with other markers) in multiple carcinomas including: breast 
(CD44+/CD24-) (Al-Hajj et al. 2003; Honeth et al. 2008; Idowu et al. 2012), pancreas 
(CD44+/CD133+ or CD44+/CD24+) (Li et al. 2007; Soner et al 2014), prostate 
(CD44+/CD133+) (Collins et al. 2005; Hurt et al. 2008; Lui et al. 2011), colon 
(CD44+/CD133+) (Du et al. 2008; Sahlberg et al. 2014), and gallbladder 
(CD44+/CD133+/CD24-) (Shi et al. 2010; Yin et al. 2011) where it has been reported 
to be associated with metastasis, chemo- and/or radioresistance, disease relapse and 
poor prognosis. However, whilst CD44 has been widely identified as a CSC maker in 
multiple organs, it remains unclear which isoforms of CD44 are specifically associated 
with the stem cell phenotype. Recent studies have shown that in particular, the 
presence of the CD44v6 isoform has been suggested to be a marker of CSCs in breast 
(Synder et al. 2009), pancreatic (Gaviraghi et al. 2011; Wang et al. 2013), prostate (Ni 
et al. 2014), colorectal (Todaro et al. 2014), bladder (Yang and Chang 2008) and 
tongue (Yanamoto et al. 2014) where it has been shown to contribute to tumour 
development and aggressive phenotype. 
Overall these studies suggest a substantial role for CD44 as a marker of tumour 
initiating cancer stem cells and as a protein involved in multiple processes critical for 
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tumour progression behaviours, however results remain contradictory. Therefore 
additional analyses are required to further substantiate the role of individual 
isoforms within these processes and divulge the mechanisms through which these 
proteins may contribute to disease progression.  
1.6.5 Therapeutic targetting of CD44 in cancer 
In light of its strong association with disease progression and poor prognosis in many 
cancer types including breast cancer, CD44 could present as an attractive therapeutic 
target. Multiple groups have investigated the value of CD44 as a therapeutic target 
in numerous cancers through the use of various techniques including: monoclonal 
antibodies against CD44 proteins (Seiter et al. 1993; Koppe et al. 2004; Tijink et al. 
2006), mimic peptides, miRNA therapies (Liu et al. 2011) or tumour specific 
nanocarriers/shRNA nanoparticles (Misra et al. 2009; Qian et al. 2013). Whilst these 
approaches have been met with some success in multiple cancers including 
pancreatic (Qian et al. 2013), colon (Misra et al. 2009) and prostate (Liu et. al. 2011) 
their effectiveness in breast cancer remains limited. These limited successes may be 
due to the development of therapies designed to target total CD44 proteins and may 
suggest a requirement for more specified targetting of individual CD44 variant 
isoforms.  
To reduce the off target effects of chemotherapeutic drugs in normal non-cancerous 
cells, researchers are investigating approaches in which to exploit the HA-binding 
properties of CD44 as a mechanism of localising drugs to specific sites and through 
which they can be endocytosed by cancer cells. HA is the principle ligand of CD44 and 
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is often found in abundance within the breast tumour stroma where it is correlated 
with poor prognosis (Auvinen et al. 2000; Auvinen et al. 2013). Recent studies have 
shown that these approaches have been met with some success in breast cancer cells 
highly expressing CD44 proteins (Ganesh et al. 2013; Yang et al. 2013) however more 
research is required before these treatments can be taken to clinical trials.  
However in recent years, studies have tended to focus upon CD44 targetting in the 
context of CSCs, defined by their CD44+/CD24- expression in breast cancer cells 
amongst other markers. This has been met with some success as Diessner et al. 2014 
revealed that targetting breast CSCs with the new antibody drug conjugate T-DM1 
(comprised of the potent chemotherapeutic agent, DM1, coupled with the HER2 
targetted antibody, trastuzumab) led to the depletion of a pre-existing subset of 
CD44+/CD24- stem cells and efficiently suppressed colony formation across a panel 
of breast cancer cell lines and primary tumours. Furthermore, therapies which act to 
induce differentiation of stem cells have shown that knockdown of CD44 in breast 
CSCs sensitised them to the anti-tumour drug doxorubicin and inhibited the 
‘stemness’ and differentiation properties of these cells (Pham et al. 2011). Whilst 
Ginestier et al. 2009 revealed that modulation of retinoid signalling may be sufficient 
to induce differentiation of breast CSCs. Additionally, multiple pathways are known 
to play a fundamental role in the maintenance and regulation of stem cells, of which, 
the Notch signalling pathway has been well-established. Studies aiming to target this 
pathway have been met with success including McGowan et al. 2011 which revealed 
that inhibition of Notch1 signalling significantly reduced the CD44+/CD24-/low 
subpopulation in a breast cancer cell line whilst also lowering the incidence of 
  
 
 
 
42 
 
metastases to the brain. In support of this, Harrison et al. 2010 revealed that 
inhibition of Notch4 mediated signalling decreased CSC populations in breast cancer 
cells whilst simultaneously inhibiting tumour initiation. 
Taken together, these studies reveal promising results for CD44 proteins as 
candidates of novel therapeutic strategies for breast cancer. Therefore it is hoped 
that with the advent of breast CSC targetted therapies, specific targetting of CD44 
variant isoforms and exploitation of the HA binding capacity of CD44 proteins, better 
therapies may become available in the future for the treatment of CD44+ breast 
cancer and patients who experience disease progression from endocrine-, chemo- 
and radio- therapies.  
1.7 Aims and Objectives 
CD44 expression has been extensively shown to become upregulated in numerous 
carcinomas where it correlates with an enhanced metastatic phenotype (Ma et al. 
2005; Afify et al. 2009; Saito et al. 2013; Shi et al. 2013; Ni et al. 2014) however these 
findings are controversial due to contradictory results. One aspect of CD44 that may 
account for variability between studies is the extensive alternative splicing attributed 
to this molecule which may lead to the production of novel CD44 isoforms with 
enhanced migratory/invasive functions. At present there is no substantial data 
surrounding the role of CD44 variant isoforms in clinical endocrine resistance, 
however previous work by the Breast Cancer Molecular Pharmacology Group 
(BCMPG) showed elevated total CD44 expression in a model of acquired tamoxifen 
resistance which associated with an increase in their migratory capacity (Hiscox et al. 
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2012). Therefore, the overall goals of this thesis were to characterise CD44 variant 
isoform expression across cell models of acquired tamoxifen-resistance and further 
extend these studies into a model of fulvestrant-resistant breast cancer to explore 
the hypothesis that upregulation of specific CD44 isoforms in endocrine resistant 
breast cancer promote an aggressive phenotype. To achieve this, a number of 
objectives were decided: 
1. To characterise CD44 isoform expression in endocrine sensitive and 
endocrine resistant breast cancer cells.  
2. To determine whether CD44-overexpressing resistant cells were sensitised to 
their principle ligand, HA, leading to enhanced activation of receptor tyrosine 
kinases and augmented cellular behaviours. 
3. To validate a potential link between CD44 and an adverse cellular phenotype 
in resistance by exploring the effects of CD44 suppression in endocrine 
resistant cells and investigating specific CD44 isoform overexpression upon 
the phenotype of endocrine sensitive cells. 
4. To define a mechanism through which CD44 specific isoforms promote 
aggressive cellular behaviours.  
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2. Materials and Methods 
2.1 Materials and reagents 
The materials and reagents used for experimental procedures in this project and their 
source of purchase are listed in Table 2.1.  
Materials/Reagents Supplier 
2-propanol (isopropanol) Sigma-Aldrich, Poole, Dorset, UK 
Acetic acid, glacial Sigma-Aldrich, Poole, Dorset, UK 
Acrylamide/bis-acrylamide (30 % solution, 
29:1 ratio) 
Sigma-Aldrich, Poole, Dorset, UK 
Activated charcoal Sigma-Aldrich, Poole, Dorset, UK 
Agarose Bioline Ltd, London UK 
Alexa Fluor 488 conjugated secondary 
antibody (anti-rabbit) 
Life Technologies, Inc. UK 
Alexa Fluor 594 conjugated secondary 
antibody (anti-mouse) 
Life Technologies, Inc. UK 
Ammonium Persulphate (APS) Sigma-Aldrich, Poole, Dorset, UK 
Amphortericin B (Fungizone) Invitrogen, Paisley, UK 
Ampicillin Sigma-Aldrich, Poole, Dorset, UK 
Anti-mouse IgG HRP-linked antibody Cell Signaling Technology, UK 
Anti-rabbit IgG HRP-linked antibody Cell Signaling Technology, UK 
Antibiotics: Penicllin/Streptomycin Life Technologies, Inc. UK 
Aprotinin Sigma-Aldrich, Poole, Dorset, UK 
BamHI 
New England Biolabs Inc, Ipswich, 
UK 
BglII restriction endonuclease 
New England Biolabs Inc, Ipswich, 
UK 
Bijou vials – sterile (5 ml) Bibby Sterilin Ltd, Stone, UK 
Bio-Rad Dc Protein Assay 
Bio-Rad Laboratories Ltd, Herts, 
UK 
Bovine serum albumin (BSA) Sigma-Aldrich, Poole, Dorset, UK 
Bromophenol Blue (BPB) BDH Chemicals Ltd, Poole, UK 
RPMI 1640 (containing Glutamine (200 mM) 
phenol-red-free RPMI 1640 
Life Technologies Inc, UK 
Sterile cell culture Corning plasticware 
(flasks, Petri-dishes, 24-, 48- and 96-well 
plates) 
ThermoFisher Scientific, 
Leicestershire, UK 
Cell scrapes 
Greiner Bio-One Ltd, 
Gloucestershire, UK 
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Chemiluminescent Supersignal West HRP 
Substrate (Pico, Dura, Femto) 
Pierce and Warriner Ltd, Chesire, 
UK 
Chloroform Sigma-Aldrich, Poole, Dorset, UK 
Corning Standard Transwell inserts (6.5 mm 
diameter, 8 µm pore size) 
Fisher Scientific, Leicestershire, 
UK 
Coulter Counter counting cups and lids 
Sarstedt AG and Co.,  Numbrecht, 
Germany 
Crystal Violet Sigma-Aldrich, Poole, Dorset, UK 
Dako diaminobenzidine (DAB)/substrate 
chromogen system solution 
Dako Ltd, Cambridgeshire, UK 
Dako Envision+ system-HRP labelled polymer 
anti-mouse, 
Dako Ltd, Cambridgeshire, UK 
Dextran from Leuconostoc spp. Sigma-Aldrich, Poole, Dorset, UK 
DharmaFECT 1 Transfection Reagent 
Thermo Scientific Dharmacon, GE 
Healthcare, UK 
Disposable cuvettes 
Fisher  Scientific UK Ltd, 
Loughborough, UK 
Di-thiothreitol (DTT) Sigma-Aldrich, Poole, Dorset, UK 
Deoxyribonucleotides (dNTPs) Invitrogen, Paisley, UK 
DPX mountant (06522) Sigma-Aldrich, Poole, Dorset, UK 
Dulbecco’s Phosphate Buffered Saline Sigma-Aldrich, Poole, Dorset, UK 
Ethidium Bromide (EtBr) Sigma-Aldrich, Poole, Dorset, UK 
Ethylene diamine tetraacetic acid (EDTA) Sigma-Aldrich, Poole, Dorset, UK 
Ethylene glycol-bis(2-aminoethylether)-
N,N,N’,N’-tetraacetic acid (EGTA) 
Sigma-Aldrich, Poole, Dorset, UK 
Falcon tubes – sterile (15 ml and 50 ml) 
Sarstedt AG and Co, Numbrecht, 
Germany 
Fibronectin (from human plasma; 1 mg/ml in 
0.05 TBS. pH 7.5) 
Sigma-Aldrich, Poole, Dorset, UK 
Filter paper (Grade 3) Whatman, Maidstone, UK 
Foetal calf serum (FCS) Life Technologies Inc, UK 
Formaldehyde solution Sigma-Aldrich, Poole, Dorset, UK 
FuGENE 6 transfection reagent Promega, Southampton, UK 
Gefitinib Gift from Astrazeneca, UK 
General laboratory glass and plastic ware 
Fisher  Scientific UK Ltd, 
Loughborough, UK 
Glacial Acetic Acid 
Fisher  Scientific UK Ltd, 
Loughborough, UK 
Glass coverslips (thickness no. 2, 22 mm2) 
BDH Chemicals Ltd, Poole, 
Dorset, UK 
Glass slides (1.0 – 1.2 mm thickness) 
Fisher  Scientific UK Ltd, 
Loughborough, UK 
Glycerol 
Fisher  Scientific UK Ltd, 
Loughborough, UK 
Glycine Sigma-Aldrich, Poole, Dorset, UK 
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Hydrochloric acid (HCI; 5M) 
Fisher  Scientific UK Ltd, 
Loughborough, UK 
HyperladderTM I and HyperladderTM IV Bioline Ltd, London, UK 
Isoton II azide-free balanced electrolyte 
solution 
Beckman Coulter Ltd, High 
Wycombe, UK 
Kodak MXB Autoradiography film (blue 
sensitive; 18 cm x 24 cm) 
Genetic Research 
Instrumentation (GRI), Rayne, UK 
Lennox L Agar  Sigma-Aldrich, Poole, Dorset, UK 
LB broth EZmixTM powder dust Sigma-Aldrich, Poole, Dorset, UK 
Leupeptin Sigma-Aldrich, Poole, Dorset, UK 
L-glutamine Life Technologies Inc, UK 
Liquid DAB+ substrate chromogen substrate DAKO, Cambridgeshire, UK 
Lower buffer for SDS-PAGE Gels (Tris 1.5 M, 
pH 8.8) 
Bio-Rad Laboratories Ltd, 
Hertfordshire, UK 
Magnesium Chloride (MgCl2) Sigma-Aldrich, Poole, Dorset, UK 
MatrigelTM Basement Membrane Matrix BD Biosciences, Oxford, UK 
Max Efficiency DH5αTM E.coli competent cells Life Technologies Inc, U 
Methyl green (M8884) Sigma-Aldrich, Poole, Dorset, UK 
Micro-centrifuge tubes (0.5 and 1.5 ml) 
Elkay Laboratory Products, 
Basingstoke, UK 
Mineral oil  PCR reagent Sigma-Aldrich, Poole, Dorset, UK 
Molony-murine leukemia virus (MMLV) 
reverse transcriptase enzyme 
Promega, Southampton, UK 
NEBuffer 3 
New England Biolabs Inc, Ipswich, 
UK 
N,N,N’,N’-tetramethylene-diamine (TEMED) Sigma-Aldrich, Poole, Dorset, UK 
Nitrocellulose transfer membrane (Protran 
B85; 0.45 µm pore size) 
Thermo Fisher Scientific, 
Leicestershire, UK 
Normal goat serum (10 %) Sigma-Aldrich, Poole, Dorset, UK 
PCR Buffer (10X) without MgCl2 Sigma-Aldrich, Poole, Dorset, UK 
Phenol Sigma-Aldrich, Poole, Dorset, UK 
Phenylarsine oxide Sigma-Aldrich, Poole, Dorset, UK 
Phenylmethylsulfonyl fluoride (PMFS) Sigma-Aldrich, Poole, Dorset, UK 
Phosphate buffered saline – sterile (PBS) Life Technologies Inc, UK 
Pipette tips 
Greiner Bio-One Ltd, 
Gloucestershire, UK 
Polyoxyethlene-sorbitan monolaurate 
(Tween 20) 
Sigma-Aldrich, Poole, Dorset, UK 
Ponceau S solution  Sigma-Aldrich, Poole, Dorset, UK 
Potassium Chloride (KCI) Sigma-Aldrich, Poole, Dorset, UK 
Potassium di-hydrogen orthophosphate 
(KH2PO4) 
Fisher Scientific UK Ltd, 
Loughborough UK 
Precision Plus ProteinTM All Blue Standards 
(10 – 250 kDa) 
Bio-Rad Laboratories Ltd, 
Hertfordshire, UK 
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Protein Assay Reagent A 
Bio-Rad Laboratories Ltd, 
Hertfordshire, UK 
Protein Assay Reagent B 
Bio-Rad Laboratories Ltd, 
Hertfordshire, UK 
Protein Assay Reagent C 
Bio-Rad Laboratories Ltd, 
Hertfordshire, UK 
pUC19 vector Life Technologies Inc, UK 
Random Hexamers (RH) Amersham, Little Chalfont, UK 
Recombinant RNasin Ribonuclease Inhibitor Promega, Southampton, UK 
RestoreTM Western blot Stripping Buffer  
RNase-free H2O Sigma-Aldrich, Poole, Dorset, UK 
Serological pipettes – sterile, disposable (5 
ml, 10 ml, 15 ml) 
Sigma-Aldrich, Poole, Dorset, UK 
siRNA buffer (5X) 
Thermo Fisher Scientific, 
Leicestershire, UK 
Super Optimal broth with Catabolic 
repression (SOC) media 
Life Technologies Inc, UK 
Sodium Azide Sigma-Aldrich, Poole, Dorset, UK 
Sodium Chloride (NaCl) Sigma-Aldrich, Poole, Dorset, UK 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich, Poole, Dorset, UK 
Sodium Fluoride (NaF) Sigma-Aldrich, Poole, Dorset, UK 
Sodium hydroxide (NaOH; 5M) 
Fisher Scientific UK Ltd, 
Loughborough, UK 
Sodium Molybdate (Na2,M0O4) Sigma-Aldrich, Poole, Dorset, UK 
Sodium Orthovanadate (Na3VO4) Sigma-Aldrich, Poole, Dorset, UK 
Solvents (acetone, chloroform, ethanol, 
formaldehyde, isopropanol, methanol) 
Fisher Scientific UK Ltd, 
Loughborough, UK 
Sucrose Sigma-Aldrich, Poole, Dorset, UK 
Syringe filters – sterile (0.2 µm) 
Corning Inc, Corning, New York, 
USA 
Syringe needles – sterile (BD MicrobalanceTM 
3/25G x 5/8) 
Becton Dickenson (BD) UK Ltd, 
Oxford, UK 
Syringe needles – sterile (Sherwood Medical 
Monoject; 21G x 11/2) 
Sherwood Davis and Geck, 
Gosport, Hampshire, UK 
Sucrose 
Fisher Scientific UK Ltd, 
Loughborough, UK 
T4 DNA ligase 
New England Biolabs Inc, Ipswich, 
UK 
T4 DNA ligase reaction buffer 10X 
New England Biolabs Inc, Ipswich, 
UK 
Taq DNA polymerase (BioTaqTM; 5 U/µl) Bioline Ltd,  London, UK 
Test tubes – sterile (5 mls) 
Fisher Scientific UK Ltd, 
Loughborough, UK 
TRI Reagent Sigma-Aldrich, Poole, Dorset, UK 
Tris HCI Sigma-Aldrich, Poole, Dorset, UK 
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Tris-EDTA buffer solution (100X) Sigma-Aldrich, Poole, Dorset, UK 
Triton X-100 Sigma-Aldrich, Poole, Dorset, UK 
Trizma (Tris) base Sigma-Aldrich, Poole, Dorset, UK 
Trypsin/EDTA 10x solution Life Technologies Inc, UK 
TWEEN20 Sigma-Aldrich, Poole, Dorset, UK 
Universal containers – sterile (30 ml) 
Greiner Bio-One Ltd, 
Gloucestershire, UK 
Upper Buffer for SDS-PAGE gels (Tris 0.5 M, 
pH 6.8) 
Bio-Rad Laboratories Ltd, Inc, 
Hertfordshire, UK 
VectorShield hard-set mounting medium 
containing DAPI nuclear stain 
Vector Laboratories, Inc, 
Peterborough Ukk 
Western Blocking Reagent 
Roche Diagnostics,  Mannheim, 
Germany 
Whatman qualitative filter paper, Grade 4 
(diameter, 125 mm) 
Sigma-Aldrich, Poole, Dorset, UK 
X-ray film developer solution (X-O-dev) 
X-O- graph Imaging System, 
Tetbury, UK 
X-ray film fixative solution (X-O-fix) 
X-O- graph Imaging System, 
Tetbury, UK 
Table 2.1. A list of the materials and reagents used within this project and their source of purchase.  
2.2 Cell culture 
2.2.1 In vitro cell models of endocrine sensitive and endocrine resistant breast 
cancer 
To model a hormone sensitive ER+ breast cancer, MCF-7 (Michigan Cancer 
Foundation-7) wild type cells (a gift from AstraZeneca Pharmaceuticals (Macclesfield, 
Chesire, UK) and obtained from American Type Cell Collections (ATCC) Number HTB-
22TM) were maintained as a monolayer culture in vitro. The routine maintenance 
media used to culture MCF-7 cells was composed of: phenol-red pH indicator (RPMI-
medium 1640) media containing glutamine (200 mM) and supplemented with 5 % 
(v/v) foetal calf serum (FCS) and 1 % antibiotics (Fungizone (2.5 µg/ml) and penicillin 
(100 IU/ml)/streptamycin (100 µg/ml)). For experimental comparison between cell 
lines, MCF-7 cells were transferred into experimental media composed of: phenol-
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red-free pH indicator 1640 media (WRPMI) and supplemented with 5 % (v/v) 
charcoal-stripped foetal calf serum (SFCS), 2 % (v/v) L-Glutamine (200 mM) and 1 % 
antibiotics (Fungizone (2.5 µg/ml) and penicillin (100 UI/ml)/streptomycin (100 
µg/ml)).  
In vitro cell models of acquired-resistance to the endocrine agents, 4-
hydroxytamoxifen (tamoxifen) and fulvestrant (trade name faslodex), were 
previously created by the Breast Cancer Molecular Pharmacology Group (BCMPG) 
through culturing MCF-7 cells in the presence of tamoxifen (100 nM) or fulvestrant 
(100 nM) respectively, for 6 months. Upon acquisition of endocrine resistance (as 
determined by the ability of the cells to grow in the presence of the endocrine agent) 
these cells were then maintained for a further 3 months to develop a stable resistant 
phenotype which could then be used for routine culture. MCF-7 cells which have 
acquired resistance to the endocrine agent tamoxifen are denoted as Tam-R cells. 
MCF-7 cells which have acquired resistance to the endocrine agent fulvestrant are 
denoted as Fas-R cells. Both the Tam-R and Fas-R cell lines used within these 
experimental studies are models of early acquired endocrine resistance and have 
been cultured for 18 months in their respective endocrine agent. Tam-R and Fas-R 
cells were routinely maintained in phenol-red-free pH indicator (WRPMI-medium 
1640) supplemented with 5 % (v/v) charcoal-stripped foetal calf serum (SFCS), 2 % 
(v/v) L-Glutamine (200 mM), 1 % antibiotics (Fungizone (2.5 µg/ml) and penicillin (100 
UI/ml)/streptomycin (100 µg/ml)) and 4-hydroxytamoxifen (100 nM) or fulvestrant 
(100 nM) respectively. The key molecular features and characteristics of all cell 
models used in this project are described in Table 2.2.  
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Table 2.2. Key molecular features and characteristics of the cell models used in this project (adapted 
from Neve et al., 2006). 
2.2.2 Routine maintenance of in vitro cell models 
For routine maintenance and experimental studies, all cell lines were grown under 
sterile conditions in a 37 ˚C/5 % CO2 incubator (Sanyo MCO-17AIC incubators, Sanyo 
Gallenkamp, Loughborough, UK). Cell culture was carried out under sterile conditions 
in an MDH Class II laminar-flow safety cabinet (Bioquell UK Ltd, Andover, UK) and all 
equipment and consumables were either purchased sterile for single use or sterilised 
at 119 °C in a Denley BA825 autoclave (Thermoquest  Ltd, Basingstoke, UK). 
2.2.2.1 Cell passaging 
Growth of the cell lines was visually assessed using a phase-contrast microscope 
(Nikon Eclipse TE200n, Nikon Ltd, Kingston-upon-Thames, UK). At 70 – 80 % 
confluency, cell lines were passaged through the aspiration of culture media and 
addition of 0.05 % trypsin (with 0.02% EDTA) to each flask. The flasks were then 
returned to the incubator for 3 – 5 minutes to allow complete cell detachment from 
the flask walls. The trypsin suspension containing the detached cells was then 
transferred to a universal tube where it was combined with an equal volume of 
routine maintenance media, the suspension was then centrifuged for 5 minutes at 
1000 rpm (Mistral 3000i centrifuge, Sanyo Gallenkamp, Loughborough, UK). After 
Cell Line 
Molecular 
Subtype 
ER 
status 
PR 
status 
Original source of 
cells 
Tumour  
type 
MCF-7 Luminal + + Pleural effusion 
Invasive ductal 
carcinoma 
Tam-R Luminal + + Pleural effusion 
Invasive ductal 
carcinoma 
Fas-R Luminal - - Pleural effusion 
Invasive ductal 
carcinoma 
  
 
 
 
51 
 
centrifugation, the supernatant was discarded and the pellet was resuspended in 10 
ml of maintenance media and mixed gently. A 1:10 dilution of cell suspension to 
maintenance media was then dispensed into a clean flask and returned to the 
incubator. Flasks were subsequently replaced with fresh maintenance media every 3 
days until harvesting for experimentation or further passaging was required. Cell 
lines were passaged in total for no more than 25 times and then discarded. Cell line 
stocks were stored in liquid nitrogen and thawed as necessary. 
2.2.2.2 Setting up cells for experimental analysis 
For experimental analysis, cells underwent the primary trypsin/EDTA dispersion, 
centrifugation and re-suspension steps as described above and were then passed 
through a sterile 25G syringe needle to obtain a single cell suspension. 100 µl of this 
cell suspension was added to 10 ml Isoton II solution and cells were counted using a 
Coulter CounterTM Multisizer (Beckman Coulter Ltd, High Wycombe, UK). Once cell 
number was determined, the appropriate volume of cells was combined with 
experimental media and seeded into sterile dishes at the required density.  
2.2.3 Cell treatments 
Cell lines were subjected to various treatments for experimental procedures in this 
project. Table 2.3 lists the treatment types along with their corresponding diluent 
and source of purchase. Details of the concentration and duration of these 
treatments are displayed in the figure legends throughout the results chapters. 
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Treatment Diluent Source 
Tamoxifen Ethanol Sigma-Aldrich, UK 
Faslodex Ethanol AstraZeneca, UK 
Oestradiol Ethanol AstraZeneca, UK 
Charcoal Stripped FCS - In-house (Appendix A) 
Gefitinib Ethanol AstraZeneca, UK 
Epidermal Growth Factor (EGF) 
PBS containing 
0.1% BSA 
Sigma-Aldrich, UK 
Hyaluronan RPMI/WRPMI R&D Systems, UK 
Table 2.3. A list of the cell treatments used within this project along with their corresponding source 
of the purchase and diluents used for storage.  
2.3 Microarray analysis  
Prior to this project, RNA samples from all cell models routinely maintained by the 
BCMPG cell culture staff were obtained in triplicate and sent to the Cardiff University 
Central Biotechnology Services (CBS) to be microarrayed and gene expression 
analysis using the resultant data was used as a focus of this project. Initial 
assessments were performed on samples of the cell models by the CBS to determine 
the quality (analysis of degradation or contamination) of RNA and once satisfied 
these samples were run on Affymetrix Human Genome U133A gene chips containing 
approximately 23, 000 gene probes. The Affymetrix suite 5.0 programme used for 
microarray analysis provides powerful algorithms that analyse the data and generate 
appropriate analysis output files for subsequent analysis. The triplicate raw data 
obtained from microarraying was then uploaded onto the online bioinformatics 
software programme GeneSifter (https://login.genesifter.net/) where median 
normalisation across all datasets and log transformation was performed. Log2 
intensity plots were also generated by this programme to visualise gene expression 
changes across the models and fold change calculations for each gene were 
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performed. In some instances, the Affymetrix U133A gene chips contained more than 
one gene probe for each gene therefore particular importance was placed on the 
‘Jetset’ gene probe. Jetset is an online software programme created by the Technical 
University of Denmark which allocates each gene probe used for affymetrix analysis 
with a score (ranging from 0 – 1) determined by their performance across three 
parameters: i) specificity of the probe to bind to the target sequence, ii) ability of the 
probe to detect as many splice isoforms of the target gene as possible to estimate 
overall gene expression and iii) the degradation resistance of each probe (robust 
score). This tool then combines these scores to determine the best overall 
performing probe (on a scale of 0 – 1, with a score closer to 1 showing the best 
performance) for a given gene which is termed the ‘Jetset’ probe and identifies the 
most reliable profile in the array for the gene of interest (see Appendix B for further 
information) (Li et al. 2011). Expression ‘call’ for all gene probes assessed by 
microarraying was also analysed using the GeneSifter programme via the ‘detection 
call’ algorithm to determine the reliability of transcript expression. A detection call 
of ‘absent’ suggests unreliable or low/no detection of gene expression whilst 
‘present’ suggests existing/reliable gene expression across the cells and ‘mixed’ 
represents partial detection of gene expression. In this project, for each gene 
analysed, GeneSifter was used to a create a heatmap expression profile and 
corresponding log2 intensity plot for each Jetset probe along with their fold change 
values. Statistical significance was determined by ANOVA analysis with Tukey post-
hoc testing and significance was set at p <0.05. In this project, data created from 
microarraying and subsequent online analysis was used to explore the endogenous 
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gene expression of CD44, HMMR, LYVE-1, TL4, STAB2, ICAM-1, VCAN, HAS1, HAS2, 
HYAL1, HYAL2 and HYAL3 across MCF-7, Tam-R and Fas-R cells. All microarray and 
subsequent statistical analysis was performed by the CBS and the BCMPG statistician 
Lynne Farrow respectively.   
2.4 Kaplan Meier plotter analysis 
The Kaplan Meier (KM) plotter is a publically available online database tool 
(http://kmplot.com/analysis/) which was used in this project to assess the 
relationship between the expression levels of CD44 and clinical outcome with 
endocrine therapy. The KM plotter interrogates Affymetrix microarray chip-derived 
mRNA expression data accumulated from breast cancer patients prior to therapy in 
relation to survival outcome measures (Györffy et al. 2010). The database utilises this 
information to derive survival plots which are used to relate gene expression levels 
to clinical outcome by splitting patients into two groups based on various quantile 
expression of the proposed gene and integrating this data simultaneously with 
clinical data (Györffy et al. 2010). In this project, KM survival curves were generated 
to examine the clinical relevance of CD44 gene expression in an ER+ breast cancer 
patient cohort where any endocrine treatment (n=1190) or tamoxifen treatment 
alone (n=615) was known with up to 20 year follow up, to determine the relationship 
between CD44 and overall survival (OS) and relapse-free survival (RFS). All analyses 
were generated using the Jetset Affymetrix CD44 gene probe (212063_at) and output 
was displayed as KM survival curves with associated Hazard ratio (HR) and 
significance value (log rank p < 0.05).  
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2.5 Reverse transcription polymerase chain reaction (RT-PCR) analysis 
2.5.1 RNA extraction 
MCF-7, Tam-R and Fas-R cells were seeded into 150 mm dishes at a density of 3.4 x 
106 cells/dish and cultured until 70 – 80 % confluency. Media from the dishes was 
removed and cells were washed twice with 10 ml tissue culture grade PBS (1X). 1 ml 
TRI Reagent/10 cm2 surface area was added to each dish and gently rocked for 1 
minute to ensure complete coverage. Cell lysates were then collected using a sterile 
disposable cell scraper, transferred into a 1.5 ml eppendorf tube and equilibrated for 
5 minutes at room temperature. 200 µl Chloroform/1 ml TRI Reagent was added to 
the lysates followed by brief vortexing (20 seconds) and incubation at room 
temperature for 10 minutes. Lysates were then placed into a pre-cooled centrifuge 
(Labofuge 400R centrifuge, Heraeus, Germany) and spun for 15 minutes at 4 ˚C, 12, 
000 rpm. After centrifugation, the lysate separates into 3 phases; the upper aqueous 
phase containing the RNA, the middle layer containing the DNA and the lower 
phenolic phase containing proteins. The upper aqueous phase of each supernatant 
was carefully removed without disturbing the interface to avoid genomic DNA 
contamination and transferred to a clean 1.5 ml eppendorf tube. 500 µl isopropanol 
was added to each tube and briefly vortexed before incubation at room temperature 
for 10 minutes to precipitate the RNA. The samples were then returned to the 
centrifuge and spun at 12, 000 rpm, 4 ˚C for 15 minutes. The supernatant was 
removed from the tubes and the RNA pellet was washed in 1 ml 75 % ethanol. 
Samples were then briefly vortexed and centrifuged at 7, 500 rpm, 4 ˚ C for 5 minutes. 
Ethanol was discarded from the tubes and the RNA pellets were air dried for 5 
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minutes and re-dissolved in 20 µl RNase-free distilled water. RNA concentration 
(µg/ml) and purity was quantified by diluting 1 µl RNA in 499 µl RNase-free water and 
absorbance was measured at 260 nm (A260) on a spectrophotometer (Cecil CE2041, 
Cambridge UK) based on the following formula: RNA = A260 x 40 x dilution factor. A 
ratio of 1.8 – 2.0 represented pure preparations of RNA. RNA integrity was assessed 
via gel electrophoresis for each sample. Intact RNA would lead to the formation of 
two bands identifying the 18S and 28S ribosomal RNA with a smear in between 
denoting mRNA of different sizes. Intact RNA was observed in all samples examined 
in this project. Samples were stored at – 80 ˚C.  
2.5.2 Reverse transcription  
This procedure converts isolated RNA molecules into their complementary DNA 
(cDNA) which is required for RT-PCR experiments. For each reverse transcription 
reaction, 1 µg RNA (diluted to a total volume of 7 µl in sterile RNase-free water) was 
added to 11.5 µl master mix solution in an sterile eppendorf tube on ice comprising 
of: 5 µl dNTPs (2.5 mM), 2 µl 10 x PCR buffer (10 mM Tris-HCI, pH 8.3, 50 mM NH4, 
0.001 % w.v gelatin), 2 µl Dithiothreitol (DTT), (0.1 M), 2 µl random hexamers (100 
µM), 0.5 µl MgCl2 (50 mM). Samples were then denatured at 95 ˚C for 5 minutes in a 
PTC-100 thermocycler (MJ Research Ltd, USA) and rested on ice for 5 minutes. The 
samples were then pulse spun in a microfuge (Biofuge, Heraeus, Germany) and 
returned to ice. To each reaction, 1 µl Molony-murine leukemia virus (MMLV) 
(200U/µl) reverse transcriptase enzyme and 0.5 µl commercial RNase inhibitor 
RNasinTM (40U/µl) was added to give a final volume of 20 µl. Samples were then 
transferred to the thermocycler and reverse transcribed using the following 
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parameters: annealing at 22 ˚C for 10 minutes, reverse transcriptase extension at 42 
˚C for 40 minutes, denaturation at 95 ˚C for 5 minutes. The resultant cDNA was then 
stored at - 20 ˚C. 
2.5.3 Oligonucleotide primer design 
The oligonucleotide primers used for RT-PCR analysis were designed using the 
Invitogen OligoPerfectTM Designer software 
(http://tools.lifetechnologies.com/content.cfm?pageid=9716) using the CD44 
(Appendix C) and HMMR (Appendix D) gene sequences obtained from the National 
Centre for Biotechnology Information (NCBI) online database 
(http://www.ncbi.nlm.nih.gov/). This programme allowed the consideration of 
product size, melting temperature and likelihood of undesirable primer-dimer 
formation between the primer pairs. Table 2.4 lists the target gene along with the 
corresponding designed forward and reverse primer sequences, parameters 
required for the RT-PCR reaction and expected product sizes. Once primer pairs were 
selected, these sequences were inputted into the online bioinformatics programme 
Basic Local Alignment Search Tools (BLAST) (http://blast.ncbi.nlm.nih.gov/) which 
allowed similarity comparison of the primer sequences to other DNA sequences 
across the human genome. BLAST analysis confirmed the high level of specificity of 
these primers to the gene of interest for all primer pairs used within this project.  
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Table 2.4. A list of each target gene along with their corresponding forward and reverse primer 
sequences, reaction conditions used for RT-PCR analysis and expected product size.  
2.5.4 RT-PCR analysis 
RT-PCR reactions were performed in 0.5 ml sterile eppendorf tubes containing a total 
volume of 25 µl consisting of 0.5 µl cDNA and 24.5 µl master mix solution for each 
sample. The master mix was prepared on ice and contained: 2 µl dNTPs (2.5 mM), 
2.5 µl 10X PCR buffer (10 mM Tris-HCl pH 8.3, 50 mM KCI, 1.5 mM MgCl2 and 0.001 
% w/v gelatin), 0.625 µl forward primer (20 µM), 0.625 µl reverse primer (20 µM), 
0.2 µl Taq DNA polymerase (5 U/µl) and 18.6 µl sterile RNase free water. For each RT-
PCR reaction, an eppendorf containing the master mix solution without the cDNA 
was used as a negative control. The reaction mixture was briefly vortexed and a drop 
of sterile mineral oil was placed on top of the solution to prevent evaporation during 
the reaction. The samples were then placed into a PTC-100 thermocycler (MJ 
Research Ltd, Massachussets, USA). Table 2.5 reveals the thermocycle parameters 
performed for RT-PCR detection and describes the optimal conditions required for 
Gene Forward Sequence Reverse Sequence 
RT-PCR 
reaction 
Expected
product 
size  
CD44 Std 
5’-GACACATATTGC 
TTCAATGCTTCAGC-3’ 
5’-GATGCCAAGATGAT 
CAGCCATTCTGGAAT-3’ 
61 ˚C 
30 cycles 
482 – 
1496 bp 
CD44v3 
5’-CGTCTTCAAAT 
ACCATCTCAGC-3’ 
5’ TCATCATCAA 
TGCCTGATCC-3’ 
60 ˚C 
29 cycles 
100 bp 
CD44v6 
5’-CAACGGAAGA 
AACAGCTACCC-3’ 
5’ CCTGTTGTCG 
AATGGGAGTC-3’ 
61 ˚C 
30 cycles 
100 bp 
CD44v10 
5’-GGAATGATGTCA 
CAGGTGGA-3’ 
5’-AAGGTCCTGCT 
TTCCTTCGT-3’ 
57 ˚C 
29 cycles 
109 bp 
HMMR 
5’-TGCAGCTCAG 
GAACAGCTAA-3’ 
5’-GCTGACAGCGG 
AGTTTTGAT-3’ 
60 ˚C 
29 cycles 
149 bp 
β-actin 
5’-GGAGCAATGATC 
TTGATCTT-3’ 
5’-CCTTCCTGGGCA 
TGGAGTCCT-3’ 
55 ˚C 
27 cycles 
204 bp 
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the detection of each target gene. To visualise the results of the RT-PCR, the samples 
were electrophoresed on a 2 % agar gel (2 g agar, 100 ml 1X Tris Acetate (TAE) buffer 
(20 ml 50X TAE buffer (242g Tris, 57.1 ml glacial acetic acid, 100 ml 0.5 EDTA, 1 L 
distilled water, pH 8.3) diluted in 1 L distilled water), 1 µl ethidium bromide). The set 
agar gels were placed into a Mini-Sub Cell GT electrophoretic tank (Bio-Rad 
Laboratories Ltd, Hertfordshire, UK) filled with 1 X TAE buffer. To 9 µl RT-PCR product 
was added 5 µl loading buffer (6 g sucrose, 2 mg bromophenol blue, 10 ml distilled 
water) and pipetted into the wells of the 2 % agar gel and 5 µl hyperladder IV was 
used as a marker. The electrophoresis reaction was allowed to run for 1 hour at 75 
volts constant. RT-PCR products were visualised and photographed using a Bio-Rad 
GS-690 Imaging Densitometer (Bio-Rad Laboratories Ltd, Hertfordshire, UK). 
Qualitative quantitation of RNA bands was performed using densitometry analysis 
(ImageJ software programme) (Appendix E).  
 Table 2.5. Thermocycle program conditions required for RT-PCR amplification. 
 
 
 
Phase Step Temperature  (˚C) Duration 
Cycle 
Number 
1 
denaturing 
annealing 
extension 
95 
dependent on target gene 
72  
2 minutes 
1 minute 
2 minutes 
1 x 
2 
denaturing 
annealing 
extension 
94  
dependent on target gene 
72 
1 minute 
30 seconds 
1 minute 
dependent 
on target 
gene 
3 denaturation 94  1 minute 1 x 
4 
final 
extension 
60  7 minutes 1 x 
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2.6 Western Blotting analysis 
2.6.1 Cell lysis 
For cell lysis, protease inhibitors were added immediately before use to the required 
volume of lysis buffer (0.61 g TRIS base (50 mM), 0.19 g EGTA (5 mM), 0.875 g NaCl 
(150 mM), 1 ml 1 % TritonX-100 (diluted in 1X PBS), 100 ml distilled water, pH 7.6) on 
ice (Table 2.6). Cells were then removed from the incubator, placed onto ice and 
briefly washed 3 times with PBS (1X) ensuring thorough drainage on the final wash. 
A sufficient volume of lysis buffer (dependent on cell container volume and cell 
density) to cover the surface of the culture dish was added and the cell material was 
collected using a disposable cell scraper and transferred into a 1.5 ml eppendorf. The 
cell lysate was incubated on ice for 5 minutes before centrifugation at 12, 000 rpm, 
4 ˚C for 15 minutes to remove insoluble cell debris. The resultant supernatant was 
then transferred to a clean eppendorf and stored at – 20 ˚C. 
Inhibitor 1 ml Lysis Buffer Final Concentration 
Sodium Orthovanadate (100 mM) 20 µl 2 mM 
Sodium Fluoride (2.5 M) 20 µl 50 mM 
Phenylmethylsulfonyl (100 mM) 10 µl 1 mM 
Sodium molybdate (1M) 10 µl 10 mM 
Phenylarsine (20 mM) 1 µl 20 µM 
Leupeptin (5 mg/ml) 2 µl 10 µg/ml 
Aprotinin (2 mg/ml) 4 µl 8 µg/ml 
Table 2.6. The volume of protease inhibitors required for 1 ml Lysis Buffer for cell lysis.  
2.6.2 Bio-Rad Detergent Compatible protein assay 
The concentration of total soluble protein contained within the collected cell lysates 
was determined using a Bio-Rad colorimetric Detergent Compatible (DCTM) protein 
assay which is a modified version of the Lowry protein assay (Lowry et al. 1951; 
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Peterson 1977). A standard curve was prepared in duplicate using 1.45 mg/ml BSA 
stock diluted in lysis buffer (described in Table 2.7). To each 1 ml cuvette was added, 
5 µl cell lysate diluted in 45 µl of lysis buffer. 250 µl Protein Assay Reagent A 
(containing 5 µl Protein Assay Reagent S) was then added to each cuvette followed 
by 2 ml Protein Assay Reagent B. The contents of the cuvettes were thoroughly mixed 
by pipetting and allowed to incubate for 5 minutes. The absorbance of the standard 
curve and cell lysate samples was then measured at 750 nM using a 
spectrophotometer (Cecil CE2041 Spectrophotomer, Cecil Instruments, Cambridge, 
UK) to obtain the total amount of protein contained within each lysate.   
BSA Concentration BSA Stock (1.45 mg/ml) Lysis Buffer Solution 
0 mg/ml 0 µl 50 µl 
0.247 mg/ml 8.5 µl 41.5 µl 
0.508 mg/ml 17.5 µl 32.5 µl 
0.754 mg/ml 26 µl 24 µl 
1.0 mg/ml 34.5 µl 15.5 µl 
1.45 mg/ml 50 µl 0 µl 
Table 2.7. The volume of BSA stock (1.45 mg/ml) and lysis buffer solution required for the final BSA 
concentration to generate a standard curve for a Bio-Rad Detergent Compatible protein assay.  
2.6.3 Preparation of samples for SDS-PAGE 
To prepare samples for SDS-PAGE, 3x Laemmli loading buffer (400 µl distilled water, 
3 ml SDS (20 %), 3 ml Glycerol, 3.6 ml TRIS base (0.5 M), 2 mg bromophenol blue, 24 
mg/ml dithiothreitol (DTT)) was added to each lysate. The volume of loading buffer 
added to each sample was calculated as 50 % of the total cell lysate volume. The 
lysates were then placed into a heating block for denaturation (Techne DRI-Block 
DB.2, Bibby Scientific Limited, Staffordshire, UK) and boiled at 100 ˚C for 5 minutes. 
Samples were briefly centrifuged for 5 seconds and stored at - 20˚C.  
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2.6.4 SDS-PAGE analysis 
Each gel for SDS-PAGE analysis was prepared as follows: 2 x 1.5 mm glass plates were 
cleaned with 70 % ethanol and placed into a casting stand (Bio-Rad Laboratories Ltd, 
Hertfordshire, UK). An 8 % resolving gel was prepared (Table 2.8) and poured 
between glass plates until ¾ full and overlaid with distilled water to prevent 
evaporation and produce a sharp interface between the resolving gel and stacking 
gel. Once set, the overlaying water was removed and a 4 % stacking gel was then 
prepared (Table 2.8) and poured on top of the resolving gel. A 10 or 15 well (1.5 mm) 
moulding comb (Bio-Rad Laboratories Ltd, Hertfordshire, UK) was then inserted into 
the stacking gel. The set gel/glass plate cassette was then assembled into the inner 
chamber of the electrophoresis unit as per manufacturer’s instructions (Bio-Rad 
Mini-Protean III apparatus power pack, Bio-Rad Laboratories Ltd, Hertfordshire, UK) 
and the inner and outer reservoir of the tank was filled with SDS-PAGE 1X running 
buffer (3.03 g TRIS Base, 14.4 g glycine, 1 g SDS in 1 L distilled water, pH 8.3). 5 µl 
protein molecular weight marker (Precision Plus ProteinTM All Blue Standards (10 – 
250 kDa)) was loaded into the first lane of the gel followed by 20 - 40 µg of cell lysate 
into the proceeding wells. Electrophoresis was performed at 120 volts constant 
current for approximately 90 minutes or until the marker reached the bottom of the 
gel.  
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Substrate 8 % Resolving Gel 4 % Stacking Gel 
Distilled water 4.6 ml 3.05 ml 
Lower buffer (1.5 M Tris pH 8.8) 2.5 ml - 
upper buffer (0.5 M Tris pH 6.6) - 1.25 ml 
30 % acrylamide/bis Acrylamide (29:1) 2.7 ml 650 µl 
10 % SDS (in distilled water) 100 µl 50 µl 
10 % APS (in distilled water) 100 µl 25 µl 
TEMED 10 µl 3 µl 
Table 2.8. The volume of substrates required to produce one electrophoresis gel with an 8 % resolving 
gel and a 4 % stacking gel.  
2.6.5 Western Blotting transfer 
Proteins separated by SDS-PAGE were transferred onto a protran B85 nitrocellulose 
membrane (0.45 µm pore size) using a Bio-Rad Protean III Mini Trans Blot apparatus 
(Bio-Rad Laboratories Ltd, Hertfordshire, UK). For each gel, a Western blot transfer 
cassette was assembled by placing a Teflon sponge fibre pad onto the side of the 
negative electrode followed by two filter papers, a nitrocellulose membrane cut to 
the size of the gel, SDS-PAGE electrophoresis gel, two filter papers and a Teflon 
sponge fibre pad (depicted in Figure 2.1). All components were pre-soaked in transfer 
buffer before assembly (800 ml distilled water, 3.03 g TRIS base, 14.4 g glycine, 200 
ml methanol). The cassette was then inserted into the Trans Blot module with the gel 
positioned nearest to the negative electrode. The module was then placed into a tank 
containing transfer buffer along with an ice block and a magnetic stirrer to maintain 
an even temperature and ion distribution. The transfer process was performed at 
100 volts constant current for 60 minutes for sufficient protein transfer.  
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2.6.6 Immunoprobing of Western blots 
The nitrocellulose membrane onto which the proteins were transferred was then 
removed from the transfer apparatus and washed briefly with 10 ml 1X Tris-Buffered 
Saline-Tween (TBS-Tween) (1.2 g TRIS Base, 8.7 g NaCl, 50 µl Tween20, pH 7.6 in 1 L 
distilled water). To assess the efficiency of protein transfer and loading, the 
membrane was briefly incubated in 10 ml Ponceau S solution (475 ml distilled water, 
25 ml acetic acid, 0.5 g Ponceau S powder) to stain the proteins. The membrane was 
subsequently washed with 1X TBS-Tween until the Ponceau S stain was completely 
removed. A blocking step was performed using 25 ml/membrane of 5 % non-fat dried 
Figure 2.1. A diagram to show the assembly of a Western blotting transfer apparatus. NC-
membrane represents the nitrocellulose membrane.  
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dry skimmed milk (Marvel) in 1X TBS-Tween (w/v) for 1 hour at room temperature 
on a rocking platform. The nitrocellulose membrane was then incubated on a roller 
bed at 4˚ C overnight or for 1 hour at room temperature with the appropriate primary 
antibody solution (9.5 ml 1X TBS-Tween, 500 µl Western blotting reagent, 100 µl 
sodium azide (1M) and diluted primary antibody). The dilution for each primary 
antibody used in this project is listed in Table 2.9 along with the corresponding 
antibody host species, incubation conditions, predicted molecular weight and source 
of purchase. Following incubation, the nitrocellulose membrane underwent 3 x 5 
minute washes with 1X TBS-Tween before incubation with a 1:10, 000 dilution of 
secondary antibody solution (0.1 g marvel dry skimmed milk, 10 ml 1X TBS-Tween, 1 
µl anti-mouse/anti-rabbit IgG HRP-secondary antibody) at room temperature for 1 
hour. Following incubation, the membrane underwent 4 x 5 minute washes with 1X 
TBS-Tween. Chemiluminescence was then performed using the appropriate 
luminol/peroxide based enhanced chemiluminescent (ECL) reagent (SuperSignalTM 
West Pico (high sensitivity), SupersignalTM West Dura (medium sensitivity) or 
SupersignalTM West Femto (low sensitivity)). The membrane was placed into a clean 
light-proof cassette and sufficient ECL reagent (prepared according to 
manufacturer’s instructions) to cover the blot (100 – 250 µl) was pipetted onto the 
membrane. X-ray films were exposed to the membranes for different lengths of time 
to obtain the optimal signal emitted from the protein of interest bound to the 
membrane. The X-ray films were then developed using an X-O-graph compact X2 X-
ray developer (Konica Minolta SRX-101A, Photon Imaging Systems Ltd, Wiltshire, UK). 
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X-ray films were scanned and quantitation of protein bands was performed using 
densitometry analysis (ImageJ software) (Appendix E). 
2.6.7 Primary antibody stripping of nitrocellulose membranes 
For detection of proteins on the same nitrocellulose membrane with a 
similar/identical molecular weight (e.g. phospho- and total proteins) the membrane 
was stripped of primary and secondary antibodies before being re-probed.  After the 
initial immunoblotting procedure was completed, the nitrocellulose membranes 
underwent 2 x 5 minute washes in 1X TBS-Tween, followed by 2 x 5 minute washes 
in distilled water. The membranes were then immersed in 10 ml RestoreTM Western 
blot Stripping Buffer (Thermo Fisher Scientific, UK) and incubated on a rocker for 10 
minutes at room temperature, followed by 2 x 5 minute washes in 1X TBS-Tween. To 
ensure the primary antibody had been completely removed, the membrane was re-
probed with secondary antibody (as described above) and underwent immuno-
detection. If no signal was emitted from the membrane using the appropriate ECL-
chemiluminescent reagent, it was assumed that the stripping protocol was 
successful. Nitrocellulose membranes were then probed with alternative primary 
and secondary antibodies and immuno-detection was carried out as described 
above.  
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Table 2.9. A list of primary antibodies used for Western blotting analysis in this project with their 
corresponding dilution, host species, incubation conditions, predicted molecular weight (MW) (kDa) 
and source of purchase. The abbreviations represent Cell Signalling Technology, UK. (CST, UK), 
overnight (O/N) and room temperature (RT). 
 
Antibody 
Host 
species 
Incubation 
conditions 
Dilution 
MW 
(kDa) 
Source of 
Purchase 
CD44 Standard 
(Clone 156-3C11) 
Mouse O/N 4 °C 1:1000 80 
Fisher 
Scientific, UK 
anti-CD44v3 
(Clone VFF-327) 
Mouse O/N 4 °C 1:1000 85 – 250  
R&D Systems, 
UK 
anti-CD44v6 
(Clone 2F10) 
Mouse O/N 4 °C 1:1000 85 - 250 
R&D Systems, 
UK 
anti-CD44v10 
(Clone VFF-14) 
Mouse O/N 4 °C 1:1000 90 - 250 
Thermo Fisher 
Scientific, UK 
anti-
RHAMM/CD168 
Rabbit O/N 4 °C 1:1000 25 - 85  Abcam, UK 
phospho-
HER2/ErbB2 
(Y1248) 
Rabbit O/N 4 °C 1:1000 185 CST, UK 
Total HER/ErbB2 Rabbit O/N 4 °C 1:1000 185 CST, UK 
phospho-EGFR 
(Y1068) 
Rabbit O/N 4 °C 1:1000 175 CST, UK 
Total EGFR Rabbit O/N 4 °C 1:1000 175 CST, UK 
phospho-c-Met 
(Y1234/1235) 
Rabbit O/N 4 °C 1:1000 145 CST, UK 
Total c-Met Rabbit O/N 4 °C 1:1000 145 CST, UK 
phospho-FAK 
(Y397) 
Rabbit O/N 4 °C 1:1000 125 CST, UK 
Total  FAK Rabbit O/N 4 °C 1:1000 125 CST, UK 
phospho-AKT 
(S473) 
Rabbit O/N 4 °C 1:1000 60 CST, UK 
Total AKT Rabbit O/N 4 °C 1:1000 60 CST, UK 
Phospho-Src 
(Y416), 
Rabbit O/N 4 °C 1:1000 60 CST, UK 
Total Src Rabbit O/N 4 °C 1:1000 60 CST, UK 
phospho-ERK1/2 
(T202/Y204) 
Rabbit O/N 4 °C 1:1000 42,44 CST, UK 
Total ERK1/2 Rabbit O/N 4 °C 1:1000 42,44 CST, UK 
β-actin Mouse 1 hr RT 1:20000 45 CST, UK 
GAPDH Mouse 1  hr RT 1:15000 37 CST, UK 
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2.7 Immunocytochemistry 
Log phase cells were seeded into 35 mm dishes containing Tespa-coated (Appendix 
F) glass coverslips at a density of 2 x 105 cells/dish and allowed to grow to 70 – 80 % 
confluency. After incubation the media was removed from the dishes and cells were 
fixed in 1 ml 2.5 % phenol formal saline (0.25g phenol dissolved in 10 ml formal saline 
solution (1.8 g NaCl, 20 ml formaldehyde, 180 ml tap water)) for 5 minutes. Cells were 
then washed with 1 ml 100 % ethanol for 5 minutes followed by 2 x 5 minute washes 
in 1 ml 0.02 % PBS/Tween (100 µl Tween20 diluted in 500 ml PBS (0.1 M). To each 
coverslip, 50 µl primary antibody diluted in 1 % BSA/PBS (CD44 Std: 1/1200, CD44v3 
(1/40), CD44v6 (1/40), CD44v10 (1/50), RHAMM (1/50)) was added for 60 minutes. 
Cells were then washed with 0.02 % PBS/Tween for 2 x 5 minutes. Secondary 
antibody detection was performed by adding 50 µl/coverslip Dako mouse EnVision 
(Dako Envision+ system-HRP labelled polymer anti-mouse) for 30 minutes. Cells were 
then washed with 1 ml 0.02 % PBS/Tween for 2 x 5 minutes. Cells were then 
incubated with 50 µl/coverslip Dako 2,3-diaminobenzidine (DAB)/substrate 
chromogen system solution for 8 minutes followed by 3 x 5 minute washes in 1 ml 
distilled water. Counterstaining was performed using 1 ml/dish 0.05 % methyl green 
(dissolved in water) for 10 minutes followed by 3 x 5 minute washes in distilled water. 
The coverslips were then dried in a heating and drying oven (KelvitronR  t, Heraeus, 
Thermo Scientific, UK) for 1 hour and mounted onto glass microscope slides (1.0 – 
1.2 mm) using di-butylpthalatexylene (DPX) mountant (a mixture of Distyrene, a 
plasticizer, and xylene). 
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2.7.1 Analysis of immunocytochemical and immunohistochemical staining using H-
Scoring 
Cells were analysed using a light microscope (Olympus BH-2) at x10 magnification 
and photographs were taken at x20/x40 magnification. A modified histochemical 
score (H-score) method was used for semi-quantitative analysis of both the intensity 
and percentage positivity immunostaining of cells. For H-score evaluation, 6 fields of 
view/sample were analysed. To assess plasma membrane and cytoplasmic intensity, 
a score of 0 – 3 was given for each sample corresponding to negative (0), weak (1), 
moderate (2) and strong (3) immunostaining. The percentage plasma membrane and 
cytoplasmic immunostaining positivity was also estimated. Together these values 
were used to derive a total H-score value for each sample using the following 
formula: (% at 0) x 0 + (% at 1) x 1 + (% at 2) x 2 + (% at 3) x 3 to give an overall score 
ranging from 0 – 300. H-score evaluation has been successfully used for 
immunocytochemical and immunohistochemical analysis and TMA evaluation as 
seen in Rimm et al. 2001, Ginestier et al. 2002 and Callaby et al. 2003. 
2.8 Immunofluorescence 
Log phase cells were seeded into 35 mm dishes containing glass coverslips at a 
density of 2 x 105/dish and allowed to grow until cells reached 70 – 80 % confluency. 
After incubation the media was removed and the cells were fixed in 1 ml 3.7 % 
formaldehyde (diluted in 0.01 M PBS) for 10 minutes. Cells were then briefly washed 
3 times with 1 ml PBS (0.01 M). Permeabilisation was performed using 200 
µl/coverslip 0.2 % Triton-X 100 (diluted in 0.01 M PBS) for 8 minutes. Cells were then 
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briefly washed 3 times with 1 ml 0.01 M PBS. Blocking was performed using 200 
µl/coverslip 10 % normal goat serum (diluted in 1 % BSA in 0.01 M PBS solution) for 
20 minutes. The washing step was repeated with PBS. Primary antibody detection 
was performed using 200 µl/coverslip of appropriate antibody (1:100 dilution with 1 
% BSA in 0.01 M PBS solution) for 30 minutes. The wash step with PBS was then 
repeated. Secondary antibody detection was performed using 200 µl/coverslip Alexa 
Fluor 488 (anti-mouse) or 594 (anti-rabbit) conjugated secondary antibodies (1:1000 
dilution in 1 % BSA in 0.1 M PBS solution) for 30 minutes. The wash step with PBS was 
repeated. Coverslips were drained and mounted onto slides using DAPI-containing 
Vectashield mountant. The cells were analysed using a fluorescent microscope (Leica 
DMiI, Leica Microsystems Ltd, Milton Keynes, UK) at x63 magnification. For analysis, 
6 fields of view/coverslip were photographed and cell immunofluorescence was 
quantitated using a previously published approach (Burgess et al. 2010, Gavet and 
Pines 2010 and Potapova et al. 2011), details of which are described in Appendix G.  
2.9 Boyden Chamber migration assay 
In vitro cell migration was measured using 24 well plates containing Corning Standard 
Transwell porous polycarbonate inserts (6.5 mm, 8 µm pore size). Before use, the 
underside of each polycarbonate membrane was coated with 300 µl fibronectin (10 
µl/ml) diluted in 1X tissue culture grade PBS (PBS) and incubated at 37 ˚C for 2 hours. 
Following coating, insert membranes were washed twice with PBS and allowed to air 
dry. 600 µl of the appropriate experimental media (± treatments) was placed into the 
lower chamber of each well and air-dried inserts were placed into the wells taking 
care to avoid air bubble formation. Cells were then trypsinised and resuspended in 
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experimental media at 2 x 105 cells/ml and 200 µl cell suspension was placed into the 
upper chamber of each insert to obtain a cell density of 40,000 cells/insert. Transwell 
plates were then returned to the incubator for 24 hours to allow cells to migrate to 
the underside of the membrane. Following incubation, the transwell plates were 
removed from the incubator and media contained in the upper chamber of the insert 
was removed using a pipette. Any cells remaining on the upper surface of the 
membrane (non-migratory cells) was removed by gentle swabbing using a cotton 
bud. Inserts were then placed into wells containing 600 µl 3.7 % formaldehyde 
diluted in PBS for 10 minutes to fix cells that had migrated to the underside of the 
membrane. Following fixation, inserts were removed and washed twice with PBS 
(1X). Inserts were then added to wells containing 600 µl 0.5 % crystal violet for 30 
minutes to stain fixed cells for viewing under the microscope. Following staining, 
inserts were washed twice with PBS and allowed to air dry. Upon analysis using a 
light microscope (Olympus BH-2) at X20 objective, 6 fields of view/insert were 
assessed to obtain the average cell number count for each insert. Each determination 
represents the average of 3 individual experiments, each performed in duplicate. 
2.10 Boyden Chamber invasion assay 
In vitro cell invasion was measured using 24 well plates containing Corning Standard 
Transwell porous polycarbonate inserts (6.5 mm, 8 µm pore size). Insert membranes 
were coated on their upper surface with 50 µl Matrigel (9.6 mg/ml) (diluted in 
WRPMI (1:3)) and incubated at 37˚C for 2 hours. 600 µl of the appropriate 
experimental media (± treatments) was placed into the lower chamber of each well 
and air-dried inserts were placed into the wells taking care to avoid air bubble 
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formation. Cells were then trypsinised and resuspended in experimental media at 2 
x 105 cells/ml and 200 µl cell suspension was placed into the upper chamber of each 
insert to obtain a cell density of 50,000 cells/insert. Transwell plates were then 
returned to the incubator and cells were allowed to invade to the underside of the 
membrane for 3 days. Following incubation, the transwell plates were removed from 
the incubator and media contained in the upper chamber of the insert was removed 
using a pipette. The Matrigel and any remaining (non-invasive) cells was then 
removed from the upper surface of the membrane using a cotton bud by gentle 
swabbing. Inserts were then placed into wells containing 600 µl 3.7 % formaldehyde 
in PBS (1X) for 10 minutes to fix cells that had invaded to the underside of the 
membrane. Following fixation, inserts were removed and washed twice with PBS (1X) 
and allowed to air dry for 1 hour. The membrane from each insert was then excised 
using a scalpel blade and placed cell side up onto a glass microscope slide (1.0 – 1.2 
mm) containing a drop of DAPI-containing Vectashield hardset mountant. An 
additional drop of the Vectashield mountant was then added to the top of the insert 
and overlaid with a glass coverslip. The slides were allowed to set at room 
temperature and stored at 4 ˚C. For quantification of the number of cells that had 
invaded to the underside of each membrane, the slides were analysed using a 
fluorescent microscope (Leica DMiI, Leica Microsystems Ltd, Milton Keynes, UK) and 
cell nuclei counts and photographs were taken from 6 fields of view at X63 
magnification. Each determination represents the average of 3 individual 
experiments.  
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2.11 Coulter Counter proliferation assay  
Log phase cells were harvested and seeded into a 24 well plate at a density of 1 x 106 
cells/plate and returned to the incubator for 24 hours. Following incubation the 
media was removed and replaced with 1 ml/well experimental media (± treatments) 
and returned to the incubator for the required incubation time. The media was 
replaced every 3 days. After the treatment time had elapsed the media was removed 
and 1 ml trypsin was added to each well and incubated until cells were in suspension. 
To each well 1 x 3 ml Isoton was added and drawn into a sterile 25G 5 ml syringe to 
separate cells into a single cell suspension and this solution was added to 6 ml Isoton. 
The 10 ml Isoton cell suspension was counted twice on a Coulter counter (CoulterTM 
Multisizer II (Beckam Coulter UK, Ltd, High Wycombe, UK) according to 
manufacturer’s instructions. The average count was multiplied by 20 to calculate 
cells/well.  
2.12 Genetic Manipulation of CD44 expression  
In this project, CD44 expression was manipulated in endocrine resistant and sensitive 
cell models by siRNA knockdown or transfection respectively in order to determine 
the role of CD44 in cellular behaviours. 
2.12.1 siRNA-mediated CD44 suppression  
Global CD44 expression was suppressed in endocrine resistant cells using a pool of 
CD44 siRNAs supplied by Dharmacon. Similarly, RHAMM expression was suppressed 
using a pool of RHAMM siRNAs obtained from Santa Cruz Biotechnology. For specific 
knockdown of CD44v6, an siRNA sequence was designed using the Invitrogen online 
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stealth RNAiTM siRNA design tool, BLOCK-iTTM RNAi Designer 
(http://rnaidesigner.lifetechnologies.com/rnaiexpress/) from the gene sequence 
encoding the CD44v6 exon obtained from the online NCBI database (Appendix C). 
This programme allowed the consideration of GC content and knockdown probability 
as calculated by the online tool for each sequence generated. Once the siRNA 
sequence was selected, the corresponding DNA sequence was inputted into the 
online bioinformatics programme BLAST which compared sequence similarity to 
other DNA sequences across the human genome. BLAST analysis confirmed the high 
level of specificity for the CD44 and CD44v6 siRNA sequences used within this project 
(listed in Table 2.10) to their respective gene target, however RHAMM specificity 
could not be determined as these sequences were not supplied. For additional 
confirmation, the gene sequences for CD44 and CD44v6 obtained from the NCBI 
online database were used to verify siRNA sequence target specificity (Appendix C). 
Target siRNA, their corresponding RNA sequences and source of purchase for all 
siRNAs used within this project are detailed in Table 2.10. 
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Target 
siRNA 
RNA sequences Source 
  
CD44 
(total) 
GAAUAUAACCUGCCGCUU 
CAAGUGGACUCAACGGAGA 
CGAAGAAGGUGUGGGCAGA 
GAUCAACAGUGGCAAUGGA 
ON-TARGETplus SMARTpool 
Human CD44) Thermo 
scientific Dharmacon,  
Leicestershire, UK 
        
CD44v6 
   
CAGAUGGCAUGAGGGAUUCGCCAA 
BLOCK-iTTM RNAi Designer, 
InvitrogenTM, 
 Life Technologies, UK 
 
RHAMM  
 
siRNA pool sequences not supplied 
RHAMM siRNA Santa Cruz 
Biotechnology, Inc.  
Heidelberg, Germany 
NT-siRNA 
(control) 
UGGUUUACAUGUCGACUAA 
UGGUUUACAUGUUGUGUGA 
UGGUUUACAUGUUUUCUGA 
UGGUUUACAUGUUUUCCUA 
ON-TARGETplus control pool 
Non-Targeting Pool, Thermo 
scientific Dharmacon,  
Leicestershire, UK 
Table 2.10.  A list of target siRNA, RNA sequences and source of purchase for all siRNAs used within 
this project. 
2.12.2 CD44 siRNA transfection protocol 
Log phase cells were seeded into 35 mm dishes (2 x 105 cells density) in experimental 
media without the presence of antibiotics and returned to the incubator until 50 % 
cell confluency was reached. To achieve a working solution of 100 nM, siRNA stock 
solution was diluted to 2 µM using 1 x siRNA buffer (5 x siRNA buffer diluted in sterile 
RNase free water). Table 2.11 lists the 3 control arms that were used for each siRNA 
experiment: control (cells grown in experimental media), lipid-only (cells incubated 
with lipid transfection reagent only (DharmaFECT 1 Transfection Reagent)) and non-
targetting (NT)-siRNA (negative control siRNA, described in Table 2.10). The 
constituents for each sample were assembled into 2 sterile eppendorf tubes (A and 
B) according to Table 2.11, mixed by gentle pipetting and incubated at room 
temperature for 5 minutes. The eppendorfs (A and B) for each sample were then 
combined, mixed by gentle pipetting and incubated at room temperature for 20 
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minutes. Each sample was then diluted 1:5 in warmed media (WRPMI containing 5% 
SFCS, 2 % glutamine, no antibiotics). Experimental media was removed from the 35 
mm dishes and replaced with 1 ml siRNA control or transfection media. Dishes were 
gently rocked to ensure even coverage of transfection media and returned to the 
incubator for 48 hours to allow sufficient siRNA protein knockdown before harvesting 
the cells for experimental purposes. 
Table 2.11. The volumes required for the transfection of 35 mm dishes at a working solution of 100 
nM. All volumes are in µl.  
2.12.3 Transformation of plasmid DNA 
To determine the role of CD44 in endocrine sensitive MCF-7 cells that express low 
levels of endogenous CD44, a transfection-based method was used. Plasmid DNA 
constructs containing CD44v3 and CD44v6 isoforms and their cytoplasmic tail 
truncation mutation counterparts (denoted as CD44v3∆cyt and CD44v6∆cyt 
respectively) were a kind gift from Dr Ursula Gunthert (Basel University, Switzerland). 
Each plasmid construct is fused with an EGFP-tag at the carboxy terminus and 
contained in a p-PGKT-T7/2 vector (plasmid map shown in Appendix H). Previous use 
of these plasmids are found in the 2006 and 2007 publications by Mielgo et al.  
 
100 nM 
working 
Solution 
Control Lipid-only NT-siRNA 
Target-specific 
siRNA 
Eppendorf A B A B A B A B 
WRPMI 100  100 100 98.4 50 98.4 50 98.4 
2 µM siRNA - - - - 50 - 50 - 
Dharmafect #1 - - - 1.6  1.6  1.6 
Total Volume 200 200 200 200 
  
 
 
 
77 
 
2.12.3.1 Recovering plasmid DNA from filter paper 
Plasmid DNA constructs were sent embedded onto filter papers. To extract the 
plasmid DNA, each filter paper was placed into a 1.5 mm sterile eppendorf tube and 
immersed in 100 µl TE buffer (10 mM Tris, 1 mM EDTA), briefly vortexed and 
incubated at room temperature for 15 minutes. 1 - 10 µl of this solution was then 
removed from the eppendorf and added to 100 µl DH5α competent E.coli cells. The 
remainder of the plasmid DNA/TE buffer solution was stored at -20 ˚ C as a permanent 
archive.  
2.12.3.2 Transformation procedure 
DH5α E.coli cells were thawed on wet ice. Once thawed, 100 µl DH5α cells were 
placed into the required number of 17 x 100 mm polypropylene tubes on ice and 
gently mixed. Any unused DH5α cells were refrozen in a dry ice/ethanol bath for 5 
minutes before returning to -70 ˚C for storage. To determine transformation 
efficiency, a control of 5 µl stock pUC19 solution (0.01 µg/ml) was added to a 
polypropylene tube containing 100 µl DH5α E.coli cells and the tube was mixed by 
gentle tapping. 1 – 10 ng of plasmid DNA/TE solution was added to a polypropylene 
tube containing 100 µl DH5α cells and the tube was mixed by gentle tapping. The 
tube was then allowed to incubate on ice for 30 minutes. The DH5α cells were heat 
shocked in a 42 ˚C water bath (Grant W14, Grant Instruments, UK) for 45 seconds to 
allow entrance of the plasmid and immediately placed onto ice for 2 minutes to 
reclose the cell walls. 900 µl room temperature Super Optimal broth with Catabolite 
repression (SOC media, nutrient rich bacterial growth medium for maximal 
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transformation efficiency of E.coli cells) was then added to each polypropylene tube 
and the tubes were incubated for 1 hour with vigorous shaking, 37 ˚C, 225 rpm 
(Gallenkamp cooled orbital incubator, Sanyo, UK). Following incubation, the control 
pUC19 and experimental plasmid were each diluted 1:100 with SOC media. 100 µl of 
each of these diluted media was then spread onto individual LB agar plates 
containing 100 µg/ml ampicillin and the plates were incubated upside down 
overnight at 37 ˚ C. After the overnight incubation a single colony from each plate was 
selected and inoculated in a starter culture containing 2 ml warm LB media with 100 
µg/ml ampicillin. The starter cultures were contained in a vessel of at least 4 times 
the volume of the culture and incubated with vigorous shaking for 8 hours at 37 ˚C, 
300 rpm (Gallenkamp cooled orbital incubator, Sanyo, UK). Following incubation, the 
starter culture was diluted 1:1000 into selective warm LB medium containing 100 
µg/ml ampicillin. The cultures were contained in a vessel of at least 4 times the 
volume of the culture and incubated with vigorous shaking for 14 hours at 37 ˚C, 300 
rpm (Gallenkamp cooled orbital incubator, Sanyo, UK).  
2.12.3.3 Harvesting bacterial cells for collection and purification of plasmid DNA 
The bacterial cells were then harvested and purified using an Endotoxin Free Plasmid 
Maxiprep Kit (10) (QIAGEN Ltd, Manchester, UK #12632), all equipment and reagents 
used for this process were enclosed within the kit upon purchase. Table 2.12 lists all 
reagents used with their corresponding composition, storage temperature and 
function. After the 14 hour incubation, bacterial cells were transferred into a sterile 
container and centrifuged at 6000 rpm for 15 minutes, 4 °C (Sorvall RC5B PLUS, 
Thermo Scientific, UK). The bacterial pellets were then resuspended in 10 ml pre-
  
 
 
 
79 
 
chilled (4 °C) Buffer P1 (containing RNase and pre-mixed with LyseBlue reagent) by 
pipetting until no cell clumps remained. 10 ml Buffer P2 was then added to the 
solution and mixed thoroughly by vigorously inverting the sealed tube 4 – 6 times 
and then incubated at room temperature for 5 minutes. 10 ml pre-chilled (4 °C) 
Buffer P3 was then added to the lysate and mixed immediately and thoroughly by 
vigorously inverting the sealed tube 4 – 6 times. The lysate was then immediately 
poured into the barrel of the QIAfilter Cartridge (with the cap screwed onto the outlet 
nozzle and placed in a convenient tube) and incubated at room temperature for 10 
minutes ensuring the cartridge was not agitated during this incubation period. The 
cap from the QIAfilter cartridge outlet nozzle was then removed, the plunger was 
gently inserted into the cartridge and the cell lysate was filtered into a 50 ml sterile 
falcon tube recovering approximately 25 µl of the lysate. 2.5 ml of Buffer ER was then 
applied to the filtered lysate, mixed by inversion 10 times and incubated on ice for 
30 minutes. During the incubation period, a QIAGEN-tip 500 column was equilibrated 
by applying 10 ml Buffer QBT and the column was allowed to empty by gravity flow. 
After incubation, the filtered lysate was then applied to the equilibrated QIAGEN-tip 
500 column and allowed to enter the resin by gravity flow. The QIAGEN-tip 500 
column was then washed twice with 30 ml Buffer QC and allowed to empty by gravity 
flow. The DNA attached to the column was then eluted with 15 ml Buffer QN and 
collected in a 30 ml endotoxin/pyrogen-free tube. The DNA was then precipitated by 
adding 10.5 ml (0.7 volumes diluted with RNase free water) room-temperature 
isopropanol to the eluted DNA, mixed and centrifuged immediately at 9000 rpm for 
30 minutes, 4˚C. The supernatant was then carefully decanted at room temperature 
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and the resultant DNA pellet was washed with 5 ml endotoxin-free room 
temperature 70 % ethanol and centrifuged at 9, 000 rpm for 10 minutes. The 
supernatant was carefully decanted without disturbing the DNA pellet and allowed 
to air dry for 5 – 10 minutes. The DNA pellet was then re-dissolved in 100 µl of 
endotoxin-free Buffer TE without pipetting the DNA up and down to avoid shearing. 
The DNA yield was then determined by UV spectrophotometry at 260 nm and 
quantitative analysis on a 2 % agarose gel. DNA concentration (µg/ml) and purity was 
quantified using the DNA260/280 programme on the spectrophotometer where A260 
readings should lie between 0.1 and 1. To measure DNA concentration, 1 ml 1X TNE 
buffer (100 µl 10X TNE buffer in 900 µl RNAse free water) was placed into a glass 
cuvette and used as a blank. 2 µl DNA sample was added to 1 ml 1X TNE buffer and 
placed into the glass cuvette, the absorbance was measured at 260 nm (A260) on the 
spectrophotometer (Cecil CE2041, Cambridge UK). DNA concentration was 
calculated using the following formula: DNA = A260 x 50 x dilution factor. DNA integrity 
was also assessed via gel electrophoresis for each sample. Samples were stored at - 
20 ° C.  
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Component Composition Storage (°C) Function 
Buffer P1 
50 mM Tris HCI pH 8 
100 mM EDTA 
100 µg/ml RNase A 
2 - 8 
Resuspension buffer 
  
Buffer P2 
200 mM NaOH 
1 % SDS (w/v) 
15 – 25 Lysis buffer 
Buffer P3 
3 M potassium acetate 
pH 5.5 
2 - 8 Neutralisation buffer 
Buffer ER Not disclosed 15 - 25 
Endotoxin removal 
buffer 
Buffer QBT 
750 mM NaCl 
50 mM MOPS pH 7 
15 % isopropanol (v/v) 
0.15 % triton-X-100 
15 – 25 Equilibration buffer 
Buffer QC 
1 M NaCl 
50 mM MOPS pH 7 
15 % isopropanol (v/v) 
15 - 25 
Wash buffer 
(removes excess salt 
residues/contaminants) 
Buffer QN 
1.6 mM NaCl 
50 mM MOPS pH 7 
15 % isopropanol (v/v) 
15 - 25 
Elution buffer 
 
Isopropanol 
70 % isopropanol 
30 % sterile water 
15 - 25 
Precipitates DNA 
Removes excess salts 
Ethanol 
70 % ethanol 
30 % endotoxin-free 
water 
15 - 25 Removes excess salts 
TE buffer 
10 mM Tris Cl pH 8 
1 mM EDTA 
15 - 25 
Solubilised DNA  
Protects from DNA 
degradation 
Table 2.12. A list of the components purchased with the Endotoxin-Free Plasmid Maxiprep kit (10) 
(QIAGEN, Manchester, UK) detailing their composition, storage temperature and function.  
2.12.4 DNA sequencing of plasmid constructs 
The successful transformation of the plasmid constructs was verified by DNA 
sequencing. The plasmid constructs and corresponding primers were transferred on 
dry ice to the CBS where they underwent a clean-up procedure and DNA sequencing 
analysis. To obtain an accurate read, each CD44 plasmid construct underwent a 
sequence reaction with 3 primers including: T7 promoter primer, CD44 Std forward 
primer and CD44v3/CD44v6 primer (dependent on plasmid construct). Table 2.13 
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lists each primer used for DNA sequence and their corresponding sequence, 
concentration and source of purchase. The sequencing results files were then 
analysed using the Chromas Lite software programme 
(http://technelysium.com.au/) and the DNA sequences for each plasmid construct 
are shown in Appendix I. To determine whether any changes in DNA base pair 
sequence resulted in amino acid changes in the protein structure, the DNA sequence 
obtained for each plasmid was uploaded onto the online protein translation tool 
ExPasy (http://web.expasy.org/translate/) and the results are shown in Appendix I). 
Primer Sequence Source of Purchase 
T7 promoter 
5’-TAATACGACTCAC 
TATAGGG-3’ 
Integrated DNA Technologies, Belgium 
CD44 Std 
5’-GACACATATTGC 
TTCAATGCTTCAGC-3’ 
Life Technologies Inc, UK 
CD44v3 
5’-CGTCTTCAAAT 
ACCATCTCAGC-3’ 
Life Technologies Inc, UK 
CD44v6 
5’-CAACGGAAGA 
AACAGCTACCC-3’ 
Life Technologies Inc, UK 
Table 2.13. A list of each primer sent to the CBS for DNA sequencing analysis of the plasmid constructs 
along with their corresponding sequence and source of purchase. 
2.12.5 CD44 transient transfection protocol 
MCF-7 cells were seeded (2 x 105 cells density) into 35 mm dishes in RPMI with 5 % 
FCS (no antibiotics) and incubated at 37 ˚C until cells reached 50 % cell confluency. 
For transfection of one 35 mm dish, 117.5 µl pre-warmed RPMI was combined with 
7.5 µl FuGENE 6 transfection reagent, mixed by pipetting and incubated for 5 minutes 
at room temperature. 100 ng plasmid DNA was added to each eppendorf (3:1 
FuGENE 6:DNA), mixed by gentle pipetting and incubated for 15 minutes at room 
temperature. 125 µl transfection solution was then added to 1.5 ml RPMI with 5 % 
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FCS (no antibiotics) and placed into a 35 mm dish. Dishes were rocked gently to 
ensure even coverage of transfection media and returned to the incubator for 48 
hours before harvesting to allow optimal transfection to occur.  
2.13 Statistical analysis 
In the results chapters, all data from 3 independent experiments are shown or 
representative images/immunoblots are presented. Statistical analysis of the results 
were carried out where data allowed. Where replicates were performed, 
quantitative data are presented as standard error of the means (SEM). For 
comparison between two groups, paired/unpaired student’s t-tests were performed. 
For comparisons between 3 or more groups, a one-way ANOVA was carried out with 
Tukey post-hoc analysis. Significance was determined as p < 0.05. 
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3. Characterisation of CD44 isoform expression in endocrine resistant 
breast cancer cell models versus their endocrine sensitive counterpart 
3.1 Introduction 
Whilst a large body of evidence has been gathered to support a role for CD44 as a 
significant factor in tumour progression, this area remains controversial due to 
contradictory findings and a lack of clear association between CD44 expression and 
clinical outcome. Indeed, CD44 has been heavily implicated as a contributor towards 
the metastatic phenotype of numerous carcinomas including breast, pancreatic and 
ovarian, however, whilst some studies report that elevated CD44 expression 
correlates with poor prognosis in these carcinomas (Takada et al. 1994; Looi et al. 
2006; Li et al. 2008a; Huh et al. 2009; Klingbeil et al. 2010; Auvinen et al. 2014) others 
suggest that the presence of CD44 associates with a favourable outcome (Sillanpaa 
et al. 2003; Diaz et al. 2005; Lopez et al. 2005; Al-Maghrabi et al. 2012; Takahara et 
al. 2012). Furthermore, reports have suggested that both overexpression 
(Lokeschwar et al. 1995; Hao et al. 2012) and loss (Verkaik et al. 2000; Kito et al. 2001) 
of CD44 is associated with advanced progression and metastasis of prostate cancer. 
One aspect which makes CD44 difficult to study and undoubtedly contributes to 
variability between studies is the extensive alternative splicing attributed to this 
molecule. Thus a possible explanation for these discrepancies may lie in the fact that 
a high proportion of studies have analysed total CD44 expression and not taken into 
account the differential expression of specific CD44 variant isoforms. For example, it 
has been extensively established that individual CD44 exons have the potential for 
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the addition of specific post-translational modifications thus conferring differential 
affiliation for membrane receptor binding and ligand sensitivity (Jalkanen et al. 1988; 
Bennet et al. 1995; Hasenauer et al. 2013). Therefore, the incorporation of specific 
exons into the CD44 molecule via alternative splicing may lead to novel cell functions 
through association of these molecules with, and subsequent activation of, various 
growth factor receptors and their downstream targets. Indeed, alternative splicing, 
a phenomenon known to be upregulated in cancer cells, allows for the formation of 
an extensive array of CD44 isoforms, each with a potentially distinct function with 
regards to their role in cancer development (Goldstein and Butcher 1990; 
Stamenkovic et al. 1991; Screaton et al. 1992).  
With relation to the characterisation and function of specific CD44 isoforms in breast 
cancer, this area remains largely unstudied, however multiple reports present 
convincing evidence for the role of several individual isoforms in breast cancer 
progression (Cheng et al. 2006; Lian et al. 2006; Afify et al. 2009; Lida et al. 2014), 
although these reports have also been contradictory. Olsson et al. 2011 published 
findings indicating that individual CD44 isoform expression may be associated with 
specific breast cancer characteristics and molecular subtypes and may also 
contribute to specific oncogenic signalling pathways. In addition, previous studies by 
the BCMPG (Hiscox et al. 2012) suggested a role for CD44 expression in acquired 
tamoxifen-resistance where it correlated with an enhanced migratory phenotype. 
However, given the lack of knowledge regarding the role of individual CD44 isoforms 
in cancer, particularly within the context of acquired endocrine resistance, this was 
explored further in this project.  
  
 
 
 
86 
 
To begin these studies, it was first necessary to characterise CD44 variant isoform 
expression in endocrine sensitive MCF-7 cells along with two endocrine resistant cell 
models, a tamoxifen-resistant (Tam-R) and fulvestrant-resistant (Fas-R) cell line, both 
derived from MCF-7 cells (see Materials and Methods 2.2.1). For the purpose of this 
project, it was decided to focus on CD44 Std, CD44v3, CD44v6 and CD44v10 as these 
isoforms have previously been identified as markers of poor prognosis and related to 
tumour progression functions in breast cancer (Kalish et al. 1999; Herrera-Gayol and 
Jothy 1999; Bourguignon et al. 2008; Afify et al. 2009; Lida et al. 2014; Fahe et al. 
2014). An important aspect of CD44-mediated function is its ability to bind to its 
principle ligand HA, an extracellular matrix component abundantly expressed in 
breast carcinomas and correlated with poor outcome (Auvinen et al. 2000; Auvinen 
et al. 2014). Therefore, in addition to CD44, alternative members of the HA-binding 
family (hyaladherins) which have been implicated in breast cancer progression were 
also investigated to evaluate their contribution to the endocrine resistant phenotype 
of Tam-R and Fas-R cells.  
3.1.1 Objectives 
1. To explore the expression of CD44 variant isoforms and additional 
hyaladherin family members across endocrine sensitive and endocrine 
resistant cell models at gene level using an existing microarray database. 
2. To validate microarray gene expression data by RT-PCR analysis. 
3. To determine hyaladherin expression and cellular localisation at protein level 
by Western blotting, immunocytochemistry and immunofluorescence 
analysis.  
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3.2 Results 
3.2.1. Analysis of hyaladherin family member gene expression in cells models of 
acquired endocrine resistance compared to their endocrine sensitive counterpart 
Of the multiple hyaladherins identified to date, several have been implicated in 
breast cancer progression including: RHAMM (HMMR) (Wang et al. 1998; Hamilton 
et al. 2007; Maxwell et al. 2011), lymphatic vessel endothelial hyaluronan acid 
receptor 1 (LYVE-1) (Bono et al. 2004), Stabilin 2 (STAB2) (Hirose et al. 2012), Toll-like 
receptor 4 (TL4) (Yang et al. 2010; Yang et al. 2013) versican (VCAN) (Du et al. 2013) 
and intracellular adhesion molecule 1 (ICAM-1) (Rosette et al. 2005; Guo et al. 2014). 
Therefore the gene expression of these hyaladherins, along with CD44, were 
assessed using affymetrix analysis. 
Following the completion of microarray gene expression profiling of RNA samples 
from the cell models, the resultant triplicate expression data for each gene analysed 
was uploaded into the software analysis programme GeneSifter (see Materials and 
Methods 2.3). Using this programme, the raw data underwent median normalisation 
and log transformation which led to the construction of heatmap profiles and log2 
intensity plots for the visualisation of individual gene expression changes across the 
cell models. In some instances, the affymetrix U133A gene chips contained more than 
one probe set ID for each gene. Therefore upon analysis, particular importance was 
placed upon the best performing ‘Jetset’ probe for each gene which was determined 
by the online Jetset programme based upon the performance of each probe across 
three parameters (shown in Table 3.1). Figure 3.1 reveals the heatmap profile for 
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each gene probe assessed within this project along with log2 intensity plots 
displaying the average normalised data (±SEM) for each Jetset probe (with their 
corresponding fold change values shown in Table 3.2). Heatmap analysis revealed 
that the expression of the majority of gene probes corresponding to LYVE-1, STAB2, 
TL4, ICAM-1 and VCAN in Tam-R and Fas-R cells were either reduced or unaltered 
compared to MCF-7 cells. Furthermore, the detection calls for each Jetset probe 
corresponding to these genes were absent in all cell lines and the log2 expression 
values were below 0, indicative of absent/very low expression of these genes across 
all cell models. Statistical analysis to compare gene fold changes revealed that STAB2 
expression was significantly reduced in Tam-R and Fas-R cells compared to MCF-7 
cells (Table 3.2) however these data may be unreliable as the detection of this gene 
was determined as absent across these cells. No other statistically significant 
differences in fold changes for these gene probes were detected across all cell 
models.  
In contrast, heatmap analysis revealed increased HMMR gene expression in Tam-R 
and Fas-R cells compared to MCF-7 cells (Figure 3.1). Detection calls revealed that 
HMMR was present in both endocrine resistant cell models but absent in MCF-7 cells 
(Table 3.1) which was confirmed by the log2 expression values from the Jetset probe 
(Figure 3.1). Fold change analysis revealed substantially enhanced HMMR gene fold 
changes in both Tam-R and Fas-R cells compared to MCF-7 cells however these 
changes were not statistically significant (Table 3.2). Additionally, heatmap analysis 
revealed that the majority of gene probes corresponding to CD44 showed enhanced 
gene expression in Tam-R and Fas-R cells compared to MCF-7 cells. However, these 
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probes showed poor ‘overall scores’ (Table 3.1) and thus data for these genes may 
be unreliable. The Jetset probe for CD44 (indicated on row 5 of the heatmap profile) 
appeared as ‘present’ across all cell models suggesting that CD44 is expressed within 
these cells. Furthermore, log2 expression and fold change analysis for the Jetset 
probe revealed enhanced CD44 expression in Fas-R cells, but not Tam-R cells, 
compared to MCF-7 cells and statistical testing revealed a significant increase in gene 
fold change in Fas-R cells compared to both MCF-7 and Tam-R cells (Table 3.2). Based 
on these data, CD44 and HMMR expression were explored further in these cell 
models. 
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Gene 
Probe Set 
 ID 
Specificity 
Score 
Cover 
Score 
Robust 
Score 
Overall 
Score 
Detection Call 
(MCF-7/Tam-R/Fas-R) 
HMMR 207165_at 1 1 0.8064 0.8064 A/P/P 
CD44 209835_x_at 0.8182 0.8421 0.0037 0.0026 P/P/P 
CD44 204489_s_at 0.9091 0.8947 0.115 0.0093 M/M/P 
CD44 212014_x_at 0.8182 0.8421 0.0036 0.0025 P/P/P 
CD44 212063_at 0.8182 0.8947 0.4285 0.3508 P/P/P 
CD44 210916_s_at 0.8182 1 0.0005 0.0004 A/A/P 
CD44 204490_s_at 0.9091 0.8947 0.0037 0.003 P/P/P 
CD44 217523_at - 1 - - A/A/P 
HMMR 209709_s_at 0.901 1 0.4785 0.3896 A/P/P 
LYVE-1 219059_s_at 0.9091 1 0.2277 0.2070 A/A/A 
LYVE-1 220037_s_at 0.9091 1 0.0883 0.0803 A/A/A 
TL4 221060_s_at 1 1 0.0285 0.0285 A/A/A 
CD44 216056_at - 1 - - A/A/A 
STAB2 220114_s_at 0.8182 0.6666 0.4901 0.2673 A/A/A 
ICAM-1 202637_s_at 0.9091 1 0.1809 0.1644 A/A/A 
ICAM-1 202638_s_at 0.7277 1 0.4848 0.3566 A/A/A 
ICAM-1 215485_s_at 1 1 0.0631 0.0631 A/A/A 
VCAN 211571_s_at 0.7272 1 0.2021 0.0146 A/A/A 
VCAN 204620_s_at 0.1818 1 0.0894 0.0732 A/A/A 
VCAN 215646_s_at 1 1 0.0319 0.0319 A/A/A 
VCAN 204619_s_at 0.9090 1 0.6459 0.5872 A/A/A 
VCAN 221731_x_at 0.5454 1 0.1230 0.0671 M/A/M 
Table 3.1. A list of the probe set IDs for each gene assessed using the GeneSifter programme with their 
corresponding performance across an array of parameters and detection call. Each probe appears in 
accordance to the sequence shown in the heatmap profile (Figure 3.1). Jetset probe identifies the probe 
set ID which scored the highest overall performance score for each gene and is indicated in bold. All 
parameters are assessed on a scale ranging from 0 – 1 with a score closer to 1 indicating a better 
performance. Detection call identifies whether the gene expression was determined as absent (A), 
present (P) or mixed (M) for each probe set ID in MCF-7, Tam-R and Fas-R cells respectively. 
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Figure 3.1. A heatmap profile displaying changes in gene expression for all hyaladherins analysed 
and the log2 intensity plots for the Jetset probe of each gene with the average normalised gene 
expression (±SEM) across 3 independent experiments.   
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Gene MCF-7 versus Tam-R MCF-7 versus Fas-R Tam-R versus Fas-R 
HMMR 2.45 3.64 1.48 F 
CD44 1.06 6.71 6.30 F 
LYVE-1 1.15 1.16 1.33 T 
TL4 1.06 3.14 2.97 F 
STAB2 2.84 3.19 1.12 F 
ICAM-1 1.21 1.04 1.17 F 
VCAN 1.08 1.14 1.23 T 
Table 3.2. The fold change values in gene expression of the Jetset probes for each gene analysed by 
affymetrix. ANOVA testing with Tukey post-hoc analysis was performed to identify any significant 
changes in gene fold across all 3 cells models and significant changes are highlighted in bold and 
underlined. Green represents decreased fold changes, red indicates increased fold changes and black 
indicates no change in fold levels. CD44 gene fold change was significantly increased in Fas-R cells 
compared to MCF-7 cells (p = 0.00038) and Tam-R cells (p value = 0.00045). STAB2 gene fold changes 
were significantly decreased in Tam-R cells (p = 0.0291) and Fas-R cells (p = 0.0186) compared to MCF-
7 cells. In the final column, fold change values relating to either Tam-R or Fas-R cells are indicated by 
‘T’ or ‘F’ respectively.  
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3.2.2 Validation of microarray data by RT-PCR analysis 
Whilst microarray analysis provided important insight into CD44 and HMMR gene 
expression across the cell models, this technique cannot distinguish between 
different splice variants of these genes. Therefore, to validate microarray results and 
further investigate the presence of different CD44 and HMMR splice variants across 
the cell lines, RT-PCR was performed on mRNA isolated from MCF-7, Tam-R and Fas-
R cells using CD44 isoform and HMMR specific primers designed in-house. Primers 
designed for detection of CD44 Std and HMMR were situated in the domain common 
to all isoforms therefore use of these primers was anticipated to result in multiple 
PCR products. It should also be noted that primers used for detection of CD44v3, 
CD44v6 and CD44v10 detected any isoforms containing these exons. Figure 3.2 
reveals the expression of multiple bands (200 – >1000 bp) using the CD44 Std primer 
across all cell models, however overall these bands showed stronger expression 
within Tam-R and Fas-R cells compared to MCF-7 cells. Figure 3.2 further reveals the 
upregulation of bands corresponding to the predicted base pair sizes of CD44v3 (100 
bp) and CD44v6 (100 bp) in Tam-R and Fas-R cells compared to MCF-7 cells. The band 
corresponding to CD44v10 (109 bp) expression showed a modest increase in Fas-R 
cells compared to MCF-7 cells (Figure 3.2). No signal could be detected for HMMR 
across the cell models (Figure 3.2). Densitometry analysis revealed enhanced gene 
expression of CD44 Std and CD44v6-containing isoforms in Fas-R cells compared to 
MCF-7 cells (Figure 3.3).  
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Figure 3.2. Representative RT-PCR images from 3 independent experiments showing CD44 isoform 
expression in MCF-7, Tam-R and Fas-R cells with ß-actin loading control. 
 
displaying the average normalised data (±SEM) 
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RT-PCR densitometry analysis
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Figure 3.3. Densitometry graph for CD44 isoform expression detected in MCF-7, Tam-R and Fas-R 
cells by RT-PCR analysis normalised to ß-actin. Error bars represent the average normalised data 
±SEM from 3 independent experiments and statistical analysis was performed using a one-way 
ANOVA with Tukey post-hoc testing to identify any significant changes across all 3 cell models. 
Significance was set at p < 0.05.  
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3.2.3 Protein expression of CD44 and RHAMM in endocrine resistant cells versus 
their endocrine sensitive counterparts 
Given that CD44 isoform gene expression appeared to be elevated in resistant cell 
models versus their MCF-7 counterparts, the next step was to assess CD44 isoform 
expression at the protein level along with their cellular localisation patterns. Whilst 
HMMR was undetectable by RT-PCR analysis, microarray data revealed elevated 
expression of this gene across the endocrine resistant cell models compared to their 
endocrine sensitive counterpart, MCF-7 cells. Therefore HMMR (RHAMM) expression 
was also investigated at the protein level across the cell models. 
3.2.3.1 Western blotting  
Western blotting analysis revealed enhanced expression of an 80 kDa band 
corresponding to the hypothetical size of CD44 Std in Tam-R and Fas-R cells 
compared to MCF-7 cells; with the highest expression level observed in Fas-R cells 
(Figure 3.4). Further analysis revealed elevated expression of protein products 
corresponding to CD44v3 (85 kDa), CD44v6 (85 kDa) and CD44v10 (90 kDa) in Tam-R 
and Fas-R cells compared to MCF-7 cells (Figure 3.4). Interestingly, detection of 
CD44v6 and CD44v10 resulted in the presence of multiple bands (130 – 250 kDa) in 
the endocrine resistant cell lines that were not observed in MCF-7 cells (Figure 3.4). 
These are likely to be due to the presence of unidentified splice variants containing 
these exons and/or differences in glycosylation of these exons, also observed by 
other groups including Dougherty et al. 1991; Gansauge et al. 1995; Kuncova et al. 
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2005. Western blotting analysis also detected an 85 kDa band corresponding to a 
variant of RHAMM with a similar expression profile across all cell models (Figure 3.4).  
 
Figure 3.4. Representative Western blot images from 3 independent experiments showing 
CD44 isoform and RHAMM expression in MCF-7, Tam-R and Fas-R cells with a GAPDH loading 
control.  
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Densitometry analysis confirmed significantly elevated CD44 Std and CD44v6 protein 
expression in Fas-R cells compared to both MCF-7 and Tam-R cells and enhanced 
CD44v10 expression in Fas-R cells compared to MCF-7 cells (Figure 3.5). Furthermore, 
these analyses revealed increased CD44 Std and CD44v3 protein expression in Tam-
R cells compared to MCF-7 cells (Figure 3.5). 
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Figure 3.5. Densitometry graph showing CD44 isoform and RHAMM expression detected in MCF-
7, Tam-R and Fas-R cells by Western blotting analysis normalised to GAPDH. Error bars represent 
the average normalised data ±SEM from 3 independent experiments and statistical analysis was 
performed using a one-way ANOVA with Tukey post-hoc testing to identify any significant changes 
across all 3 cell models. Significance was set at p < 0.05.  
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3.2.3.2 Immunostaining analysis  
Immunostaining approaches were used to quantify the expression and subcellular 
localisation pattern of CD44 and RHAMM proteins across all cell lines. These 
approaches detected all CD44 isoforms containing the specific variant exon.  
Immunocytochemical analysis revealed intense staining of CD44 Std and CD44v6-
containing isoforms in Tam-R and Fas-R cells versus MCF-7 cells, particularly at the 
cell surface (Figure 3.6). A similar trend for increased expression of CD44v3- and 
CD44v10-containing isoforms was observed in the resistant cell models compared to 
the endocrine sensitive MCF-7 cells although to a lesser degree than CD44 Std and 
CD44v6 proteins (Figure 3.7). Interestingly, CD44v3 and CD44v10 proteins showed 
predominant cytoplasmic localisation in the resistant cells (Figure 3.6). Upregulated 
protein expression of these isoforms in the resistant cells was further confirmed by 
quantitative assessment of immunostaining by H-score analysis (Figure 3.7). H-score 
quantitation suggested enhanced membrane staining of CD44 Std in Tam-R and Fas-
R cells compared to MCF-7 cells, and increased CD44v6 expression in Fas-R cells, 
compared to MCF-7 and Tam-R cells (Figure 3.7). These analyses also revealed 
increased cytoplasmic CD44 Std, CD44v6 and CD44v10 protein expression in Fas-R 
cells compared to MCF-7 cells (Figure 3.7) and CD44v6 and CD44v10 expression was 
enhanced in Fas-R cells compared to Tam-R cells (Figure 3.7). Cytoplasmic expression 
of CD44v6 was increased in Tam-R cells compared to MCF-7 cells (Figure 3.7). Analysis 
of RHAMM showed decreased staining in Tam-R and Fas-R cells compared to MCF-7 
cells and H-score analysis revealed reduced cytoplasmic RHAMM expression in Fas-R 
cells compared to MCF-7 cells (Figure 3.6 and 3.7 respectively).  
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Figure 3.6. Representative images from 3 independent experiments showing CD44 isoform and 
RHAMM expression by immunocytochemical analysis (x20 magnification). 
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Figure 3.7. Membrane and cytoplasmic H-score assessment of CD44 isoform and RHAMM 
expression in MCF-7, Tam-R and Fas-R cells by immunocytochemistry analysis. Error bars represent 
the average normalised data ±SEM from 3 independent experiments and statistical analysis was 
performed using a one-way ANOVA with Tukey post-hoc testing to identify any significant changes 
across all 3 cell models. Significance was set at p < 0.05.  
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To further validate CD44 and RHAMM expression, immunofluorescence microscopy 
was undertaken. This assessment also revealed intense staining of CD44 Std and 
CD44v6-containing isoforms in Tam-R and Fas-R cells compared to MCF-7 cells, with 
elevated staining observed on the plasma membrane (Figure 3.8). These data further 
revealed intense cytoplasmic staining of proteins corresponding to CD44v3- and 
CD44v10- containing isoforms in Tam-R cells compared to MCF-7 cells (Figure 3.8). 
Quantitative analysis using ImageJ to determine total cell fluorescence revealed 
enhanced staining of CD44 Std and CD44v6 in Fas-R cells compared to MCF-7 and 
Tam-R cells (Figure 3.9). Analysis of RHAMM revealed a heterogeneous staining 
pattern in MCF-7 and Fas-R cells, interestingly these proteins revealed cytoskeletal 
localisation across all cell models, an observation also shown by others (Assmann et 
al. 1999; Jiang et al. 2013) (Figure 3.8). 
  
 
 
 
103 
 
 
 
 
 
Figure 3.8. Representative images from 3 independent experiments showing CD44 isoform and 
RHAMM expression by immunofluorescence analysis (x63 magnification). 
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Figure 3.9. Total cell fluorescence analysis of CD44 isoform and RHAMM expression in MCF-7, Tam-
R and Fas-R cells by immunofluorescence analysis. Error bars represent the average normalised 
data ±SEM from 3 independent experiments and statistical analysis was performed using a one-
way ANOVA with Tukey post-hoc testing to identify any significant changes across all 3 cell models. 
Significance was set at p < 0.05.  
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3.3 Discussion 
The purpose of this chapter was to explore whether the expression of CD44 isoforms 
and alternative hyaladherin family members were altered in cell models of acquired 
endocrine resistance versus their endocrine sensitive counterparts. It has been well-
established that deregulated CD44 expression contributes to the metastatic 
behaviour of numerous carcinomas (Klingbeil et al. 2010; Al-Maghrabi et al. 2012; 
Takahara et al. 2012; Hao et al. 2012), therefore the overall goal of this thesis was to 
explore the hypothesis that augmented CD44 isoform expression may confer an 
aggressive phenotype onto endocrine resistant cell models, potentially through 
enhanced growth factor pathway activation. Thus in order to elucidate the function 
of CD44 in the context of resistance, initial studies focussed around characterization 
of CD44 and related hyaladherin family members in endocrine sensitive and resistant 
breast cancer models.  
Of the multiple hyaladherins identified to date, several have been reported to be 
implicated in various cancers including: CD44, HMMR, LYVE-1, TL4, STAB2, ICAM-1 
and VCAN (Gao et al. 2006; Li et al. 2009; Hirose et al. 2012). In particular, CD44 (Afify 
et al. 2009; Ma et al. 2005; Lian et al. 2006), HMMR (Hamilton et al. 2007; Maxwell 
et al. 2011), LYVE-1 (Bono et al. 2004), TL4 (Yang et al. 2010; Yang et al. 2013), STAB2 
(Hirose et al. 2012), VCAN (Du et al. 2013), and ICAM-1 (Rosette et al. 2005; Guo et 
al. 2014) have all been reported to be highly expressed in breast cancer where they 
have been shown to correlate with poor prognosis. However, with the exception of 
CD44 and HMMR, results obtained from affymetrix analysis did not suggest a role for 
these hyaladherin family members in endocrine resistance. It could be suggested that 
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downregulation, rather than overexpression, of specific hyaladherin genes may 
confer an aggressive phenotype in endocrine resistance through a tumour 
suppressor function, however no known tumour suppressor functions have been 
reported for the alternative hyaladherins assessed in this project. Despite microarray 
analysis revealing elevated gene expression of HMMR in both endocrine resistant cell 
models versus their MCF-7 counterpart, this effect was not statistically significant. 
Although HMMR gene expression was unable to be detected across the cell models 
by RT-PCR analysis, protein detection revealed a similar level of RHAMM expression 
across all cell models and staining appeared to show predominant cytoskeletal 
localisation. Thus together, these data could infer that RHAMM may not act as a 
major contributor towards the aggressive phenotype of these endocrine resistant cell 
models, however it could be argued that the presence of RHAMM in these cells alone 
is important to their aggressive phenotype.  
In contrast, both affymetrix analysis and RT-PCR validation demonstrated elevated 
CD44 gene expression in endocrine resistance, however significant upregulation of 
CD44 splice variants was only observed for CD44 Std- and CD44v6-containing 
proteins in Fas-R cells compared to MCF-7 cells. Western blotting analysis confirmed 
upregulation of CD44 Std in both endocrine resistant cell models versus their 
endocrine sensitive MCF-7 counterpart. However these data revealed a differential 
expression profile of CD44 variants between Tam-R and Fas-R cells, with a significant 
upregulation of CD44v6 and CD44v10 proteins in Fas-R cells and enhanced CD44v3 
in Tam-R cells, compared to MCF-7 cells (depicted in Figure 3.10). Interestingly, 
Western blotting data suggested the presence of multiple CD44v6- and CD44v10-
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containing isoforms in the resistant cell models that were undetectable in MCF-7 
cells, potentially suggesting that greater amounts of alternative splicing may occur in 
endocrine resistance. Indeed, aberrant splicing frequently occurs in carcinomas, 
although it remains unclear whether the production of abnormal transcripts is of 
functional importance to cancer cells or merely a by-product of transformation. 
However, growing evidence suggests that aberrant splicing contributes to the 
aggressive phenotype of cancer cells through the production of proteins with altered 
or novel functions (Xing et al. 2003; Hiller et al. 2005; Fackenthal and Godley 2008). 
Indeed numerous reports document upregulation of CD44 splice variants in 
aggressive carcinoma tissues compared to their normal tissues (Herrera-Gayol et al. 
1999; Ni et al. 2002; Ma et al. 2005; Shi et al. 2013; Misra et al. 2012). These data 
may suggest that upregulation of CD44 splicing leading to the production of 
alternative CD44 variant isoforms, as observed within Tam-R and Fas-R cells, may 
contribute to the acquisition of an aggressive phenotype observed in resistant 
models since these CD44 isoforms may have altered pro-invasive/migratory 
functions.   
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Immunostaining analysis confirmed upregulation of CD44 Std, CD44v6 and CD44v10 
in Fas-R cells and revealed elevated expression of CD44 Std and CD44v6 proteins in 
Tam-R cells compared to their MCF-7 counterparts. Furthermore, these techniques 
revealed distinct subcellular localisation patterns of individual CD44 isoforms across 
cell models. Whereas CD44 Std- and CD44v6-containing isoforms appeared to 
localise to the membrane, CD44v3- and CD44v10-containing proteins showed 
predominant cytoplasmic staining in models of endocrine-resistance; and these 
expression patterns may allude to differential cellular functions. For example, whilst 
CD44 Std and CD44v6 isoforms may interact with extracellular factors at the cell 
surface (including extracellular matrix components, growth factor receptors and 
growth factors themselves), CD44v3 and CD44v10 isoforms may have more 
distinguished roles within intracellular signalling, receptor/ligand internalisation and 
cytoskeleton binding. Indeed, CD44 Std has been suggested to confer enhanced HA 
Figure 3.10. A diagram to represent the level of CD44 isoform expression and presence of splice 
variants in endocrine resistant Tam-R and Fas-R cells compared to their endocrine sensitive 
counterpart MCF-7 cells according to the characterisation results in Chapter 3. The size of each CD44 
isoform represents its expression level across the cell lines with an increase in size corresponding to 
enhanced protein expression. The arrows represent the presence of multiple isoforms containing 
the specific exon in the cell models. In MCF-7 cells, the level of CD44 Std, CD44v3, CD44v6 and 
CD44v10 is low and multiple splice isoforms containing specific exons are not present in these cells. 
In Tam-R cells, CD44 Std, CD44v3 and CD44v6 protein expression becomes enhanced compared to 
MCF-7 cells and multiple splice variants containing variant exons 6 and 10 are present in these cells. 
In Fas-R cells, CD44 Std, CD44v6 and CD44v10 expression becomes upregulated compared to MCF-
7 cells, and to a greater level compared to Tam-R cells, and multiple splice variants containing variant 
exons 6 and 10 are also present in these cells. 
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binding through the accessibility of its extracellular HA-binding N-terminus and its 
expression has been tightly coupled with HER2 in cancer cells and found to be 
strongly expressed in HER2-enriched breast tumours (Bourguignon et al. 1997; Bao 
et al. 2011, Olsson et al. 2011). In support of this, Hiscox et al. 2012 reported that HA 
activation of CD44 led to dimerization with HER2 and subsequent downstream 
signalling resulting in promotion of aggressive cellular behaviours in Tam-R cells. 
Additionally, it has been reported that CD44v6 is required for the full activation of 
the membrane tyrosine kinase receptor c-Met (Orian-Roussea et al. 2002; Hasenauer 
et al. 2013); a protein overexpressed in approximately 20 – 30 % of invasive basal 
breast cancers (Lengyel et al. 2005; Zagouri et al. 2013; Ho-Yen et al. 2014) and shown 
to be an independent predictor of poor clinical outcome (Ghoussoub et al. 1999; 
Camp et al. 1999; Gonzalez-Angulo et al. 2012). Further, Hiscox et al. 2006 reported 
that the c-Met receptor is overexpressed in Fas-R cells where it is has been suggested 
to augment an aggressive cellular phenotype. These data may implicate a role for 
CD44v6 in the activation of the c-Met receptor in Fas-R cells where it may play a role 
in the initiation of signalling pathways leading to enhanced invasive behaviours. 
However unlike CD44 Std, the contribution of CD44v6 to HA-binding and ErbB 
receptor activation currently remains unknown.  
Conversely, the CD44v10 exon has been shown to undergo extensive post-
translational modifications within cells that subsequently prevents dimerization of 
CD44 molecules at the cell surface, an event known to promote high affinity HA-
binding (Droll et al. 1995; Bourguignon et al. 1998). Therefore it is thought that 
CD44v10 proteins exhibit reduced capability of HA binding and may thus provide an 
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explanation for its predominant cytoplasmic localisation in endocrine resistant cells 
potentially through its enhanced turnover. Furthermore, CD44v3 and CD44v10 
variant isoforms have been shown to be involved in enhanced cellular motility 
through interactions with cytoskeletal proteins, ROK and ankyrin (Bourguignon et al. 
1999; Singleton and Bourguignon 2002; Singleton and Bourguignon 2004). Therefore, 
it may be suggested that within these cell models, the role of CD44v3- and CD44v10- 
containing proteins may predominantly involve cytoskeletal-mediated functions and 
may therefore support evidence for the cytoplasmic localisation of these proteins. 
Taken together, the intracellular localisation of CD44 isoforms containing variant 
exons 3 and 10 may be postulated to be a result of enhanced turnover and 
degradation, cytoskeletal binding, endosomal signalling, receptor/ligand endocytosis 
or cellular processing in the endoplasmic reticulum. Whilst numerous studies report 
cytoplasmic localisation of CD44 proteins, intracellular roles for variant isoforms have 
not yet been reported in literature.  
Several approaches were undertaken to explore CD44 isoform expression across 
these cells models as discrepancies in antibody detection have previously been 
reported due to differences in immunostaining techniques which may alter or mask 
the access of antibodies to protein epitopes (Martegani et al. 1999; Louderbough et 
al. 2011). The analyses revealed a similar expression profile of CD44 isoforms across 
these techniques (Table 3.3) suggesting an accurate representation was gained 
across the cell models in Fas-R cells, however some variation was shown in Tam-R 
cells. A limitation to using immunostaining analysis for the detection of specific CD44 
variants in this study was that antibodies detected any CD44 variant possessing the 
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specific exon and could not distinguish between different splice variants. This effect 
was overcome by Western blotting analysis which detected multiple bands 
potentially correlating to CD44 variant-containing isoforms, however the 
composition of these splice variants across the cell models remains undetermined. It 
must be noted that the CD44 Std antibody used in this study detected all CD44 
isoforms present in the cell models and therefore was a representation of total CD44 
expression. Given that CD44 Std and CD44v6 detection appeared to show similar 
expression profiles between all cell models, it may be suggested that the CD44 Std 
antibody mainly detected the CD44v6-containing proteins. Thus, the expression of 
the CD44 Std isoform alone may be difficult to interpret in this study. This thesis 
therefore highlights the importance of using a breadth of detection techniques to 
gain an accurate representation of CD44 isoform expression across models and may 
go some way to explain experimental discrepancies between studies. 
 RT-PCR WB ICC (M) ICC (C) IF 
MCF-7 v Tam-R - Std, v3 Std v6 - 
MCF-7 v Fas-R Std, v6 Std, v6, v10 Std, v6 Std, v6, v10 Std, v6 
Tam-R v Fas-R - Std, v6, v10 Std, v6 Std, v6, v10 Std, v6 
Table 3.3. A table to show significant differences observed in CD44 isoform expression between all 
cell models across several detection techniques. Abbreviations represent: WB (Western blotting), ICC 
(M) (immunocytochemistry, membrane H-score), ICC (C) (immunocytochemistry, cytoplasm H-score), 
IF (immunofluorescence), Std (CD44 Std), v3 (CD44v3), v6 (CD44v6) and v10 (CD44v10).  
Overall, the data demonstrated that the expression of specific CD44 splice variants 
was increased in endocrine resistant cell models versus their endocrine sensitive 
counterpart. Interestingly, analyses revealed a greater level of CD44 isoform 
expression in the ER- Fas-R cells, compared to ER+ Tam-R cells (Table 3.3), which 
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supports previous research suggesting that CD44 expression is inversely proportional 
to ER expression (Klingbeil et al. 2010; Montgomery et al. 2012), although suggests 
that this relationship is not absolute. Both Tam-R and Fas-R cells are known to display 
an aggressive, metastatic phenotype (Hiscox et al. 2011) mediated in part by altered 
growth factor signalling. A number of studies support a role for CD44 isoforms as 
contributors towards the aggressive cellular features that may ultimately promote 
tumour spread. For example, a pioneering study by Gunthurt et al. 1991 revealed 
that CD44v6 transfection into non-metastatic rat carcinomas converted them into 
metastatic cells and subsequent co-injection of anti-CD44v6 antibody suppressed 
this metastatic behaviour. Furthermore, Yae et al. 2012 showed that inoculation of 
the CD44 variant (v8-v10) isoform-expressing subpopulation of breast cancer cells 
into mice conferred metastatic potential and led to the formation of lung metastases 
which was accompanied by an expansion of stem-like cancer cells, an observation 
that was not seen in the CD44 variant-negative (CD44 Std) subpopulation. Indeed, it 
is generally considered that tumours expressing specific CD44 variants are more 
aggressive than those which display the CD44 Std protein alone. In support of this, 
Banky et al. 2012 reported that CD44 proteins containing variant exons 3 and 6 
showed dominant expression compared to other CD44 variants across colorectal 
cancer cell lines and suggested that in a minority of tumour subclones these variants 
may act as ‘metastasis genes’ and drivers of the metastatic phenotype in these cells.  
3.3.1 Summary 
In this chapter it was demonstrated that CD44 variant isoforms are upregulated in 
acquired endocrine resistance, however a differential expression profile of CD44 
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isoforms was detected between the resistant cell models, with the greatest level of 
CD44 isoform expression found in Fas-R cells compared to their endocrine sensitive 
MCF-7 parental cells. Given that these resistant cells display an aggressive phenotype 
combined with the well-established roles for CD44 proteins in tumour progression 
behaviours, these observations may point to a role for CD44 isoforms in acquired 
endocrine resistance.  
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4. CD44 overexpression in endocrine resistant breast cancer models 
augments their aggressive phenotype and sensitisation to HA 
4.1 Introduction 
In the previous chapter, it was demonstrated that the expression of multiple CD44 
isoforms are elevated within endocrine resistant cell models versus their endocrine 
sensitive counterpart. However the contribution of CD44 proteins to the aggressive 
resistant phenotype of these cells remains unclear. Many studies have shown a link 
between high levels of CD44 expression and enhanced metastatic behaviour in a 
number of cancer cell models, which is mirrored in the clinical setting (Lui et al. 2005; 
Lian et al. 2006; Harrison et al. 2006; Shi et al. 2013; Ni et al. 2014) however results 
remain contradictory. Whilst the full extent of CD44 contribution towards tumour 
progression remains to be elucidated, two key mechanisms underlying CD44 function 
appears to be mediated through binding to their principle ligand hyaluronan (HA), 
and associations with, and regulation of, receptor tyrosine kinases (RTKs) (Kim et al. 
2008; Hiscox et al. 2012; Hasenauer et al. 2013). 
HA is found in abundance within the tumour stroma of many carcinomas where its 
accumulation is often predictive of unfavourable prognosis (Anttila et al. 2000; 
Nykopp et al. 2010; Kultti et al. 2014). In particular, HA concentration in breast 
carcinomas has been shown to be an independent predictor of poor patient outcome 
(Auvinen et al. 2000; Auvinen et al. 2014). However the origins of HA in these 
tumours remains under debate and whilst numerous studies have shown that HA is 
produced by stromal cells stimulated by tumour cells (Anttila et al. 2000; Tammi et 
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al. 2008), others reveal evidence that carcinoma cells also synthesise HA (Kimata et 
al. 1983; Heldin et al. 1996; Simpson et al. 2002). 
HA is synthesised within the inner face of the plasma membrane by HA synthases 
which produce different length HA polymers that are subsequently extruded into the 
tumour matrix or retained at the cell surface (Udabage et al. 2005a; Weigel and 
DeAngelis 2007). HA polymers that are released into the microenvironment 
contribute to the provision of structural integrity, tissue hydration and homeostasis 
of the tumour (Turley et al. 2002; Toole and Hascall 2002). Alternatively, HA retained 
at the cell surface may further aggravate tumourigenecity through binding to 
hyaladherins leading to the activation of signalling cascades, or become endocytosed 
(via a CD44-mediated mechanism), together resulting in the consequent induction of 
numerous cellular processes including angiogenesis, migration and differentiation 
(Tammi et al. 1998; Knudson et al. 2002; Evanko et al. 2007 Qhattal and Lui 2011). 
Indeed, CD44 proteins have been shown to be strongly expressed at sites of HA 
accumulation in breast cancer cells thus suggesting a link between enhanced HA 
levels, CD44 expression and poor patient survival (Udabage et al. 2005a, Auvinen et 
al. 2014). Furthermore, Hamilton et al. 2007 showed that the highly CD44-expressing 
invasive MDA-MB-231 breast cancer cell line produced higher levels of endogenous 
HA compared to the low CD44-expressing less invasive MCF-7 cell line. From these 
findings this group proposed that invasive breast cancer cells rely more upon 
endogenous HA production and establish an autocrine mechanism required for rapid 
rates of motility; a mechanism which less invasive cells lack.  
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Furthermore, CD44 activation of RTK signalling, which occurs endogenously or upon 
HA-activation, has been implicated towards the induction of the metastatic cascade 
in numerous carcinomas (Palyi-Krekk et al. 2008; Bao et al. 2011; Hasenauer et al. 
2013). Indeed, several receptor tyrosine kinase (RTKs), including EGFR, HER2 and c-
Met are commonly found to be expressed in invasive breast carcinomas were they 
correlate with an aggressive phenotype (Lengyel et al. 2005; Reis-Filho et al. 2006; 
Graveel et al. 2009; Dawood et al. 2010; Baek et al. 2011; Auvinen et al. 2013). 
Numerous studies have reported that CD44 proteins act as co-receptors for EGFR, 
HER2 and c-Met leading to the subsequent transduction of downstream signalling 
cascades and enhanced tumourigenic activity (Kim et al. 2008; Bao et al. 2011; 
Hatano et al. 2011; Hasenauer et al. 2013). Importantly, these RTKs have been 
implicated in the acquisition of tamoxifen- and/or fulvestrant-resistance (Knowlden 
et al. 2003; Britton et al. 2006; Hiscox et al. 2006) coinciding with upregulated CD44 
expression. 
Taken together, the fact that CD44, HA and RTKs have been shown to become 
elevated in invasive breast carcinomas (separately or in combination) and correlated 
with poor prognosis suggests that these factors may be a critical requirement for 
breast tumour progression. Therefore, the aims of this chapter were to investigate 
whether CD44 contributes to the aggressive phenotype of endocrine resistant breast 
cancer models by augmenting RTK activation and/or sensitising these cells to HA. 
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4.1.1 Objectives 
1. To explore the effects of exogenous HA upon migration, invasion, growth and 
modulation of RTK signalling in endocrine sensitive versus endocrine resistant 
cell models. 
2. To investigate whether CD44 contributes to the intrinsic aggressive nature of 
endocrine resistant cells by RTK activation and/or response to HA through 
global CD44 siRNA knockdown.  
3. To determine whether endocrine resistant cells express the relevant 
machinery required for HA production at the gene level. 
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4.2 Results  
4.2.1. Exogenous HA stimulation enhances the aggressive phenotype of Tam-R and 
Fas-R cells and modulates receptor tyrosine kinase signalling 
To begin to explore whether upregulated CD44 expression may alter the aggressive 
phenotype of endocrine resistant cell models, it was first necessary to measure their 
endogenous cellular behaviours. Given that high levels of CD44 have been associated 
with metastatic behaviours of breast cancer cells (Afify et al. 2009; Montgomery et 
al. 2012; Babina et al. 2014), primary exploration was focused upon the basal level of 
cellular migration, invasion and proliferation across all cell models. Boyden chamber 
assays revealed that Fas-R cells exhibited a higher level of endogenous migration 
across fibronectin-coated membranes and enhanced proliferative capacity 
compared to MCF-7 cells (Figure 4.1). Further, these analyses revealed that both 
Tam-R and Fas-R cells exhibited enhanced endogenous invasive capacity through 
Matrigel compared to their endocrine sensitive counterpart (Figure 4.1). 
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Figure 4.1. The endogenous migratory, invasive and proliferative responses of MCF-7, Tam-R and 
Fas-R cells were determined using Boyden Chamber (migration and invasion) and Coulter Counter 
(proliferation) assays. Error bars represent the average normalised data ±SEM from 3 independent 
experiments. Statistical analysis was performed using a one-way ANOVA with Tukey post-hoc 
testing to identify any significant changes across all 3 cell models. Significance was set at p < 0.05.  
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Given that CD44 is the principle receptor for HA, an extracellular matrix component 
found in abundance in the tumour stroma and identified as an independent predictor 
of poor patient outcome (Auvinen et al. 2000; Auvinen et al. 2014), it was next 
explored whether the highly CD44-expressing endocrine resistant cell models were 
sensitised to HA, compared to their low CD44-expressing endocrine sensitive 
counterpart. As HA has been well documented to activate signalling cascades that 
induce cell migration, invasion and growth in breast tumours through CD44-
mediated mechanisms (Bourguignon et al. 2002; Kung et al. 2012; Montgomery et al. 
2012), the effect of exogenous HA stimulation upon these functions across the cell 
models was evaluated. 
Optimisation procedures (Appendix J) revealed that medium molecular weight HA 
(215 kDa) induced the best signalling response across the cell models, an effect also 
observed by other groups (Hamilton et al. 2007; Montgomery et al. 2012; Ouhtit et 
al. 2013), and was therefore used for subsequent exogenous stimulation. MCF-7, 
Tam-R and Fas-R cells were treated with HA in a dose dependent manner for the 
times indicated and the resultant effects on cellular function were measured.  
Boyden chamber assays revealed HA stimulation enhanced the migratory capacity of 
Tam-R and Fas-R cells compared to their MCF-7 counterpart; this effect was dose-
dependent in Tam-R cells up to a concentration of 200 µg/ml HA (Figure 4.2). Boyden 
chamber invasion assays revealed a dose-dependent increase in Fas-R cell invasion 
compared to MCF-7 cells, this effect was not seen in Tam-R cells (Figure 4.2). 
Proliferation assays revealed enhanced growth of Fas-R cells in response to 100 
µg/ml HA stimulation compared to MCF-7 cells (Figure 4.2).  
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Figure 4.2. The migratory, invasive and proliferative responses of MCF-7, Tam-R and Fas-R cells 
upon HA stimulation (215 kDa, 0 – 400 µg/ml) were determined using Boyden Chamber (migration 
and invasion) and Coulter Counter (proliferation) assays. Error bars represent the average 
normalised data ±SEM from 3 independent experiments and data is presented as the percentage 
of the untreated control. Statistical analysis was performed using a one-way ANOVA with Tukey 
post-hoc testing to identify any significant changes across all 3 cell models. Significance was set at 
p < 0.05.  
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Deregulation of receptor tyrosine kinase signalling has been heavily implicated in the 
acquisition of tamoxifen- and fulvestrant- resistance and previous studies from the 
Breast Cancer Molecular Pharmacology group (BCMPG) have shown that these cell 
models display enhanced EGFR and/or HER2 endogenous expression compared to 
their parental MCF-7 cells (McClelland et al. 2001; Knowlden et al. 2003; Hiscox et al. 
2006). Thus, given that CD44 is known to activate these receptors upon HA binding 
(Bourguignon et al. 1997; Kim et al. 2008; Hatano et al. 2011), the effect of exogenous 
HA stimulation upon ErbB receptor activation across the cell models was next 
investigated. MCF-7, Tam-R and Fas-R cells were treated with HA in a dose dependent 
manner and the effects upon EGFR and HER2 activation and subsequent induction of 
the downstream effector, ERK1/2, was assessed across all cell models by Western 
blotting analysis. 
The results revealed a dose-dependent increase in HER2 and EGFR activation up to 
200 µg/ml and 400 µg/ml HA stimulation in Tam-R cells respectively (Figure 4.3). 
Densitometry analysis confirmed a significant increase in HER2 phosphorylation upon 
stimulation with 100 – 200 µg/ml HA in Tam-R cells in comparison to MCF-7 cells 
(Figure 4.4). Western blotting analysis revealed that Fas-R cells showed modestly 
enhanced HER2 and EGFR activation in response to HA stimulation and densitometry 
assessment revealed enhanced HER2 (200 µg/ml), but not EGFR activation, in these 
cells compared to MCF-7 cells (Figures 4.3 and 4.4). Western blotting analysis also 
revealed a dose dependent increase in ERK1/2 activation in Tam-R and Fas-R cells 
compared to MCF-7 cells (Figure 4.3). Densitometry assessment showed that this 
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effect was significant in Fas-R cells (50 – 400 µg/ml) and Tam-R cells (200 µg/ml) 
compared to MCF-7 cells (Figures 4.3 and 4.4). 
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Figure 4.3. Representative Western blot images from 3 independent experiments showing HER2, 
EGFR and ERK1/2 activation in MCF-7, Tam-R and Fas-R cells in response to dose-dependent HA 
stimulation (215 kDa, 0 – 400 µg/ml) for 10 minutes with ß actin as a loading control. Total protein 
levels were unchanged. 
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Figure 4.4. Densitometry graphs for HER2, EGFR and ERK1/2 activation across MCF-7, Tam-R and 
Fas-R cell models in response to dose dependent HA stimulation (215 kDa, 0 – 400 µg/ml) for 10 
minutes before cell lysis and detection by Western blotting analysis. The data shows the relative 
protein levels in the cell lines expressed as a ratio of the active protein:total protein normalised 
to ß-actin. Error bars represent the average normalised data ±SEM from 3 independent 
experiments and the data is presented as the percentage of the untreated control. Statistical 
analysis was performed using a one-way ANOVA with Tukey post-hoc testing to identify any 
significant changes across all 3 cell models.  
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4.2.2 CD44 suppression reduces endogenous migration, invasion and proliferation 
in Tam-R and Fas-R cells 
To explore whether CD44 proteins may play a role in the observed endogenous 
aggressive nature and HA-sensitised phenotype of the endocrine resistant cell 
models, an siRNA-based approach was used to suppress global CD44 expression and 
re-evaluate these behaviours. In this chapter it was also investigated whether 
RHAMM, an additional hyaladherin family member, previously shown to be 
expressed by endocrine resistant cell models and implicated in breast cancer 
(Hamilton et al. 2007; Veiseh et al. 2014), may play a role in any observed HA 
responses. For all subsequent experiments, 100 µg/ml HA was chosen for exogenous 
stimulation of resistant cell lines based upon previous data which showed that this 
concentration enhanced cellular behaviours in both Tam-R and Fas-R cells.  
Optimisation experiments using Western blotting analysis and 
immunocytochemistry revealed that treatment of Tam-R and Fas-R cells with CD44 
siRNA resulted in suppression of global CD44 protein expression compared to the 
non-targetting (NT) controls between 24 hours to 144 hours post-transfection 
(Figures 4.5 and 4.6 respectively). Densitometry analysis revealed a significant 
suppression of CD44 global expression (including CD44 Std (Figure 4.5) CD44v3, 
CD44v6 and CD44v10 (Appendix K)) between 48 hours – 144 hours post-transfection 
in Tam-R and Fas-R cells compared to the NT-siRNA control cells (however CD44v6 
suppression was only significant in Tam-R cells between 72 – 144 hours), but did not 
alter RHAMM expression (Appendix K). Analysis of the functional effects of CD44 
suppression in endocrine resistant cell lines revealed that Tam-R and Fas-R cells 
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treated with CD44-siRNA showed reduced endogenous and HA-stimulated migration, 
invasion and proliferation compared to the NT-siRNA control (Figure 4.7 and Figure 
4.8 respectively). 
 
 
 
Figure 4.5. Representative Western blot images from 3 independent experiments showing CD44 
isoform and RHAMM expression in Tam-R and Fas-R cells after treatment with global CD44 siRNA 
for 24 – 144 hours post transfection in comparison to the untreated and NT-siRNA treated 
controls. GAPDH was used as a loading control. Densitometry graphs show CD44 Std expression 
in Tam-R and Fas-R cells between 24 – 144 hours post-transfection. Error bars represent the 
average normalised data ±SEM from 3 independent experiments. Data is normalised to GAPDH 
and presented as the percentage of the untreated control. Statistical analysis was performed 
using an ANOVA test with tukey post-hoc analysis and values were compared to the NT-siRNA.  
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Figure 4.7. Measurement of endogenous and HA-stimulated behavioural responses of Tam-R cells 
after CD44 suppression. Tam-R cells were treated with NT- and CD44- siRNA for 48 hours prior to 
the assessment of migration, invasion (Boyden Chamber) and proliferation (Coulter Counter) 
assays in the presence (100 µg/ml) or absence of HA. Error bars represent the average normalised 
data ±SEM from 3 independent experiments and the data is presented as the percentage of the 
untreated control. Statistical analysis was performed using an unpaired t-test and significance set 
at p < 0.05.  
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Figure 4.8. Measurement of endogenous and HA-stimulated behavioural responses of Fas-R cells 
after CD44 suppression. Fas-R cells were treated with NT- and CD44- siRNA for 48 hours prior to 
the assessment of migration, invasion (Boyden Chamber) and proliferation (Coulter Counter) in 
the presence (100 µg/ml) or absence of HA. Error bars represent the average normalised data 
±SEM from 3 independent experiments and the data is presented as the percentage of the 
untreated control. Statistical analysis was performed using an unpaired t-test and significance set 
at p < 0.05.  
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Since the data suggested a potential role for CD44 in HA-mediated EGFR, HER2 and 
ERK1/2 activation in endocrine resistant cell models, the next approach was to 
investigate the ability of HA to induce activation of these components in the absence 
of CD44, using siRNA. This approach additionally allowed the analysis of endogenous 
CD44-induced cellular signalling and c-Met, FAK, AKT and Src activation was also 
assessed as these proteins have additionally been substantially implicated in breast 
tumour progression behaviours and resistance to endocrine therapy (Hiscox et al. 
2006; Tokunaga et al. 2006; Morgan et al. 2009; Hiscox et al. 2011; Elsberger et al. 
2012; Raghav et al. 2012). Initially Western blotting analysis revealed a small increase 
in c-Met, FAK and AKT activation in Tam-R cells (Figure 4.9), and an increase in FAK 
and AKT activation in Fas-R cells (Figure 4.11), upon HA stimulation, suggesting an 
involvement of these proteins in the HA-induced behavioural responses of these 
cells. Upon CD44 suppression, Western blotting analysis further revealed a reduction 
in endogenous and HA-stimulated HER2, EGFR and ERK1/2 activation and HA-
stimulated FAK and AKT signalling in Tam-R cells treated with CD44-siRNA compared 
to the NT-siRNA control (Figure 4.9) which were confirmed to be significantly reduced 
by densitometry analysis with the exception of HER2 (Figure 4.10). Comparatively, 
CD44 suppression in Fas-R cells led to a reduction in endogenous c-Met, FAK and AKT 
activation and HA-stimulated FAK activation compared to the NT-siRNA control 
(Figure 4.11), which was confirmed by densitometry analysis (Figure 4.12). 
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Figure 4.9. Representative Western blot images from 3 independent experiments showing HER2, 
EGFR, c-Met, FAK, AKT, Src and ERK1/2 activation in Tam-R cells after 48 hour treatment with 
global CD44 siRNA in the presence (215 kDa, 10 minutes, 100 µg/ml) or absence of HA. Total levels 
of each protein analysed were unchanged and GAPDH was used as a loading control. 
 
 
 
 
 
Figure 4.7. Measurement of endogenous and HA-stimulated cell behaviour responses of 
Fas-R cells after CD44 suppression. Fas-R cells were treated with CD44 siRNA for 48 hours 
prior to the assessment of migration, invasion and proliferation in the presence (100 
µg/ml) and absence of HA. Error bars represent standard error of the means and 
statistical analysis was performed using an unpaired t-test and significance set at p < 0.05.  
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Figure 4.10. Densitometry graphs showing CD44 Std expression and HER2, EGFR, c-Met, FAK, AKT, 
Src and ERK1/2 activation in Tam-R cells after 48 hour treatment with global CD44 siRNA in the 
presence (215 kDa, 100 µg/ml, 10 minutes) or absence of HA, before cell lysis and detection by 
Western blotting analysis. The data shows the relative protein levels in the cell lines expressed as 
a ratio of the active protein:total protein normalised to GAPDH. Error bars represent the average 
normalised data ±SEM from 3 independent experiments and the data is presented as the 
percentage of the untreated control. Statistical analysis was performed using an unpaired t-test 
and significance was set at p < 0.05.  
across all 3 cell models. Significance was set at p < 0.05.  
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Figure 4.11. Representative Western blot images from 3 independent experiments showing HER2, 
EGFR, c-Met, FAK, AKT, Src and ERK1/2 activation in Fas-R cells after 48 hour treatment with global 
CD44 siRNA in the presence (215 kDa, 10 minutes, 100 µg/ml) or absence of HA. Total levels of 
each protein analysed were unchanged and GAPDH was used as a loading control.  
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Figure 4.12. Densitometry graphs showing CD44 Std expression and HER2, EGFR, c-Met, FAK, AKT, 
Src and ERK1/2 activation in Fas-R cells after 48 hour treatment with global CD44 siRNA in the 
presence (215 kDa, 100 µg/ml, 10 minutes) or absence of HA, before cell lysis and detection by 
Western blotting analysis. The data shows the relative protein levels in the cell lines expressed as 
a ratio of the active protein:total protein normalised to GAPDH. Error bars represent the average 
normalised data ±SEM from 3 independent experiments and the data is presented as the 
percentage of the untreated control. Statistical analysis was performed using an unpaired t-test 
and significance was set at p < 0.05.  
.  
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4.2.3 Endogenous HA synthesis and metabolism does not contribute to the 
aggressive phenotype of Tam-R and Fas-R cells 
Numerous studies have revealed correlations between high levels of HA synthases 
(HAS) and degradation enzymes (hyaluronidases (HYAL)) and enhanced breast cancer 
progression and poor patient prognosis (Udabage et al. 2005a; Tan et al. 2011; 
Auvinen et al. 2014). Given that the data implicated an important role for CD44 as a 
mediator of the highly migratory and invasive behaviour of endocrine resistant cell 
lines, it was hypothesised that this may be due to autocrine CD44 activation through 
HA synthesis (as previously reported by Hamilton et al. 2007). To begin to explore 
this, the gene expression of the HA synthases (HAS1/2/3) and hyaluronidases 
(HYAL1/2/3/SPAM1) was characterised across the cell models using affymetrix 
analysis.  
Figure 4.13 reveals the heatmap profile for each gene probe assessed in this project 
with the corresponding log2 intensity plots displaying the average normalised data 
(±SEM) and Table 4.1 lists the gene probe set IDs with their performance scores and 
detection calls. It should be noted that the HAS3 gene probe was not available on the 
U133A microarray gene chip and therefore subsequently could not be assessed 
within this study. Heatmap analysis revealed no change or reduced expression for all 
gene probes assessed in Tam-R and Fas-R cells compared to MCF-7 cells (Figure 4.13). 
Furthermore, the detection calls for each probe corresponding to HAS1, HAS2, 
HYAL1, HYAL3 and SPAM1 were absent in all cell lines and the log2 expression values 
were below 0, indicative of very low/no expression of these genes across all cell 
models (Figure 4.13, Table 4.1). Conversely, log2 intensity values for HYAL2 were 
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above 0 and the detection calls showed that this gene was present across all cell 
models (Figure 4.13, Table 4.1). Statistical analysis to compare gene fold changes 
across the cell models (shown in Table 4.2) revealed that HYAL2 gene expression was 
significantly reduced in Fas-R cells compared to MCF-7 cells. Further analysis revealed 
a significant suppression of HYAL1 gene expression in Tam-R cells versus MCF-7 cells, 
however, these data may be unreliable as the detection of this gene probe was 
determined as absent across these cells. Taken together, microarray analysis 
revealed a reduced expression of HYAL2 in Fas-R cells compared to their MCF-7 
counterpart and suggests that HAS and HYAL gene expression is very low/absent 
across all the cell models. This data does not implicate these genes towards the 
aggressive phenotype of the endocrine resistant cells thus verification of gene 
expression by RT-PCR analysis would likely be unsuccessful. Based on these data, 
further exploration of HAS/HYAL gene expression was not undertaken.  
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Figure 4.13. Heatmap profile displaying changes in gene expression of all HAS and HYAL genes 
analysed and their corresponding log2 intensity plots with the average normalised gene 
expression (±SEM) across 3 independent experiments.   
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Gene Probe Set 
ID 
Specificity 
Score 
Coverage 
Score 
Robust 
Score 
Overall 
Score 
Detection Call 
 
HAS1 207316_at 0.5454 1 0.6175 0.3368 A/A/A 
HAS2 206432_at 0.5454 1 0.2974 0.1622 A/A/A 
HYAL1 210619_s_at 0.7272 0.75 0.6002 0.3274 A/A/A 
HYAL2 206855_s_at 1 1 0.5577 0.5577 P/P/P 
HYAL3 211728_s_at 0.9090 1 0.5596 0.5987 A/A/A 
SPAM1 210536_s_at 1 1 0.4357 0.4357 A/A/A 
Gene MCF-7 versus Tam-R MCF-7 versus Fas-R Tam-R versus Fas-R 
HAS1 1.13 1.26 1.42 F 
HAS2 1.90 4.96 2.62 T 
HYAL1 3.90 1.67 2.34 F 
HYAL2 1.06 1.49 1.40 F 
HYAL3 1.30 1.21 1.57 F 
SPAM1 1.20 3.38 2.80 F 
Table 4.2. The fold change values in gene expression for each gene analysed by affymetrix. ANOVA 
testing with Tukey post-hoc analysis was performed to identify any significant changes in gene fold 
expression across all 3 cells models and significant changes are highlighted in bold and underlined. 
Green represents decreased fold changes, red indicates increased fold changes and black 
represents no change. HYAL1 gene fold change was significantly decreased in Tam-R cells 
compared to MCF-7 cells (p = 0.02554) and HYAL2 gene fold change was significantly decreased in 
Fas-R cells compared to MCF-7 cells (p = 0.036404). In the final column, fold change values relating 
to either Tam-R or Fas-R cells are indicated by ‘T’ or ‘F’ respectively. 
Table 4.1. A list of the probe set IDs for each gene assessed using the GeneSifter programme, their 
performance scores across an array of parameters and corresponding detection calls. All 
parameters are assessed on a scale ranging from 0 – 1 with a score closer to 1 indicating a better 
performance. Detection call identifies whether the gene expression was determined as absent (A), 
present (P) or mixed (M) for each probe set ID in MCF-7, Tam-R and Fas-R cells respectively. 
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4.3 Discussion 
This chapter set out to explore the consequence of CD44 overexpression for both the 
intrinsic and HA-stimulated phenotype of endocrine resistant cell models. In 
particular, the hypothesis that upregulated expression of CD44 proteins in Tam-R and 
Fas-R cells leads to HA-sensitisation and subsequently induced migratory, invasive 
and/or proliferative responses by RTK activation was explored.  
The results primarily revealed that enhanced CD44 expression correlated with an 
increase in the endogenous aggressive phenotype of endocrine resistant cell models. 
Analysis showed an enhanced basal invasive capacity of Tam-R cells compared to 
MCF-7 cells, however Fas-R cells (which exhibit the highest level of CD44 expression) 
displayed an elevated migratory, invasive and proliferative capacity compared to 
their endocrine sensitive MCF-7 counterpart. This association was validated by global 
suppression of CD44 proteins which reduced the endogenous migratory, invasive and 
proliferative capacity of Tam-R and Fas-R cells. However, upon investigation of the 
signalling mechanisms through which CD44 proteins may mediate these events, 
differences in RTK activation and downstream signalling was observed between 
these resistant cell models. Indeed, the siRNA data suggested a role for CD44 proteins 
within the endogenous activation of the RTKs, EGFR and HER2, leading to 
downstream activation of ERK1/2 in Tam-R cells. These results were not surprising as 
EGFR and HER2 have been heavily implicated within the acquisition of tamoxifen 
resistance and high levels of endogenous HER2 and EGFR expression are exhibited in 
Tam-R cells (Knowlden et al. 2003; Hiscox et al. 2012). Furthermore, these data 
corroborate with other studies which have shown dimerization to occur between 
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CD44 and ErbB receptors in carcinoma cells (Bao et al. 2011; Hatano et al. 2011; 
Hiscox et al. 2012) and revealed a role for CD44-mediated activation of these RTKs 
leading to enhanced cellular motility (Wang et al. 2006; Kim et al. 2008). However, 
although previous data from the BCMPG revealed elevated levels of EGFR and HER2 
in fulvestrant-resistant cells (McClelland et al. 2001; Gee et al. 2005), the contribution 
of these receptors to their aggressive phenotype remains to be elucidated and data 
here suggests that these receptors do not play a prominent role in CD44-mediated 
behaviours in these cells. However, previous studies by the Hiscox group (2006) 
revealed that c-Met is overexpressed in fulvestrant-resistance and CD44 global 
suppression data in this study revealed reduced endogenous c-Met activation in Fas-
R cells, thus potentially suggesting a role for CD44-mediated c-Met activation in this 
cell line. In support of this, Orian-Rousseau et al. 2002 identified that CD44 is required 
for the full activation of the c-Met receptor and Hasenauer et al. 2013 published 
evidence for the requirement of CD44v6 in c-Met internalisation. In further support 
of an association between CD44 and c-Met, numerous clinical studies have revealed 
upregulation of both CD44 (Klingbeil et al. 2010; Montgomery et al. 2012) and c-Met 
(Garcia et al. 2007; Graveel et al. 2009; Ho-Yen et al. 2014) expression to be strongly 
correlated with the aggressive triple negative basal subtype of breast cancer and 
poor prognosis. Interestingly, an ER-negative, basal-like phenotype is also exhibited 
by Fas-R cells. Taken together, whilst our siRNA suppression data revealed an 
importance for CD44 proteins towards the aggressive phenotype of both endocrine 
resistant cell models, the signalling mechanisms through which they contribute to 
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these behaviours appear to be mediated through differential pathways, potentially 
due to variances in the bioavailability of specific co-receptors between these cells.  
To explore whether enhanced CD44 protein expression sensitised endocrine 
resistant cells to HA, these cells were treated with exogenous HA and their 
behavioural responses were re-evaluated. The results revealed that HA stimulation 
led to an enhanced migratory response in Tam-R cells and elevated migration, 
invasion and growth responses in Fas-R cells, an effect not observed in MCF-7 cells. 
These results implicate CD44 proteins towards the augmentation of HA responses in 
the endocrine resistant cell models, particularly within Fas-R cells which exhibit the 
greatest level of CD44 expression compared to MCF-7 and Tam-R cells. As a further 
demonstration that CD44 was responsible for these HA-induced cellular behaviours, 
it was also observed that HA failed to elicit a response in endocrine resistant cells 
upon CD44 suppression by siRNA. These data are supported by findings from 
Hamilton et al. 2007 which revealed that the highly CD44- (and RHAMM-) expressing 
invasive MDA-MB-231 breast cancer cell line showed significantly enhanced motility 
in response to HA stimulation, which was not found in MCF-7 cells. Furthermore, 
Vieseh et al. 2014 revealed that the more malignant MDA-MB-231 and T4-2 breast 
cancer cells (high CD44 and RHAMM expression) showed enhanced total levels of HA 
binding and a greater degree of HA heterogeneity binding compared to MCF-7 and 
SKBr3 cells (low CD44 and RHAMM expression), and conversion of MDA-MB-231 cells 
to a less malignant phenotype reverted these HA binding capabilities. The data also 
suggested that CD44, and not the alternative hyaladherin RHAMM (also present 
within the endocrine resistant cells), mediated these effects as RHAMM expression 
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was not substantially impaired upon CD44 suppression. Taken together, the data 
corroborates with previously reported findings and suggests that enhanced HA 
binding capabilities in cells may act as a determinant towards the degree of their 
malignant behaviour; an effect likely to be the result of enhanced CD44 expression 
in the endocrine resistant cell models. 
To determine the mechanisms through which HA stimulation may enhance the 
adverse cellular behaviour of these endocrine resistant cell models, the effect of 
exogenous HA induction upon ErbB activation was investigated. The results revealed 
enhanced HER2 and EGFR activation in Tam-R cells upon HA stimulation, an effect 
observed to a lesser degree in MCF-7 and Fas-R cells. Furthermore, these 
investigations revealed a dose dependent increase in HER2 activation in Tam-R cells 
upon HA stimulation which mirrored their migratory response, thus potentially 
implicating CD44 in the activation of HER2 and subsequently enhanced migration in 
these cells. These data were further verified through CD44 siRNA analyses which 
revealed that suppression of CD44 proteins reduced both migration and HER2 
signalling upon HA stimulation in Tam-R cells. These data corroborate with published 
studies which implicate CD44 (particularly the standard isoform) in the activation of 
HER2-mediated signalling and subsequently enhanced tumour progression 
behaviours of cancer cells (Bourguignon et al. 1997; Palyi-Krekk et al. 2008; Bao et al. 
2011). Furthermore, studies by Duru et al. 2012 showed that HER2+/CD44+ breast 
cancer stem cells exhibited a more aggressive phenotype and were found to be more 
frequently detected in recurrent tumours as compared to the HER2-/CD44+ 
subpopulation. These findings have also been observed in the clinical setting through 
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strong associations between the co-expression of CD44, HA and HER2 in breast 
cancer patients and poor prognosis (Baek et al. 2011; Auvinen et al. 2013).  
The siRNA data also suggested an important role for CD44 proteins in the HA-induced 
invasive and growth capabilities of Tam-R cells; an effect which may involve 
downstream ErbB receptor signalling activation of FAK, AKT and ERK1/2 cascades. 
Indeed, numerous studies have reported a role for CD44-ErbB dimer complexes in 
enhanced cellular motility through the activation of various signalling molecules 
including those identified in this study (Wang and Bourguignon et al. 2006; Kim et al. 
2008; Bao et al. 2011; Hatano et al. 2011). In Fas-R cells, HA also promoted a CD44-
dependent increase in migration, invasion and proliferation although the 
mechanisms through which this occurs remains unclear. Western blotting data 
suggested an involvement of FAK, AKT and ERK1/2, however did not implicate the 
activation of these effectors downstream of the ErbB receptor signalling cascade.  
As the data revealed an important role for HA towards the augmentation of adverse 
cellular behaviour in the resistant cells, the role of endogenous HA synthesis across 
all cell models was investigated. Whilst the majority of HA is thought to be produced 
by stromal cells in the tumour microenvironment, several studies have revealed that 
carcinoma cells themselves can also synthesise HA (Kimata et al. 1983; Heldin et al. 
1996; Simpson et al. 2002) and numerous reports have shown a role for the enzymes 
responsible for HA synthesis and degradation in the development of a pro-metastatic 
environment and enhanced breast tumourigenesis (Li et al. 2007; Tan et al. 2011; 
Auvinen et al. 2014). Furthermore, Hamilton et al. 2007 revealed that the highly 
CD44-expressing invasive MDA-MB-231 breast cancer cell line produced higher levels 
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of endogenous HA compared to the low CD44-expressing, less invasive MCF-7 cell 
line. From these findings this group suggested that invasive breast cancer cells 
establish an autocrine HA-CD44 mechanism to promote cellular motility. In this 
context, HA production by breast cancer cells could involve an alteration in its 
synthesis and/or metabolism. 
Whilst many reports have correlated high levels of HAS/HYAL gene expression with 
breast cancer progression and poor prognosis (Udabage et al. 2005a; Tan et al. 2011; 
Auvinen et al. 2014), the microarray data suggested that enzymes involved in HA 
synthesis or metabolism were not overexpressed in the endocrine resistant cell 
models. Whilst endogenous HA production by these cells through alternative 
measures such as an ELISA was not examined, it is unlikely that significant levels of 
HA synthesis occur in these cells due to the low/absent levels of these enzymes 
detected by microarray analysis. Whilst these results are in discordance with findings 
from Hamilton et al. 2007 and do not suggest that the aggressive endocrine resistant 
cells exhibit a greater reliance upon endogenous HA, it may be argued that 
upregulation of CD44 in these cells would sensitise them to HA present in the tumour 
microenvironment. Indeed, although Auvinen et al. 2014 found a wide expression of 
HAS enzymes in both stromal and carcinoma cells across 278 breast cancer cases, a 
stronger correlation of these enzymes with disease recurrence and poor prognosis 
was found in stromal cells. These studies suggested that enhanced HAS expression in 
stromal cells was a more robust marker for tumour progression compared with HAS 
in carcinoma cells. Whilst numerous reports present a convincing role for HAS/HYAL 
enzymes in tumour progression behaviours in multiple carcinomas, including breast 
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cancer, this area remains largely unstudied and results have been contradictory. 
Furthermore, understanding the role of HAS/HYAL enzymes in breast cancer cell 
models under cell culture conditions remains complicated as cells may exhibit 
reduced capabilities to synthesise HA in vitro, even when derived from HA-enriched 
tumours (Knudson et al. 1989). Taken together, the role of HAS/HYAL enzymes across 
the cell models in this project remains incompletely understood and requires further 
elucidation, however data may indicate a greater reliance of Tam-R and Fas-R cells 
upon HA production from the microenvironment for their subsequent utilisation and 
HA-induced activities. 
4.3.1 Summary 
In this chapter, an important role for CD44 proteins in both the basal and HA-
stimulated adverse cellular phenotype of Tam-R and Fas-R cells has been shown. 
However due to the phenotypic differences between Tam-R (ER+) and Fas-R (ER-) 
cells and differential protein compositions, results suggest that CD44 proteins may 
activate alternative RTK signalling pathways in these cell lines to mediate distinct 
behavioural functions. Taken together, these data suggest that upregulation of CD44 
proteins in endocrine resistance may enhance their aggressive phenotype through 
RTK activation and sensitivity to their principle ligand, HA.  
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5. Exploration of RHAMM as a mediator of the aggressive phenotype 
of endocrine resistant breast cancer cells 
5.1 Introduction 
In the previous chapter it was demonstrated that HA augmented the migratory, 
invasive and proliferative capacity of the endocrine resistant, but not endocrine 
sensitive, cells. Given that the endocrine resistant cell models both overexpress 
CD44, the major receptor for HA, and siRNA suppression of CD44 reduced the HA 
augmented cellular functions in these cells, it is likely that these effects are mediated 
through the CD44 receptor. However, initial characterisation studies also revealed 
the expression of an additional hyaladherin, RHAMM, in Tam-R and Fas-R cells, albeit 
at a level similar to that observed in their parental endocrine sensitive MCF-7 cell 
line, thus, the contribution of RHAMM to the endogenous and HA-induced cellular 
behaviours of the endocrine resistant cell models remains unclear. Given that several 
studies have revealed a link between RHAMM expression and enhanced metastasis 
and poor prognosis in breast cancers (Wang et al. 1998; Hamilton et al. 2011; Veiseh 
et al. 2014; Wang et al. 2014), it may be possible that RHAMM possesses tumour-
promoting activity in endocrine resistant cells. 
Similarly to CD44, RHAMM undergoes alternative splicing, however the biological 
roles of  RHAMM are complex and it is one of the first proteins to be identified in 
which its intracellular and extracellular functions are distinct (Chivasa et al. 2006; 
Tjaslma et al. 2006). Intracellular full length RHAMM isoforms are cytoskeletal, 
centrosomal and nuclear proteins which mediate functions critical for mitotic spindle 
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integrity, progression through the cell cycle and cell division fidelity (Maxwell et al. 
2003; Groen et al. 2004; Tolg et al. 2010). Conversely, truncated cell surface RHAMM 
isoforms are exported to the cell surface where they associate with integral non-
protein/protein tyrosine kinase receptors to bind HA and mediate downstream 
signalling responses leading to enhanced cellular motility (Hamilton et al. 2007; 
Hatano et al. 2011; Park et al. 2012). At present the separate and coordinated 
functions of extracellular and intracellular RHAMM proteins remains to be elucidated 
(Chivasa et al. 2006; Tjaslma et al. 2006).  
The oncogenic functions of RHAMM have been predominantly linked to its 
extracellular functions as a consequence of its HA-binding capacity. Indeed, RHAMM 
has been implicated in breast cancer progression through the activation of multiple 
signalling cascades which control the expression of cell cycle and motility genes 
including: ras (Hall et al. 1995), Src (Hall et al. 1996), and MAPK (Wang et al 1998). 
Since RHAMM proteins lack a membrane spanning domain, cell surface RHAMM 
partners with various integral membrane receptors to mediate these functions 
(Savani et al. 2001; Manzanares et al. 2007; Hatano et al. 2011; Park et al. 2012). Of 
these, the most extensively studied associations of RHAMM in breast cancer is with 
the CD44 receptor. Indeed, Veiseh et al. 2014 revealed that CD44 and RHAMM co-
expression was found to be highest in aggressive triple negative subtypes of breast 
cancer cells which also exhibited the greatest degree of HA-binding; properties 
thought to contribute to the malignant phenotype. Furthermore, Hamilton et al. 
2007 established a role for the formation of RHAMM-CD44 complexes at the cell 
surface of the highly invasive MDA-MB-231 breast cancer cell line towards the 
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promotion of an HA-induced autocrine motility mechanism in an ERK1/2 dependent 
manner. These studies, and observations from other groups, have raised the 
possibility that cell surface RHAMM may partner with CD44 to enhance its 
localisation at the cell surface and ‘unleash’ its pro-migratory and invasive functions 
(Tolg et al. 2006). 
Taken together, numerous studies potentiate a role for RHAMM proteins within 
breast cancer oncogenesis particularly through their extracellular HA-binding 
capacity. As it was previously revealed that HA stimulation enhances the aggressive 
phenotype of the endocrine resistant cell models, the contribution of RHAMM to 
these HA-mediated behaviours was explored. As initial characterisation studies 
revealed that RHAMM proteins showed predominant cytoskeletal staining across all 
cell models, the role of RHAMM proteins towards the endogenous phenotype of the 
endocrine resistant cell models was also investigated.  
5.1.1 Objectives 
1. To investigate the contribution of RHAMM proteins towards the endogenous 
and HA-stimulated migratory, invasive and proliferative phenotype of 
endocrine resistant cell models by siRNA-mediated RHAMM suppression. 
2. To determine whether RHAMM is involved in endogenous and HA-stimulated 
signalling activity across the cell models of endocrine resistance. 
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5.2 Results 
5.2.1 RHAMM suppression inhibits proliferation of Tam-R cells 
Numerous reports have shown that RHAMM proteins mediate migratory, invasive 
and proliferative behaviours in breast cancer cells (Hamilton et al. 2007; Heldin et al. 
2013; Wang et al. 2014). Therefore, to investigate the contribution of RHAMM 
towards the aggressive phenotype of Tam-R and Fas-R cells, an siRNA based 
approach was used prior to the assessment of these behaviours in the presence (100 
µg/ml) and absence of HA. Initial Western blotting and immunocytochemistry 
analysis revealed that treatment of both Tam-R and Fas-R cells with global RHAMM 
siRNA reduced RHAMM expression in comparison to the NT-siRNA control and 
untreated control samples between 24 – 144 hours post-transfection (Figures 5.1 and 
5.2 respectively). Densitometry analysis revealed that RHAMM expression was 
significantly reduced between 72 - 144 hours post-transfection in Tam-R cells and 
between 48 – 144 hours post-transfection in Fas-R cells, compared to the NT-siRNA 
control cells (Figure 5.1). Densitometry analysis also confirmed that CD44 isoform 
expression was not significantly altered in Tam-R and Fas-R cells upon RHAMM 
suppression (Appendix L).  
Analysis of the functional effects of RHAMM suppression in the endocrine resistant 
cells revealed no significant alterations in the migratory or invasive capacity of Tam-
R or Fas-R cells (Figure 5.3 and Figure 5.4 respectively), however reduced the 
endogenous and HA-stimulated proliferation of Tam-R cells, but not Fas-R cells, 
compared to the NT-siRNA control (Figure 5.3 and Figure 5.4 respectively). 
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Figure 5.1. Representative Western blot images from 3 independent experiments showing 
RHAMM and CD44 isoform expression in Tam-R and Fas-R cells after treatment with global 
RHAMM siRNA between 24 – 144 hours post transfection in comparison to the untreated and NT-
siRNA treated control. GAPDH was used as a loading control. Densitometry graphs show RHAMM 
expression in Tam-R and Fas-R cells between 24 – 144 hours post-transfection. Error bars 
represent the average normalised data ±SEM from 3 independent experiments. The data is 
normalised to GAPDH and presented as the percentage of the untreated control. Statistical 
analysis was performed using an ANOVA test with tukey post-hoc analysis and values were 
compared to the NT-siRNA control sample. Significance was set at p < 0.05.  
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Figure 5.3. Measurement of endogenous and HA-stimulated cell behaviour of Tam-R cells after 
RHAMM suppression. Tam-R cells were treated with RHAMM siRNA for 48 hours prior to the 
assessment of migration, invasion (Boyden Chamber) and proliferation (Coulter Counter) in the 
presence (100 µg/ml) and absence of HA. Error bars represent the average normalised data ±SEM 
from 3 independent experiments and the data is presented as the percentage of the untreated 
control. Statistical analysis was performed using an unpaired t-test and significance set at p < 0.05.  
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Figure 5.4. Measurement of endogenous and HA-stimulated cell behaviour of Fas-R cells after 
RHAMM suppression. Fas-R cells were treated with RHAMM siRNA for 48 hours prior to the 
assessment of migration, invasion (Boyden Chamber) and proliferation (Coulter Counter) in the 
presence (100 µg/ml) and absence of HA. Error bars represent the average normalised data ±SEM 
from 3 independent experiments and the data is presented as the percentage of the untreated 
control. Statistical analysis was performed using an unpaired t-test and significance set at p < 0.05.  
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5.2.2 RHAMM suppression augments cellular signalling in Tam-R and Fas-R cells 
Given that RHAMM suppression led to a reduction in the proliferation of Tam-R cells, 
the next step was to explore the hypothesis that RHAMM may act to control cell 
growth through activation of signalling pathways. The effect of RHAMM suppression 
upon Fas-R signalling was also investigated. To investigate this hypothesis, the effect 
of RHAMM suppression upon endogenous and HA-stimulated FAK, Src and ERK1/2 
activation in the endocrine resistant cell models was explored; effectors known to be 
involved in RHAMM-mediated motility in breast cancer cells (Hall et al. 1994; Hall et 
al. 1996; Wang et al. 1998). Western blotting analysis revealed that RHAMM 
suppression led to a non-significant reduction in endogenous ERK1/2 activation in 
Tam-R cells and suppressed endogenous and HA-stimulated FAK activation in Fas-R 
cells, however Src activity was unaltered (Figures 5.5 - 5.8).  
RHAMM binding to CD44 has been reported to impact upon the signalling 
competency of this receptor (Hatano et al. 2011; Park et al. 2012), therefore it was 
important to determine the role of RHAMM in CD44-mediated signalling. As previous 
studies in this thesis revealed a role for CD44 in the activation of ErbB receptors, c-
Met and AKT in the endocrine resistant cell models, the modulation of these 
receptors upon RHAMM suppression was investigated. Western blotting analysis 
revealed a reduction in endogenous c-Met and AKT signalling and HA-induced c-Met 
and EGFR activation in Tam-R cells compared to the NT-siRNA control, confirmed by 
densitometry analysis (Figures 5.5 and 5.6). RHAMM suppression in Fas-R cells led to 
a non-significant decrease in endogenous c-Met activation and HA-stimulated EGFR 
and AKT signalling compared to the NT-siRNA control (Figures 5.7 and 5.8). 
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Figure 5.5. Representative Western blot images from 3 independent experiments showing HER2, 
EGFR, c-Met, FAK, AKT, Src and ERK1/2 activation in Tam-R cells treated with RHAMM siRNA for 
48 hours in the presence (10 minute treatment, 100 µg/ml) and absence of HA. GAPDH was used 
as a loading control. Total levels of each protein analysed were unchanged.  
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Figure 5.6. Densitometry graphs showing RHAMM expression and HER2, EGFR, c-Met, FAK, AKT, 
Src and ERK1/2 activation in Tam-R cells after 48 hour treatment with global RHAMM siRNA in the 
presence (215 kDa, 100 µg/ml, 10 minutes) of absence of HA, before cell lysis and detection by 
Western blotting analysis. The data shows the relative protein levels in the cell lines expressed as 
a ratio of the active protein:total protein normalised to GAPDH. Error bars represent the average 
normalised data ±SEM from 3 independent experiments and the data is presented as the 
percentage of the untreated control. Statistical analysis was performed using an unpaired t-test 
and significance was set at p < 0.05.  
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Figure 5.7. Representative Western blot images from 3 independent experiments showing HER2, 
EGFR, c-Met, FAK, AKT, Src and ERK1/2 activation in Fas-R cells treated with RHAMM siRNA for 48 
hours in the presence (10 minute treatment, 100 µg/ml) and absence of HA. GAPDH was used as 
a loading control. Total levels of each protein analysed were unchanged.  
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Figure 5.8. Densitometry graphs showing endogenous and HA-stimulated (215 kDa, 100 µg/ml, 10 
minutes) RHAMM expression and HER2, EGFR, c-Met, FAK, AKT, Src and ERK1/2 activation in Fas-
R cells before cell lysis and detection by Western blotting analysis. The data shows the relative 
protein levels in the cell lines expressed as a ratio of the active protein:total protein normalised to 
GAPDH. Error bars represent the average normalised data ±SEM from 3 independent experiments 
and the data is presented as the percentage of the untreated control. Statistical analysis was 
performed using an unpaired t-test and significance was set at p < 0.05.  
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5.3 Discussion 
This chapter set out to determine the contribution of the alternative hyaladherin 
RHAMM to endocrine resistance. Given that initial characterisation studies revealed 
the presence of RHAMM across our cell models and data revealed a role for HA in 
the augmentation of adverse cellular behaviours in both endocrine resistant cell 
models, together with numerous reports implicating RHAMM in breast tumour 
progression (Wang et al. 1998; Hamilton et al. 2007; Tolg et al. 2010), it was 
important to determine the contribution of RHAMM to these processes within the 
endocrine resistant cell models.  
The findings revealed that suppression of RHAMM did not alter the basal or HA-
stimulated behavioural functions of Fas-R cells and had only a modest impact upon 
EGFR, c-Met and AKT activation in these cells, however FAK activation was 
significantly suppressed in these cells. Furthermore, RHAMM suppression did not 
significantly impair the migratory or invasive function of Tam-R cells. Despite several 
reports linking RHAMM expression with breast cancer progression, RHAMM appears 
to be transforming only when overexpressed in these cells (Wang et al. 1998; Pujana 
et al. 2007) and high levels of RHAMM correlate with an aggressive phenotype 
(Hamilton et al. 2007; Vieseh et al. 2014). Given that the previous characterisation 
data revealed a similarly low level of RHAMM expression across all cell models, 
coupled with the data here, the inference is that RHAMM may not be a major 
contributor to the endocrine resistant phenotype.   
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However, an exception to this was observed in Tam-R cells where RHAMM inhibition 
impaired their basal and HA-stimulated proliferative capabilities potentially through 
a pathway involving c-Met and EGFR signalling respectively. Numerous studies 
document a role for RHAMM proteins towards the promotion of cellular motility in 
several carcinomas, however evidence remains limited in the context of breast 
cancer (Wang et al. 1998; Hamilton et al. 2007). It is thought that HA-induced 
RHAMM-mediated motility occurs through the cell surface activity of RHAMM 
proteins. However, as RHAMM proteins do not exhibit a membrane-spanning region, 
RHAMM must partner with various membrane receptors at the cell surface to 
mediate HA-induced signalling cascades. Numerous receptors have been 
characterised to partner with RHAMM, however the most extensively studied of 
these is with the CD44 and the CD44-EGFR complex (Tolg et al. 2006; Hatano et al. 
2011; Nikitovic et al. 2013). Indeed, multiple studies have revealed that high 
expression levels of both CD44 and RHAMM proteins are restricted to highly 
aggressive breast cancer cell lines (Hamilton et al. 2007; Veiseh et al. 2014). These 
studies propose that RHAMM enhances CD44 localisation to the surface of invading 
breast cancer cells thereby promoting sustained CD44-mediated signalling and 
elevated cellular motility (Tolg et al. 2006; Hatano et al. 2011). Through this 
mechanism RHAMM is thought to activate the motogenic functions of CD44 proteins.  
Given that CD44 and EGFR expression is elevated in the highly motile Tam-R cells, in 
combination with data which reveals that suppression of both RHAMM and CD44 
separately led to reduced HA-induced EGFR activation and cellular proliferation in 
these cells, it may be postulated that RHAMM plays a role in HA-stimulated CD44-
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EGFR mediated cellular motility of Tam-R cells. In support of this hypothesis, 
Hamilton et al. 2007 revealed that RHAMM and CD44 form a complex at the cell 
surface of highly invasive breast cancer cells to coordinate enhanced cellular motility 
in an ERK1/2 dependent manner. However, this group suggested that the aggressive 
breast cancer cell lines, MDA-MB-231 and Ras-MCF10A, establish an autocrine 
mechanism to promote enhanced cellular motility through high rates of endogenous 
HA synthesis; a phenomenon which the affymetrix data in this thesis suggested may 
not be exhibited by Tam-R cells. Furthermore, this group revealed that RHAMM and 
CD44 were both highly expressed in MDA-MB-231 cells and the formation of 
RHAMM-CD44 complexes was mediated by the oncogenic cell surface 63 kDa 
RHAMM isoform; which was upregulated in these invasive cell lines compared to 
their less invasive counterparts. Here lies further discordance with the data from the 
initial Western blotting characterisation studies in this thesis which detected only the 
full length 85 kDa RHAMM isoform at low levels across all cell models (Chapter 3, 
Figure 3.4) with little/no membrane staining observed by immunostaining analysis 
(Chapter 3, Figures 3.6 and 3.8). Whilst it may be suggested that the 85 kDa RHAMM 
isoform expressed by Tam-R cells may contribute to HA-mediated cellular signalling, 
numerous reports suggest that these isoforms are predominantly localised 
intracellularly and found to be associated with microtubules and mitotic spindles 
(Assmann et al. 1999; Tolg et al. 2010; Ma et al. 2014), whereas the amino-terminal 
truncated 63 kDa isoform is primarily implicated in cell surface activity (Hoffmann et 
al. 1998; Ahrens et al. 2001; Zaman et al. 2005). Indeed, the previous immunostaining 
analyses in this thesis support these findings and revealed predominant RHAMM 
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cytoskeleton and microtubule staining across all cell models (see Chapter 3, Figure 
3.6 and 3.8). Taken together, these data do not suggest a role for RHAMM in HA-
mediated CD44-EGFR activation in Tam-R cells. However, for further investigation of 
RHAMM-CD44 complex activity in the endocrine resistant cell models, future studies 
could be undertaken using double siRNA knockdown to investigate whether an 
additive effect upon proliferation occurs upon suppression of both RHAMM and 
CD44 expression. Furthermore, utilisation of confocal microscopy to investigate 
RHAMM interactions with CD44 and EGFR at the cell surface of Tam-R cells could be 
analysed to explore the mechanisms through which RHAMM may contribute to 
cellular motility.  
Whilst the extracellular functions of RHAMM are thought to be instrumental to the 
oncogenic effects of this protein, the mitotic spindle and centrosomal binding 
properties of RHAMM also have the potential to influence tumour progression. These 
centrosomal functions of RHAMM are critical for mitotic spindle integrity, 
progression through the cell cycle and cell division fidelity of breast cancer cells 
(Maxwell et al. 2003; Groen et al. 2004; Joukov et al. 2006). Furthermore, 
intracellular RHAMM has also been shown to regulate cell directionality, migration 
and facilitate cytoskeletal reorganisation (Smith et al. 2013; Chen et al. 2014). Indeed, 
the crucial role of RHAMM in these processes has been proven through 
overexpression and loss of function studies which reveal that, in both instances, 
deregulation of RHAMM expression results in the deformation of mitotic spindles 
(Maxwell et al. 2005; Tolg et al. 2010). Therefore, it could be postulated that loss of 
RHAMM expression in Tam-R cells may significantly impair cellular division processes 
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and cytoskeletal reorganisation leading to decreased cellular growth, and may 
suggest a minimal role for RHAMM proteins in HA-mediated activities in these cells; 
however the mechanism of this remains unclear.  
5.3.1 Summary 
In this chapter it has been shown that loss of RHAMM expression did not significantly 
alter the aggressive phenotype of Fas-R cells however impaired the proliferative 
capacity of Tam-R cells through an as-yet unknown mechanism. Whilst numerous 
studies have implicated a role for CD44-RHAMM complexes in breast cancer 
progression, these studies report that high expression levels of both hyaladherin 
receptors are required for enhanced cellular motility with particular importance 
placed upon the oncogenic amino-terminal truncated 63 kDa RHAMM protein; an 
isoform not detected across these cell models. Taken together, these data may not 
implicate RHAMM as a major contributor to acquired endocrine resistance and may 
infer a greater importance for CD44 proteins within the aggressive phenotype of 
these cells and as the principle receptor of HA-mediated signalling.   
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6. CD44 variants differentially modulate the aggressive phenotype of 
breast cancer cells 
6.1 Introduction 
In the previous chapters, it was demonstrated that loss of global CD44 expression 
impaired the aggressive phenotype of endocrine resistant cell models and 
attenuated their HA responses thus suggesting an important role for CD44 proteins 
in endocrine resistance. Whilst initial characterisation studies revealed elevated 
expression of multiple CD44 variants in endocrine resistant cell models compared to 
their endocrine sensitive counterpart, it remains unclear which of these may act as 
dominant contributors to the endocrine resistant phenotype. Numerous CD44 
isoforms have been shown to become upregulated in multiple carcinomas, however 
a large proportion of in vitro studies have focused upon CD44v3 and CD44v6 isoform 
expression and their prominent roles as promoters of tumour migration, invasion and 
spread, which has also been observed in the clinical setting (Kuniyasa et al. 2002; 
Wang et al. 2007; Saito et al. 2013; Shi et al. 2013; Marzese et al. 2014).  
In breast carcinomas, CD44v3 has been implicated in cytoskeletal-mediated cellular 
migration (Bourguignon et al 1998; Bourguignon et al. 1999) and in the clinical setting 
has been found to become upregulated in highly invasive tumours (Auvinen et al. 
2005) and correlated with lymph node metastases (Kalish et al. 1999; Rys et al. 2003). 
CD44v6 expression has also been shown to become upregulated in primary breast 
carcinomas (Auvinen et al. 2005; Lian et al. 2006) and correlated with tumour size, 
lymph node metastases and patient survival (Ma et al. 2005; Lian et al. 2006; Yu et 
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al. 2010). However, whilst some studies suggest CD44v6 as an independent 
prognostic factor of breast cancer (Lian et al. 2006; Yu et al. 2010) others suggest this 
is not the case (Jansen et al. 1998; Ma et al. 2005). In recent years the presence of 
CD44v6 has also been suggested to be a marker of cancer stem cells (in combination 
with other proteins) in breast cancer (Synder et al. 2009) as well as numerous other 
carcinomas (Wang et al. 2013; Ni et al. 2014; Todaro et al. 2014). However 
controversy regarding the role of specific CD44 isoforms in breast cancer still remains 
a problem due to contradictory findings (Morris et al. 2001; Berner et al. 2003; Shah 
et al. 2010).  
Whilst the HA-binding domain is common to all CD44 isoforms, thus conferring the 
potential for HA-mediated cellular responses, individual CD44 variants exhibit 
specific ligand and membrane receptor affinity which may also enhance their 
metastatic capacity. For example, the CD44 variant 3 exon contains the attachment 
site for the proteoglycan heparan sulphate (HPS) which is responsible for the 
presentation of several growth factors to their receptors (Bennet et al. 1995; Van der 
Voort et al. 1999). In this respect, CD44v3 isoforms have been shown to contribute 
to the malignant behaviour of cancer cells through HPS binding. Indeed, in colon 
cancer cells, HPS interaction with CD44v3 proteins has been shown to enhance 
tumour growth and invasion, in some instances in collaboration with the c-met 
receptor (Van der voort et al. 1999; Wielenga et al. 2000; Kuniyasa et al. 2001). 
Additionally, CD44v3-containing isoforms have been functionally linked to TGFßR1, 
MMP-9 and the cytoskeletal proteins ankyrin and Rho-kinase, resulting in the 
promotion of breast cancer invasion and metastasis through invadopodia formation 
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and enhanced degradation of the extracellular matrix (Bourguignon et al. 1998; 
Bourguignon et al. 1999; Bourguignon et al. 2002). Alternatively, CD44v6 has been 
reported to exhibit specific co-receptor function for the activation of the receptor 
tyrosine kinases, c-Met and VEGFR2 (Tremmel et al. 2009; Hasenaeur et al. 2013; 
Elliot et al. 2014). Indeed, CD44v6 has been shown to be required for the full 
activation and internalisation of the c-Met receptor (Orian-Roussaeu et al. 2002; 
Hasenauer et al. 2013) and loss of CD44 correlates with c-Met haploinsufficiency in 
mouse models (Matkze et al. 2007). Therefore, it could be suggested that 
contradictory results involving CD44 isoforms in breast cancer may be due to the 
differential bio-availability of specific ligands/membrane co-receptors between 
tumours.  
Given that CD44v3 and CD44v6 isoforms have been strongly implicated within breast 
cancer progression and elevated in models of endocrine resistance, the aims of this 
chapter were to explore the functional contribution of these specific variant isoforms 
to the endocrine resistant phenotype.  
6.1.1 Objectives 
1. To overexpress CD44v3 and CD44v6 isoforms in endocrine sensitive MCF-7 
cells and investigate their subsequent effect upon the aggressive nature 
and/or response to HA in these cells. 
2. To suppress specific CD44 isoform expression using targetted siRNA in 
endocrine resistant Tam-R and Fas-R cells and explore the resultant effect on 
cellular phenotype and response to HA along with changes in cell signalling. 
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3. To determine whether CD44 isoforms are linked to outcome on tamoxifen 
through immunohistochemical analysis of clinical samples and to perform 
survival analysis on publically available breast cancer datasets (KM plotter). 
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6.2 Results 
6.2.1 Optimisation of CD44v3 and CD44v6 overexpression in MCF-7 cells 
To begin to explore the functional contribution of CD44v3 and CD44v6 to endocrine 
resistant cell behaviour, a transfection-based approach was used to overexpress 
these isoforms in the endocrine sensitive MCF-7 cell model. Plasmid vectors 
containing DNA encoding full length human CD44v3 and CD44v6 were obtained from 
Dr Ursula Gunthert (Basal University, Switzerland). This group additionally provided 
the cytoplasmic tail truncated counterparts of CD44v3 and CD44v6 (missing the DNA 
sequence encoding the cytoplasmic tail domain, denoted as CD44v3∆cyt and 
CD44v6∆cyt respectively) to use as transfection controls, as loss of the cytoplasmic 
tail is reported to block CD44 cellular signalling and functional activities (Mielgo et al. 
2007). All plasmid constructs contain an EGFP-tag fused at the carboxy-terminus end 
of the CD44 protein.  
Plasmid DNA constructs were transformed and purified before being utilised for 
transfection into MCF-7 cells. To confirm the successful purification of plasmid DNA 
constructs, samples were initially sequenced (see Materials and Methods 2.12.4). 
The results confirmed the presence of the variant 3 and variant 6 exon in the CD44v3 
and CD44v6 plasmid DNA construct respectively and further verified the truncation 
of the CD44 cytoplasmic tail sequence at the correct position in the CD44∆cyt 
samples (Appendix I). Sequencing analysis revealed a base pair mutation in the 
variant 3 exon of the CD44v3 and CD44v3∆cyt DNA constructs leading to an amino 
acid substitution (N239D), however subsequent investigations suggested that this 
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substitution is unlikely to alter CD44v3 function (shown in Appendix M and N) and 
evaluated in the discussion section below (6.3)). No other base pair mutations were 
detected across the plasmid DNA constructs. 
Western blotting analysis using antibodies specific for CD44v3 and CD44v6 detection 
confirmed the successful transfection of plasmid constructs and showed upregulated 
expression of CD44v3, CD44v3∆cyt, CD44v6 and CD44v6∆cyt in MCF-7 cells between 
48 - 144 hours post-transfection compared to the control cells which did not alter the 
expression of alternative CD44 variant isoforms (Figures 6.1 and 6.2). Densitometry 
analysis could not be performed on this overexpression data due to limitations by 
Western blotting analysis due to exposure issues, however analysis revealed that the 
expression of alternative isoforms were not altered upon CD44 overexpression in 
MCF-7 cells (Appendix O and P).Whilst RHAMM expression was modestly reduced in 
MCF-7 cells overexpressing CD44v3, CD44v6 and CD44v6∆cyt proteins, densitometry 
analysis revealed that this was not significant (Figure 6.1 and 6.2 and Appendix O and 
P). Whilst analysis revealed that CD44 variant overexpression in MCF-7 cells 
enhanced CD44 Std isoform expression (Figure 6.1 and 6.2) this is likely to be a result 
of the CD44 Std antibody recognising an epitope which is common to all CD44 
isoforms.  
An increase in the expected molecular weight of these proteins was observed due to 
the presence of a 27 kDa EGFP tag on each construct (Figure 6.1 and 6.2). The CD44 
cytoplasmic tail (excluding exon 19 which is not present in the majority of CD44 
transcripts (Goldstein and Butcher 1990; Jiang et al. 2001)) is encoded by 70 amino 
acids and has a molecular weight of approximately 7.8 kDa. Therefore CD44v3∆cyt 
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and CD44v6∆cyt isoforms were detected at 104 kDa in MCF-7 cells (a molecular 
weight of 7.8 kDa lower than their full length counterparts) (Figure 6.1 and 6.2). This 
observation has also been shown by other groups using CD44 cytoplasmic tail 
truncated mutants (Neame and Isacke 1993; Gal et al. 2003; Mielgo et al. 2007 
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Figure 6.1. Representative Western blot images from 3 independent experiments showing 
CD44v3 and CD44v3∆cyt protein expression levels in MCF-7 cells 24 – 144 hours post-transfection 
compared to the untreated and lipid-only control samples. Protein expression levels of CD44 Std, 
CD44v6 and CD44v10 were unchanged however CD44v3 overexpression modestly reduced 
RHAMM expression. ß-actin was used as a loading control.  
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Figure 6.2. Representative Western blot images from 3 independent experiments showing 
CD44v6 and CD44v6∆cyt protein expression levels in MCF-7 cells 24 – 144 hours post-transfection 
compared to the untreated and lipid-only control samples. Protein expression levels of CD44 Std, 
CD44v3 and CD44v10 were unchanged however RHAMM expression was modestly reduced. ß-
actin was used as a loading control.  
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Immunostaining analysis was utilised to confirm the protein expression and 
localisation of CD44 variant constructs in transfected MCF-7 cells. 
Immunocytochemistry revealed the upregulation of CD44v3, CD44v3∆cyt, CD44v6 
and CD44v6∆cyt proteins in MCF-7 cells 48 – 144 hours post transfection, compared 
to the control samples (Figure 6.3). These data also revealed that CD44v3 and CD44v6 
isoforms overexpressed in MCF-7 cells showed similar localisation patterns to their 
endogenous control cells, whilst CD44v3∆cyt and CD44v6∆cyt isoforms were 
predominantly expressed in the cytoplasm, however limited membrane expression 
of these isoforms was also observed (Figure 6.3). Furthermore, Figure 6.4 reveals that 
transfection of MCF-7 cells with CD44v6 and CD44v6∆cyt led to a similar expression 
level as that observed for the endogenous levels of CD44v6-containing proteins in 
endocrine resistant Tam-R and Fas-R cell models. Conversely, CD44v3 and 
CD44v3∆cyt transfection in MCF-7 cells led to an enhanced expression of these 
proteins as compared with levels of endogenous CD44v3-containing proteins in Tam-
R and Fas-R cells (Figure 6.4) which must be taken into consideration upon further 
analysis.  
These results were further validated by immunofluorescence analysis using CD44 
specific antibodies and visualisation of the EGFP-tagged constructs. The results also 
showed predominant cytoplasmic staining for CD44v3, CD44v3∆cyt and CD44v6∆cyt 
proteins, and predominant membrane staining for CD44v6 proteins, in MCF-7 cells 
compared to their untransfected lipid-treated control cells (Figures 6.5 and 6.6).   
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6.2.2 CD44v6, but not CD44v3, overexpression enhanced the invasive capacity of 
MCF-7 cells and attenuated their sensitivity to fulvestrant 
As previous data revealed that loss of global CD44 protein expression impaired the 
migratory, invasive and proliferative phenotype of both endocrine resistant models, 
the hypothesis that overexpression of CD44v3 and CD44v6 in endocrine sensitive 
MCF-7 cells may replicate these behaviours to some extent was explored. Previous 
data also revealed that the highly CD44-expressing endocrine resistant cell models 
were sensitised to HA, an observation not observed in the low CD44-expressing 
endocrine sensitive MCF-7 cells. Therefore it was also investigated whether 
overexpression of individual CD44 isoforms in MCF-7 cells augmented their 
sensitivity to HA leading to an enhanced aggressive phenotype. The same 
concentration of HA (100 µg/ml), previously shown to stimulate functional responses 
in the highly CD44-expressing Tam-R and Fas-R cells, was used for these assays.  
Boyden chamber assays revealed that CD44v3 overexpression in MCF-7 cells reduced 
their endogenous and HA-stimulated migratory capacity across fibronectin-coated 
membranes, however enhanced HA-induced invasion through Matrigel compared to 
the CD44v3∆cyt transfection control cells (Figure 6.7). In contrast, CD44v6-
overexpression in MCF-7 cells enhanced their endogenous invasive phenotype 
through Matrigel compared to the CD44v6∆cyt control (Figure 6.8). 
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Figure 6.7. Measurement of endogenous and HA-stimulated cell behaviour responses of MCF-7 
cells overexpressing CD44v3. MCF-7 cells were transfected with CD44v3 or CD44v3∆cyt plasmid 
DNA for 48 hours prior to the assessment of migration and invasion (Boyden Chamber assays) and 
proliferation (Coulter counter assays) in the presence (100 µg/ml) or absence of HA. Control cells 
represent lipid-treated MCF-7 cells. Error bars represent the average normalised data ±SEM from 
3 independent experiments and the data is presented as the percentage of the untreated control. 
Statistical analysis was performed using an unpaired t-test and significance set at p < 0.05. 
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Figure 6.8. Measurement of endogenous and HA-stimulated cell behaviour responses of MCF-7 
cells overexpressing CD44v6. MCF-7 cells were transfected with CD44v6 or CD44v6∆cyt plasmid 
DNA for 48 hours prior to the assessment of migration and invasion (Boyden Chamber assays) and 
proliferation (Coulter counter assays) in the presence (100 µg/ml) or absence of HA. Control cells 
represent lipid-treated MCF-7 cells. Error bars represent the average normalised data ±SEM from 
3 independent experiments and the data is presented as the percentage of the untreated control. 
Statistical analysis was performed using an unpaired t-test and significance set at p < 0.05. 
Cell Migration
Control CD44v6cyt CD44v6
0
50
100
150
No HA
HA 100 µg/ml
%
 C
o
n
tr
o
l
Cell Proliferation
Control CD44v6cyt CD44v6
0
50
100
150
No HA
HA 100 µg/ml
%
 C
o
n
tr
o
l
Cell Invasion
Control CD44v6cyt CD44v6
0
100
200
300
400
No HA
HA 100 µg/ml
* p < 0.05
*
%
 C
o
n
tr
o
l
  
 
 
 
181 
 
Previous published studies from the Hiscox group (2012) suggested that CD44 
expression may also limit endocrine response in breast cancer cells. To investigate 
this, the growth of CD44-transfected MCF-7 cells in the presence of tamoxifen or 
fulvestrant for 5 days was assessed. Coulter counter proliferation assays revealed 
that tamoxifen treatment significantly inhibited the growth of lipid-treated MCF-7 
control cells and MCF-7 cells overexpressing CD44v3, CD44v3∆cyt, CD44v6 or 
CD44v6∆cyt proteins (Figure 6.9). However, whilst treatment with fulvestrant 
significantly reduced the growth of untransfected MCF-7 control cells, no significant 
impairment in growth was observed in MCF-7 cells overexpressing any of the CD44 
constructs (Figure 6.10). Surprisingly, the CD44v3∆cyt and CD44v6∆cyt transfection 
controls exhibited a similar growth response in the presence of fulvestrant compared 
to their full length CD44v3 and CD44v6 counterparts respectively (Figure 6.10). 
ANOVA testing to reveal significant changes between each group revealed an 
increase in growth between untransfected and CD44v6-overexpressing MCF-7 cells 
in the presence of fulvestrant (Figure 6.10). These results suggest that CD44v6 
overexpression attenuates the ability of MCF-7 cells to respond to fulvestrant, 
resulting in an enhanced proliferative capacity of these cells compared to the 
untransfected control cells.  
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Figure 6.9. Measurement of growth response in MCF-7 cells overexpressing CD44 proteins in the 
presence of tamoxifen. MCF-7 cells were transfected with CD44v3, CD44v3∆cyt, CD44v6, or 
CD44v6∆cyt plasmid constructs for 48 hours prior to the assessment of growth (Coulter Counter 
assay) in the presence (100 nM) or absence of tamoxifen for 5 days. Control cells represent lipid-
treated MCF-7 cells.  Error bars represent the average normalised data ±SEM from 3 independent 
experiments and the data is presented as the percentage of the untreated control for each group. 
Statistical analysis was performed using a paired t-test and one-way ANOVA with Tukey post-hoc 
testing and significance set at p < 0.05. 
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Figure 6.10. Measurement of growth response in MCF-7 cells overexpressing CD44 proteins in the 
presence of fulvestrant. MCF-7 cells were transfected with CD44v3, CD44v3∆cyt, CD44v6 or 
CD44v6∆cyt plasmid constructs for 48 hours prior to the assessment of growth (Coulter Counter 
assay) in the presence (100 nM) or absence of fulvestrant for 5 days. Control cells represent lipid-
treated MCF-7 cells. Error bars represent the average normalised data ±SEM from 3 independent 
experiments and the data is presented as the percentage of the untreated control for each group. 
Statistical analysis was performed using a paired t-test and one-way ANOVA with Tukey post-hoc 
testing and significance set at p < 0.05. 
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6.2.3 CD44v6 overexpression in MCF-7 cells enhanced EGFR pathway activity 
Data generated from the global CD44 siRNA studies (Chapter 4) suggested a role for 
CD44 proteins in the activation of several signalling pathways potentially through co-
receptor activation of receptor tyrosine kinases, EGFR, HER2 or c-Met. To explore the 
mechanisms through which CD44v3 and CD44v6 overexpression may alter the 
behavioural phenotype of MCF-7 cells, the activation of these signalling molecules 
were reassessed by Western blotting analysis in the presence (100 µg/ml) or absence 
of HA.  
Surprisingly, the data revealed that the CD44v3∆cyt and CD44v6∆cyt transfection 
controls induced cellular signalling upon overexpression in MCF-7 cells, a previously 
unreported phenomenon (Figure 6.11 – 6.14). MCF-7 cells overexpressing either 
CD44v3 or CD44v3∆cyt proteins showed an enhanced endogenous activation of AKT, 
reduced HA-stimulated HER2 activation and reduced endogenous and HA-stimulated 
ERK1/2 compared to control cells (Figures 6.11 and 6.12). CD44v3 overexpression 
alone reduced endogenous and HA-stimulated EGFR and HA-stimulated Met 
activation compared to the control cells (Figures 6.11 and 6.12). Conversely, MCF-7 
cells overexpressing either CD44v6 or CD44v6∆cyt proteins substantially enhanced 
endogenous and HA-induced activation of EGFR, AKT and ERK1/2 and reduced c-Met 
activation compared to the untransfected control cells (Figures 6.13 and 6.14). 
CD44v6 overexpression alone reduced HA-stimulated HER2 activation compared to 
the untransfected control cells (Figures 6.13 and 6.14). Surprisingly, overexpression 
of CD44 variants in MCF-7 cells did not appear to sensitise the cells to HA (Figures 
6.11 – 6.14).  
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Figure 6.11. Representative Western blot images from 3 independent experiments showing 
HER2, EGFR, c-Met, FAK, Src, AKT and ERK1/2 activation in MCF-7 cells after 48 hour transfection 
with CD44v3 or CD44v3∆cyt plasmid DNA in the presence (10 minute treatment, 100 µg/ml) or 
absence of HA. Control cells represent lipid-treated MCF-7 cells. Total protein levels were 
unchanged however total HER2 became reduced and GAPDH was used as a loading control. 
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Figure 6.12. Densitometry graphs showing CD44v3 expression and HER2, EGFR, c-Met, FAK, AKT, 
Src and ERK1/2 activation in MCF-7 cells after 48 hour transfection with CD44v3 or CD44v3∆cyt 
plasmid DNA in the presence (10 minute treatment, 100 µg/ml) or absence of HA. The data shows 
the relative protein levels in the cell lines expressed as a ratio of the active protein:total protein 
normalised to GAPDH. Error bars represent the average normalised data ±SEM from 3 
independent experiments and the data is presented as the percentage of the untreated control. 
Statistical analysis was performed using an unpaired t-test and significance was set at p < 0.05.  
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Figure 6.13. Representative Western blot images from 3 independent experiments showing HER2, 
EGFR, c-Met, FAK, Src, AKT and ERK1/2 activation in MCF-7 cells after 48 hour transfection with 
CD44v6 or CD44v6∆cyt plasmid DNA in the presence (10 minute treatment, 100 µg/ml) or absence 
of HA. Control cells represent lipid-treated MCF-7 cells. Total protein levels were unchanged and 
GAPDH was used as a loading control. 
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Figure 6.14. Densitometry graphs showing CD44v6 expression and HER2, EGFR, c-Met, FAK, AKT, Src 
and ERK1/2 activation in MCF-7 cells after 48 hour transfection with CD44v6 or CD44v6∆cyt plasmid 
DNA in the presence (10 minute treatment, 100 µg/ml) or absence of HA. The data shows the relative 
protein levels in the cell lines expressed as a ratio of the active protein:total protein normalised to 
GAPDH. Error bars represent the average normalised data ±SEM from 3 independent experiments 
and the data is presented as the percentage of the untreated control. Statistical analysis was 
performed using an unpaired t-test and significance was set at p < 0.05.  
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6.2.4 CD44v6 overexpression in MCF-7 cells enhanced cellular invasion via EGFR 
activation and subsequent downstream signalling responses 
The data thus far suggested that CD44v6 overexpression in MCF-7 cells led to 
enhanced EGFR pathway activation and increased cellular invasion. To investigate 
the hypothesis that CD44v6 may promote the aggressive phenotype of MCF-7 cells 
through the activation of the EGFR pathway, inhibition of EGFR (by use of the 
inhibitor, gefitinib) and subsequent assessment of cellular invasion in MCF-7 cells was 
explored.  
Boyden Chamber assays revealed a significant reduction in the ability of CD44v6-
overexpressing MCF-7 cells to invade through Matrigel in the presence of gefitinib 
compared to the untreated CD44v6-overexpressing cells, and reduced their invasive 
capacity similar to the level of untransfected and CD44v6∆cyt-transfected MCF-7 
control cells (Figure 6.15). Although CD44v6∆cyt overexpression in MCF-7 cells 
enhanced EGFR signalling, this did not lead to enhanced invasion and treatment with 
gefitinib did not alter the invasive capacity of these cells (Figure 6.15).  
 
As previous data revealed that CD44v6 overexpression in MCF-7 cells enhanced the 
activation of the downstream effectors of the EGFR pathway, AKT and ERK1/2, the 
effect of gefitinib treatment upon the activity of these signalling molecules was 
investigated. Western blotting and densitometry analysis revealed that gefitinib 
treatment significantly attenuated the activity of EGFR, AKT and ERK1/2 in CD44v6- 
and CD44v6∆cyt-overexpressing MCF-7 cells compared to their untreated 
counterparts (Figure 6.16).  
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Figure 6.15. Measurement of cell invasion in MCF-7 cells overexpressing CD44v6 or CD44v6∆cyt 
proteins in the presence and absence of gefitinib. MCF-7 cells were transfected with CD44v6 or 
CD44v6∆cyt plasmid DNA for 48 hours prior to the assessment of invasion (Boyden Chamber 
assay) in the presence (1 µM) or absence of the EGFR inhibitor, gefitinib. Control cells represent 
lipid-treated MCF-7 cells. Error bars represent the average normalised data ±SEM from 3 
independent experiments and the data is presented as the percentage of the untreated control. 
Statistical analysis was performed using a paired t-test and significance set at p < 0.05. 
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Figure 6.16. Representative Western blot images and densitometry graphs from 3 independent 
experiments showing EGFR, AKT and ERK1/2 activation in MCF-7 cells after 48 hour transfection 
with CD44v6 or CD44v6∆cyt plasmid DNA in the presence (1 µM, 5 minutes) or absence of the 
EGFR inhibitor gefitinib. Control cells represent lipid-treated MCF-7 cells. Total protein levels were 
unchanged with the exception of total EFGR which was reduced in CD44v6∆cyt and CD44v6 cells 
treated with gefitinib. GAPDH was used as a loading control.  The data shows the relative protein 
levels in the cell lines expressed as a ratio of the active protein:total protein normalised to GAPDH. 
Error bars represent the average normalised data ±SEM from 3 independent experiments and the 
data is presented as the percentage of the untreated control. Statistical analysis was performed 
using an unpaired t-test and significance was set at p < 0.05.  
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6.2.5 CD44v6 suppression attenuated growth and invasion of Tam-R cells and 
enhanced their cellular migration 
Based on the transfection data which suggested a role for both CD44v3 and CD44v6 
as promoters of cellular invasion in MCF-7 cells, together with numerous reports 
revealing a correlation between overexpression of these isoforms and enhanced 
tumour metastasis and invasion in numerous carcinomas (Herrera-Gayol and Jothy 
1999; Ni et al. 2002; Lui et al. 2005; Shi et al. 2013; Ni et al. 2014), the next step was 
to investigate whether these effects were also observed in the endocrine resistant 
cell models. For this purpose, CD44v6-specific siRNA was designed using BLOCK-iTTM 
RNAi Designer (Invitrogen Life Technologies, see Materials and Methods 2.12.1). 
However, due to the small size of CD44 variant 3 exon (126 bp), no unique sequence 
was available to specifically target this isoform, therefore investigation of CD44v3 
function in endocrine resistant cell models using an siRNA based approach could not 
be undertaken.  
Optimisation experiments revealed that treatment of Tam-R and Fas-R cells with 
CD44v6 siRNA resulted in a significant suppression of all CD44v6-containing isoforms 
compared to the NT-siRNA-treated cells between 24 - 144 hours post-transfection 
(Figure 6.17 and 6.18). Furthermore, these data confirmed that CD44v6 suppression 
did not substantially alter the expression of alternative CD44 isoforms in these cells 
(Figure 6.17 and Appendix Q). Whilst Western blotting analysis revealed that 
RHAMM expression become modestly suppressed in Tam-R cells between 48 – 72 
hours post-transfection, densitometry analysis revealed that this was not significant 
(Appendix Q). Furthermore, a small reduction in CD44 Std isoform expression was 
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observed in these cells which is likely the result of the CD44 Std antibody recognising 
an epitope common to all CD44 isoforms (Figure 6.17). Densitometry analysis 
revealed that CD44 Std suppression was significant between 24 – 144 hours post-
transfection in Tam-R cells, and at 144 hours post-transfection in Fas-R cells, 
compared to the NT- siRNA control cells (Appendix Q). 
 
 
 
 
 
 
Figure 6.17. Representative Western blot images from 3 independent experiments showing CD44 
isoform and RHAMM protein expression in Tam-R and Fas-R cells after treatment with CD44v6 
siRNA for 24 – 144 hours in comparison to the untreated and NT-siRNA treated controls.  GAPDH 
was used as a loading control. Densitometry graphs show CD44v6 expression in Tam-R and Fas-R 
cells between 24 – 144 hours post-transfection. Error bars represent the average normalised data 
±SEM from 3 independent experiments. Data is normalised to GAPDH and presented as the 
percentage of the untreated control. Statistical analysis was performed using an ANOVA test with 
tukey post-hoc analysis and values were compared to the NT-siRNA control sample.  
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Analysis of the functional effects of CD44v6 suppression in the endocrine resistant 
cell lines revealed that Tam-R cells treated with CD44v6-siRNA led to a reduction in 
their invasive capacity through Matrigel and attenuated their endogenous and HA-
induced proliferative capacity compared to the NT-siRNA control cells (Figure 6.19). 
In contrast, CD44v6 suppression enhanced the endogenous and HA-stimulated 
migratory capacity of Tam-R cells compared to the NT-siRNA control cells (Figure 
6.19). Interestingly, CD44v6 suppression in Fas-R cells had no significant impact upon 
their migratory, invasive or proliferative behaviours compared to the NT-siRNA 
control cells (Figure 6.20).  
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Figure 6.19. Measurement of endogenous and HA-stimulated cell behaviour responses of Tam-R 
cells upon CD44v6 suppression. Tam-R cells were transfected with NT- or CD44v6-siRNA for 48 
hours prior to the assessment of migration and invasion (Boyden Chamber assays) and 
proliferation (Coulter counter assays) in the presence (100 µg/ml) and absence of HA. Error bars 
represent the average normalised data ±SEM from 3 independent experiments and the data is 
presented as the percentage of the untreated control. Statistical analysis was performed using an 
unpaired t-test and significance set at p < 0.05. 
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Figure 6.20. Measurement of endogenous and HA-stimulated cell behaviour responses of Fas-R 
cells upon CD44v6 suppression. Fas-R cells were transfected with NT- or CD44v6-siRNA for 48 
hours prior to the assessment of migration and invasion (Boyden Chamber assays) and 
proliferation (Coulter counter assays) in the presence (100 µg/ml) and absence of HA. Error bars 
represent the average normalised data ±SEM from 3 independent experiments and the data is 
presented as the percentage of the untreated control. Statistical analysis was performed using an 
unpaired t-test and significance set at p < 0.05. 
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Previous data revealed that CD44v6 overexpression in MCF-7 cells enhanced EGFR, 
AKT and ERK1/2 activation (Figure 6.12). To determine whether these proteins were 
modulated upon CD44v6 suppression in endocrine resistant cells, and to further 
explore the mechanisms through which CD44v6 suppression may alter the 
behavioural function of Tam-R cells, the activation of several signalling components 
were reassessed by Western blotting analysis in the presence or absence of HA. The 
effect of CD44v6 suppression upon cellular signalling was also investigated in Fas-R 
cells. 
Western blotting and densitometry analysis revealed that CD44v6 suppression 
almost significantly reduced endogenous and HA-stimulated EGFR, AKT and ERK1/2 
activation and HA-stimulated FAK in Tam-R cells compared to the NT-siRNA control 
cells (Figures 6.21 and 6.22). In Fas-R cells, CD44v6 suppression significantly reduced 
endogenous c-Met and AKT activation and HA-stimulated c-Met activation compared 
to the NT-siRNA control cells (Figure 6.23 and 6.24).  
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Figure 6.21. Representative Western blot images from 3 independent experiments showing HER2, 
EGFR, c-Met, FAK, AKT, Src and ERK1/2 activation in Tam-R cells after 48 hour transfection with NT- 
or CD44v6-siRNA in the presence (10 minute treatment, 100 µg/ml) or absence of HA. Total protein 
levels were unchanged and GAPDH was used as a loading control.  
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Figure 6.22. Densitometry graphs showing CD44v6 expression and HER2, EGFR, c-Met, FAK, AKT, 
Src and ERK1/2 activation in Tam-R cells after 48 hour treatment with CD44v6 siRNA in the presence 
(215 kDa, 100 µg/ml, 10 minutes) and absence of HA, before cell lysis and detection by Western 
blotting analysis. The data shows the relative protein levels in the cell lines expressed as a ratio of 
the active protein:total protein normalised to GAPDH. Error bars represent the average normalised 
data ±SEM from 3 independent experiments and the data is presented as the percentage of the 
untreated control. Statistical analysis was performed using an unpaired t-test and significance was 
set at p < 0.05.  
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Figure 6.23. Representative Western blot images from 3 independent experiments showing HER2, 
EGFR, c-Met, FAK, AKT, Src and ERK1/2 activation in Fas-R cells after 48 hour transfection with NT- 
or CD44v6-siRNA in the presence (10 minute treatment, 100 µg/ml) or absence of HA. Total 
protein levels were unchanged and GAPDH was used as a loading control.  
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Figure 6.24. Densitometry graphs showing CD44v6 expression and HER2, EGFR, c-Met, FAK, AKT, 
Src and ERK1/2 activation in Tam-R cells after 48 hour treatment with CD44v6 siRNA in the presence 
(215 kDa, 100 µg/ml, 10 minutes) and absence of HA, before cell lysis and detection by Western 
blotting analysis. The data shows the relative protein levels in the cell lines expressed as a ratio of 
the active protein:total protein normalised to GAPDH. Error bars represent the average normalised 
data ±SEM from 3 independent experiments and the data is presented as the percentage of the 
untreated control. Statistical analysis was performed using an unpaired t-test and significance was 
set at p < 0.05.  
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6.2.6 CD44 is associated with an increased duration of response to endocrine 
therapy in ER+ breast cancer 
To begin to establish if there is an association between CD44 and clinical parameters, 
CD44 mRNA expression was analysed in clinical breast cancer using the publically 
available online KM Plotter tool (see Materials and Methods 2.4) to determine any 
clinical value following endocrine treatment. This tool is able to study publically 
available breast cancer gene microarray mRNA expression data collected from 
clinical samples prior to endocrine therapy and also contains associated survival-
related information. KM plotter allows the generation of survival curves with Log 
Rank testing to determine any significant association between inherent expression 
levels for genes of interest and clinical outcome. As of yet, no fulvestrant-treated 
clinical microarray datasets are publically available for KM Plotter analyses.  
To analyse the association between CD44 and duration of relapse free survival (RFS) 
in this project, the patient data was split into 2 groups using the optimal cut-off tool 
provided within KM Plotter using a Kaplan-Meier plot. RFS was used as the measure 
of clinical outcome and patients selected were ER+ and had subsequently received 
any form of endocrine therapy (excluding chemotherapy). Analysis revealed that high 
CD44 mRNA expression associated with significantly increased duration of response 
to endocrine therapy compared to patients with low CD44 mRNA expression (p = 
0.0055) (Figure 6.25). However, when RFS was used as a measure of clinical outcome 
and patients selected were ER+ and subsequently received tamoxifen treatment 
only, although high levels of CD44 were again associated with increased duration of 
response, this did not reach significance (p = 0.28) (Figure 6.25).  
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Figure 6.25. Kaplan Meier survival curves generated by KM Plotter to display the association 
between CD44 mRNA expression and relapse free survival (RFS) in ER+ treated with any endocrine 
therapy (n = 1190) or confined to tamoxifen treatment (n = 615). The survival curves were 
generated using the Jetset affymetrix gene probe for CD44 (212063_at) and patients were 
grouped by optimal fit (as calculated by KM Plotter). The Hazard Ratio (HR) (with 95% confidence 
intervals) and logrank p values are shown.  
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6.2.6.1 CD44v6 and EGFR co-expression is associated with a worsened outcome in 
a small exploratory patient series of tamoxifen-treated ER+ breast cancer patients 
Whilst KM Plotter analyses revealed an association between high CD44 mRNA 
expression levels and prolonged RFS in endocrine-treated ER+ breast cancer patients, 
this analysis does not take into consideration the expression of specific CD44 
isoforms and accounts only for total CD44 mRNA expression in these patients. Given 
that the experimental data suggested evidence for different roles for CD44 isoforms 
in breast cancer behaviours, notably implicating a role for CD44v6-mediated EGFR 
activation as a contributor towards cellular invasion in tamoxifen resistance, the 
clinical relevance of these findings using in-house immunohistochemistry data was 
explored. 
A series of formalin-fixed paraffin-embedded tissue microarray (TMA) sections 
(provided by Dr Andrew Green, Nottingham University) including 140 patients with 
primary breast cancers from ER+ adjuvant tamoxifen patients with 20 year follow up 
was assessed by the group for CD44v6 using H-score analysis (see Appendix R). 
Derived H-scores were subsequently analysed in this project versus relevant 
clinicopathological parameters including: EGFR immunostaining (10 % cutpoint), 
disease-free interval (DFI) and overall survival (OS) available for all these in 
tamoxifen-treated patients. This allowed to further evaluate if any interplay existed 
between CD44v6 expression and EGFR in relation to tamoxifen resistance. The web-
based algorithm X-tile was used to define optimal CD44v6 membrane cut point (47) 
versus patient outcome and statistical testing was performed using Log Rank. Of the 
140 TMA’s studied in this series, 20 were negative for CD44v6 membrane expression. 
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After the cutpoint was applied, 71/140 TMAs were >47. Figures 6.26 reveals 
representative images of TMA cores from this series with high and low CD44v6 
immunostaining.  
Using the respective cut points, 4 CD44v6/EGFR status phenotypes were 
discriminated in the 140 ER+ breast cancers examined in this series as shown in Table 
6.1; the most abundant phenotypes were EGFR- thus reflecting this is an ER+ series. 
The survival curve data initially revealed that higher CD44v6 expression correlated 
with significantly better outcome in ER+ disease in tamoxifen-treated patients with a 
longer DFI (p = 0.013) and OS (p = 0.001) compared to patients whose tumours did 
not express CD44v6 (Figures 6.27 and 6.28). However these analyses suggested 
promising separation between CD44v6+ patients when subdivided with EGFR status. 
Whilst CD44v6+/EGFR- patients experienced the longest DFI (141.952 months), this 
was greatly reduced for patients whose tumours co-expressed CD44v6 and EGFR 
(CD44v6+/EGFR+) (105.662 months) (p = 0.023) (Figure 6.29). Interestingly, 
CD44v6+/EGFR+ patients displayed a similar DFI to patients whose tumours did not 
express either receptor (104.330 months) (Figure 6.29).  
These analyses also suggested promising separation between CD44v6+ patients with 
high and low EGFR expression and OS. Whilst CD44v6+/EGFR- patients also displayed 
the longest OS on tamoxifen treatment (161.793 months), this was reduced for the 
sub-cohort of patients co-expressing CD44v6 and EGFR (138.130 months) (p = 0.005) 
(Figure 6.30). However, patients whose tumours phenotype were CD44v6-/EGFR+ or 
CD44v6-/EGFR- tumours also showed a comparatively poorer OS (134.465 and 
132.465 months respectively) (Figure 6.30). 
CD44v6+ 153mo [95%CI 140-166mo]  
CD44v6-  128mo [95%CI 117-139mo] 
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Figure 6.26. Representative images from TMA cores with high (left) and low (right) CD44v6 
immunostaining from the Nottingham Immunohistochemical clinical series (x40 magnification). 
 
Table 6.1. The number of patients and associated percentage frequency for the 4 CD44v6 and EGFR 
tumour phenotypes in 140 ER+ tamoxifen-treated primary breast cancer patients from the TMA series. 
 
Tumour Phenotype Patient Number Patient Frequency (%) 
CD44v6+/EGFR+ 9 6.4 
CD44v6+/EGFR- 62 44.3 
CD44v6-/EGFR+ 13 9.3 
CD44v6-/EGFR- 56 40 
Total 140 100 
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Means for Disease-Free Interval (DFI) on tamoxifen 
Estimate Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
CD44v6 <47 109.480 10.219 89.452 129.509 
CD44v6 >=47 138.241 7.512 123.500 152.981 
Overall 128.548 6.901 115.022 142.024 
Figure 6.27. Investigation of high versus low CD44v6 membrane staining upon the impact of 
disease-free interval (DFI) in a small exploratory series of ER+ breast cancer patients treated with 
tamoxifen (n = 140). The Kaplain–Meier plot shows tumours grouped according to high versus low 
CD44v6 membrane expression (cut point 47) and analysed in relation to DFI (p = 0.013) in months. 
The table shows the corresponding mean survival estimates, standard error and lower and upper 
bound 95 % confidence intervals for each phenotype. 
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Means for Overall Survival (OS) on tamoxifen 
Estimate Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
CD44v6 <47 134.420 9.963 114.892 153.948 
CD44v6 >=47 159.443 6.254 147.181 171.701 
Overall 156.933 6.489 144.216 169.651 
Figure 6.28. Investigation of high versus low CD44v6 membrane staining upon the impact of 
overall survival (OS) in a small exploratory series of ER+ breast cancer patients treated with 
tamoxifen (n = 140). The Kaplain–Meier plot shows tumours grouped according to high versus low 
CD44v6 membrane expression (cut point 47) and analysed in relation to OS (p = 0.001) in months. 
The table shows the corresponding mean survival estimates, standard error and lower and upper 
bound 95 % confidence intervals for each phenotype. 
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Means for Disease-Free Interval (DFI) on tamoxifen 
Estimate Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
CD44v6+/EGFR+ 105.622 23.402 59.754 151.491 
CD44v6+/EGFR- 141.952 7.713 126.834 157.070 
CD44v6-/EGFR+ 130.077 23.485 84.046 176.108 
CD44v6-/EGFR- 104.330 11.069 82.634 126.026 
Overall 128.548 6.901 115.022 142.074 
Figure 6.29. Investigation of CD44v6 and EGFR co-expression upon the impact of disease-free 
interval (DFI) in a small exploratory series of ER+ breast cancer patients treated with tamoxifen (n 
= 140). The Kaplain-Meier plot shows tumours grouped according to the 4 phenotypes of CD44v6 
and EGFR and analysed in relation to DFI in months (Log Rank p value = 0.023). The table shows 
the corresponding mean survival estimates, standard error and lower and upper bound 95 % 
confidence intervals for each phenotype.  
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Means for Overall Survival (OS) on tamoxifen 
Estimate Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
CD44v6+/EGFR+ 138.130 22.459 94.111 182.149 
CD44v6+/EGFR- 161.793 6.230 149.583 174.003 
CD44v6-/EGFR+ 134.906 21.920 91.943 177.869 
CD44v6-/EGFR- 132.465 10.948 110.007 153.922 
Overall 156.933 6.489 144.216 169.651 
Figure 6.30. Investigation of CD44v6 and EGFR co-expression upon the impact of overall survival 
(OS) in a small exploratory series of ER+ breast cancer patients treated with tamoxifen (n = 140). 
The Kaplain-Meier plot shows tumours grouped according to the 4 phenotypes of CD44v6 and 
EGFR and analysed in relation to OS in months (Log rank p value = 0.005). The table shows the 
corresponding mean survival estimates, standard error and lower and upper bound 95 % 
confidence intervals for each phenotype. 
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6.3 Discussion 
In this chapter, the contribution of specific CD44 variant isoforms to endocrine 
resistance was explored. Given that data previously identified that loss of global CD44 
expression impaired cellular migration, invasion and proliferation in both endocrine 
resistant cell models and enhanced their sensitisation to HA (Chapter 4), it was next 
explored whether specific isoforms may act as dominant promoters of these 
processes. Initial characterisation data revealed enhanced expression of CD44v3 and 
CD44v6 proteins in endocrine resistant cells (Chapter 3), which have also been shown 
to become upregulated in primary breast carcinomas and correlate with numerous 
clinical parameters including metastasis, lymph node status and survival (Kuniyasa et 
al. 2002; Wang et al. 2007; Saito et al. 2013; Shi et al. 2013; Marzese et al. 2014), 
therefore these variant isoforms were decided to be the focus of this project. 
Initially, optimisation data revealed that CD44v6 transfection into MCF-7 cells led to 
a similar endogenous expression and localisation pattern of CD44v6-containing 
proteins found in endocrine resistant Tam-R and Fas-R cells, thus allowing 
comparisons to be made between these cell models. However CD44v3 transfection 
into MCF-7 cells led to enhanced expression compared to the endogenous levels of 
CD44v3-containing proteins in endocrine resistant cells, although localisation 
patterns were similar; this must be taken into consideration upon interpretation of 
results. Functional analysis revealed that individual CD44 isoforms may mediate 
specific roles across the cell models. Indeed, the MCF-7 transfection data revealed 
that CD44v3 may act as a suppressor of cellular migration, whilst CD44v6 appeared 
to play an important role in the attenuation of endocrine response to fulvestrant. 
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Although both CD44 isoforms were implicated in invasion processes, CD44v6 
overexpression in MCF-7 cells enhanced their endogenous invasion, whilst CD44v3 
appeared to promote invasion upon HA binding.  
The experimental data in this study which suggested CD44v3 may act to suppress 
cellular migration in MCF-7 cells appears to be in discordance with some other 
studies which suggest a role for CD44v3 proteins as promoters of a migratory 
phenotype in breast cancer (Bourguignon et al. 1998; Bourguignon et al. 1999), 
however it must be noted that these reports implicate the CD44v3,8-10 variant 
isoform in these processes. Thus, it may be suggested that CD44v3 isoforms require 
the additional presence of variant exons 8 - 10 to mediate cytoskeletal binding and 
promote a subsequently induced migratory response in these cells. Furthermore, 
discrepancies between the data and findings from others may be due to differences 
in the bioavailability of specific ligands and/or co-receptors. Indeed, CD44v3 contains 
the attachment site for HPS which has been shown to facilitate malignant behaviours 
in numerous carcinomas through the presentation of several growth factor receptors 
(Bennet et al. 1995; Van de Voort et al. 1999). Therefore variability in the expression 
of HPS and co-receptors, such as TGFßR1, MMP-9 and c-Met, between cancer cell 
lines may account for differences in the reported function of CD44v3 in the literature.  
Conversely, the data here revealed a role for CD44v3 in enhanced invasion in MCF-7 
cells upon HA stimulation, however the mechanism remains elusive (although unlike 
CD44v6-mediated invasion, a role for EGFR was not implicated) but may involve 
downstream activation of AKT, Src and ERK1/2. These results are supported by 
previous clinical findings by other groups which showed that CD44v3 was 
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upregulated in highly invasive breast tumours (Auvinen et al. 2005) where it has been 
shown to correlate with lymph node metastases (Kalish et al. 1999; Rys et al. 2003). 
Thus, given that HA is found in abundance in breast tumour stroma, this may suggest 
an important role for CD44v3 proteins in the enhancement of tumour progression 
behaviours in HA-rich environments. Taken together, the experimental data 
potentially implicate roles for CD44v3 proteins in both the suppression of cellular 
migration and enhancement of HA-stimulated invasion, however, validation of these 
results in endocrine resistant cell models could not be undertaken due to 
unavailability of siRNA to specifically target CD44v3 and lack of clinical data.  
It must also be taken into consideration that sequencing analysis revealed a base pair 
mutation at position 17 in the CD44 variant 3 exon of the plasmid DNA leading to an 
amino acid substitution (N239D) from an arginine (uncharged, polar) to an aspartic 
acid (acidic) in the protein sequence (Appendix I). Whilst use of this CD44v3 plasmid 
has been published in several articles (including Meilgo et al. 2006 and 2007) the 
effect of the amino acid mutation remains unknown and may affect the results of this 
data. However the immunostaining data revealed similar localisation of transfected 
CD44v3 proteins in MCF-7 cells compared to their endogenous localisation in Tam-R 
and Fas-R cells suggesting that this amino acid substitution does not alter the 
localisation of CD44v3 proteins in these cells. To investigate whether this amino acid 
substitution may alter the function of the CD44v3 protein, several publically available 
online programmes were used to predict the effect of amino acid substitutions on 
protein function. Three separate online programmes were utilised for this purpose 
(referenced in Ng and Heinikoff 2006) and each predicted that the amino acid 
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substitution in CD44v3 was neutral, tolerated and unlikely to cause deleterious 
effects or change protein function (results shown in Appendix M). Furthermore, the 
attachment site for HPS found in variant exon 3 and critical for its reported functions 
is located between amino acid positions 32 – 39 in the DNA sequence and not near 
the site of the amino acid substitution (position 17) (Greenfield et al. 1999) thus 
suggesting low probability that the amino acid substitution may alter HPS binding. 
Finally, to assess whether any conserved sequences were found in the CD44 variant 
3 exon which may be altered upon amino acid substitution, the publically available 
online conserved domain and protein classification database tool 
(http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi) was utilised and revealed 
no known conserved sites in this exon (Appendix N). Taken together, these analyses 
suggest that the amino acid substitution in this exon is unlikely to change its protein 
function. 
The experimental data further suggested a role for CD44v6-mediated activation of 
the EGFR pathway as a promoter of cellular invasion in tamoxifen resistance 
(depicted in Figure 6.31). Indeed the results revealed that overexpression of CD44v6 
in MCF-7 cells enhanced cellular invasion in an EGFR-dependent manner, whilst loss 
of CD44v6 protein expression in Tam-R cells reduced invasion and proliferation and 
attenuated EGFR pathway signalling. Enhanced EGFR signalling has been heavily 
implicated in the acquisition of tamoxifen-resistance, therefore it could be 
hypothesised that CD44v6-mediated EGFR activation in MCF-7 cells may reduce their 
response to tamoxifen leading to the acquisition of resistance. Although this thesis 
did not reveal a role for CD44v6 in the attenuation of tamoxifen response in MCF-7 
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cells, these experiments were conducted over a short 5 day period due to the nature 
of the transient transfections. Thus, to further explore whether CD44v6 
overexpression may reduce tamoxifen response by enhancing cellular 
invasion/proliferation through EGFR activation, future studies which involve 
culturing stable CD44v6-transfected MCF-7 cells in the presence of tamoxifen could 
be conducted. Surprisingly, loss of CD44v6 did not alter the behavioural functions of 
Fas-R cells, (although appeared to attenuate fulvestrant response in MCF-7 cells 
through an unidentified mechanism) however this endocrine resistant cell model 
expresses low levels of endogenous EGFR, which unlike Tam-R cells is not heavily 
implicated in the acquisition of fulvestrant-resistance, thus the inference would be 
that CD44v6 may play a more important role in cells where EGFR is co-expressed.  
This was supported by data from a small exploratory clinical series which revealed 
that whilst high levels of CD44v6 correlated with a significantly better outcome in 
ER+ primary breast cancers treated with tamoxifen (potentially due to the 
enhancement of cellular migration observed in the experimental data), a promising 
separation was shown between CD44v6+ patients when subdivided with EGFR status. 
This data revealed that patients whose tumours co-expressed CD44v6 and EGFR 
(CD44v6+/EGFR+) displayed a worse outcome compared to CD44v6+/EGFR- patients. 
Interestingly, the cohort that associated with the worst overall outcome were 
patients whose tumours did not express either receptor (CD44v6-/EGFR-) and data 
suggested a clear clustering of CD44v6+/EGFR+ with the CD44v6- patients away from 
the CD44v6+/EGFR- cohort in both DFI and OS survival curves, thus suggesting that 
patients expressing low/negative CD44v6 levels perform badly irrespective of EGFR 
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status. These data suggest that other signalling pathways may drive misbehaviour of 
the CD44v6- cohorts (which may or may not involve interplay with EGFR) leading to 
worsened outcome.  
 
Figure 6.31. A proposed mechanism for CD44v6-mediated EGFR activation leading to enhanced 
cellular invasion and growth. This thesis identified that CD44v6 mediated EGFR activation led to 
enhanced AKT and ERK1/2 signalling and enhanced invasion and growth in Tam-R cells. Additional 
experimental analysis is required to determine whether a direct interaction between CD44v6 and 
EGFR occurs in these cells and to further elucidate the signalling mechanisms through which 
cellular invasion and growth is activated. 
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Overall, these data infer that high levels of CD44v6 expression are protective in ER+ 
patients treated with tamoxifen, however patients whose tumours co-express 
CD44v6 and EGFR could predict earlier relapse and a poorer overall outcome on 
tamoxifen (as seen in the experimental work with CD44v6 and EGFR interplay leading 
to enhanced invasion). Whilst this study remains exploratory due to low patient 
numbers (particularly for EGFR+ subsets, given this is a ER+ sample series) these 
results are in accordance with previous data from the BCMPG (Gee et al. 2012; IACR 
Manchester Group Abstract, personal communication) which has previously shown 
that CD44v6 expression strongly correlates to a better outcome in ER+ disease. 
Although significance was shown in both survival curves in this thesis, study numbers 
were too low to compare individual subgroups, therefore further studies are needed 
with larger TMA sections (including a greater sample number of EGFR+ patients) to 
validate these preliminary findings. 
Whilst suppression of CD44v6 appeared to reduce endogenous invasion and HA-
stimulated proliferation in Tam-R cells, a concomitant significant enhancement of 
cellular migration was also observed; an effect not shown upon CD44v6 
overexpression in MCF-7 cells. Although the mechanism(s) through which this may 
occur remains undetermined and require future exploration, one hypothesis may be 
that different CD44v6-containing isoforms are involved in different cellular 
processes. Whilst only the CD44v6 isoform was overexpressed in MCF-7 cells, CD44v6 
siRNA suppressed the expression of all isoforms containing the CD44v6 exon. Given 
that the characterisation data revealed the presence of several CD44v6-containing 
isoforms in Tam-R cells (Chapter 3), it may be postulated that certain isoforms e.g. 
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containing the variant 6 exon only, may possess greater affinity for co-receptors, e.g. 
EGFR, thus promoting cellular invasion, whilst others e.g. containing a combination 
of variant exons including variant 6, may have a prominent role in the suppression of 
cellular migration. These data may infer that specific CD44v6 isoforms mediate 
distinct behaviours in cells and may in part explain the contradictory results found 
between studies which have correlated enhanced CD44v6 expression with both 
favourable (Shah et al. 2010), unfavourable (Lian et al. 2006) or no association with 
clinical parameters (Morris et al. 2001; Diaz et al. 2003 Ma et al. 2005) in breast 
cancer.  
Previous data from this study showed that CD44 global suppression in Tam-R and 
Fas-R cells reduced their migratory, invasive and proliferative phenotype. Given that 
overexpression of CD44v3/CD44v6 proteins in MCF-7 cells, and CD44v6 suppression 
in Tam-R cells, impaired cellular migration across these cell models, this may imply 
that alternative CD44 isoforms are involved in the promotion of aggressive cellular 
behaviours in Tam-R and Fas-R cells. Furthermore, CD44 global suppression 
attenuated the response of both endocrine resistant cell models to HA, thus 
potentially suggesting a role for CD44 proteins in HA-sensitisation. Therefore, it was 
hypothesised that overexpression of CD44 variants in endocrine sensitive MCF-7 cells 
would sensitise these cells to HA leading to enhanced cellular responses. However 
this was not observed in MCF-7 cells, and CD44 variant overexpression did not 
significantly impact HA-mediated signalling/responses. These data may potentially 
be explained by the lower reliance of MCF-7 cells for HA and may suggest that these 
cells require numerous changes in protein composition and phenotype, and not just 
  
 
 
 
220 
 
CD44 variant overexpression alone, to become sensitised to HA. Additionally, 
experimental environment may also account for the lack of response observed by 
MCF-7 transfected cells. Whilst both endocrine resistant cell models are maintained 
in experimental media (WRPMI media with charcoal-stripped serum), it was not 
possible to transfect MCF-7 cells in stripped serum therefore these cells were 
maintained in their maintenance media which contained foetal calf serum. An 
unquantified level of HA and additional growth factors may be present in this serum 
thus potentially masking the effect of additional HA stimulation in MCF-7 cells. Future 
experiments to determine the HA concentration required to stimulate these cells to 
observe behavioural outputs/stable CD44-overexpressing MCF-7 transfectants are 
required to assess the effect that CD44 overexpression causes upon HA sensitivity. 
An additional interesting observation from this study revealed that whilst 
overexpression of CD44∆cyt proteins in MCF-7 cells led to the activation of several 
cell surface receptors and/or downstream signalling components (a previously 
unreported phenomenon), unlike their full length CD44 isoform counterparts, no 
significant modification of cellular behavioural processes was observed in these cells 
compared to the untransfected controls. One explanation for this phenomenon may 
be that whilst CD44∆cyt proteins are capable of being transported to the plasma 
membrane (as observed by immunoanalysis data) whereupon they activate 
numerous signalling components, these events may be transient due to the 
instability of these proteins and thus not sufficient to stimulate prolonged cellular 
signalling leading to functional outputs. This is supported by observations from 
numerous studies exploring the role of CD44 cytoplasmic tail truncated mutants 
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(Isacke 1994; Perschl et al. 1995; Jiang et al. 2002). Indeed, Neame and Isacke et al. 
1993 showed that removal of the CD44 cytoplasmic tail in fibroblast cells does not 
prevent presentation of this protein at the plasma membrane however alters its 
localisation to the apical, rather than the baso-lateral, cell surface. In support of this, 
Sheik and Isacke 1996 identified a dihydrophobic leucine331/valine332 motif in the 
CD44 cytoplasmic tail required for the delivery of CD44 to the lateral plasma 
membrane of polarised epithelial MDCK cells. Furthermore, this study revealed a 
population of CD44 cytoplasmic tail mutants in intracellular vesicles suggesting that 
loss of cytoplasmic tail region may reduce protein stability leading to enhanced 
endocytosis and subsequent degradation by lysosomes and Wollner et al. 1992 
reported that tailless CD44 mutants exhibit a 2 – 4 reduced stability compared to full 
length isoforms. It has also been suggested that removal of the CD44 cytoplasmic tail 
allows easier entry into the coated pit thus leading to enhanced internalisation and 
degradation of this molecule (Pelchen-Matthews et al. 1991; Neame and Isacke 
1993).  
Additionally, the cytoplasmic tail domain of CD44 is crucial to its cellular functions. 
This domain contains numerous motifs for cytoskeletal binding proteins, sites for 
post-translational modifications required for cellular motility events (Bretscher et al. 
1997; Bourguignon et al. 1991; Legg et al. 2002; Thankamony et al. 2006; Babina et 
al. 2014), binding sites for intracellular signalling components (Bourguignon et al. 
2003; Jia-Lin et al. 2008) and cleavage sites for translocation of the intracellular 
domain to the nucleus for the regulation of several genes (Okamoto et al. 2001; 
Murakami et al. 2003). Therefore, loss of the cytoplasmic domain may attenuate 
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numerous cellular processes particularly involving cellular motility and adhesion 
through loss of cross-linking ability with the cytoskeleton and binding to 
cytoskeletal/downstream effector molecules. Taken together, these observations 
may account for the increased intracellular localisation of CD44v3∆cyt and 
CD44v6∆cyt proteins observed in MCF-7 cells upon transfection and support an 
explanation as to why these isoforms were able to enhance cellular signalling but did 
not modify cellular behaviours in these cells. However future studies to further 
elucidate the mechanisms through which these cytoplasmic tail truncations may 
mediate cellular signalling, but not functional outputs, are required.  
Given that the CD44∆cyt plasmid DNA constructs were provided by Dr Ursula 
Gunthert (Basel University, Switzerland) to use as transfection controls, however led 
to enhanced cellular signalling, experiments were undertaken at the end of this 
project to create an empty vector plasmid DNA backbone construct (without the 
inserted CD44 gene sequence) to use as an alternative transfection control. Given 
that the CD44 constructs contain a GFP-tag fused to their carboxy-terminus end, it 
was also investigated whether the presence of this tag altered cellular behaviours 
through transfection of MCF-7 cells with a pEGFP-N1 plasmid vector containing the 
GFP-tag construct only. These preliminary results (shown in Appendix S) suggest that 
the plasmid vector and GFP-tag do not substantially alter the behaviour of MCF-7 
cells thus supporting that the effects observed by CD44v3/CD44v6 transfection arise 
from the activities of these proteins alone.  
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Summary 6.3.1 
In this chapter, an important role was shown for CD44v6 proteins in EGFR-mediated 
cellular invasion in Tam-R cells which was supported by exploratory clinical analysis 
showing a trend for worsened outcome in ER+ breast cancer patients co-expressing 
high levels of CD44v6 and EGFR treated with tamoxifen. These preliminary findings 
require further exploration however suggest that co-expression of CD44v6 and EGFR 
may predict earlier relapse in a sub-cohort of ER+ breast cancer patients and could 
present as candidates for therapeutic targetting to delay resistance onset. 
Interestingly, CD44v6 suppression in Fas-R cells did not significantly alter cellular 
behaviours, and exploratory clinical analysis revealed that high levels of CD44v6 
expression alone associated with a trend for better patient outcome in ER+ breast 
cancer patients treated with tamoxifen. These findings may infer that the 
contribution of CD44v6 to resistance is likely to depend upon other contextual and 
microenvironmental factors, e.g. the presence of co-receptor proteins, which may be 
specific to each resistant state. 
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7. General Discussion 
Endocrine resistance is a major hurdle for the successful treatment of breast cancer 
therefore gaining knowledge of the molecular mechanisms that underlie this process 
may offer the opportunity for the identification of novel therapeutic targets through 
which resistance might be delayed or circumvented. Moreover, given that the 
literature supports that resistance is accompanied by an aggressive cell phenotype, 
targetting resistance mechanisms may also have the potential to suppress such cell 
behaviours. In light of a previous study by the BCMPG (Hiscox et al. 2012) which 
reported upregulation of total CD44 expression in a model of ER+ breast cancer-
derived tamoxifen resistance where it associated with an enhanced migratory 
phenotype, part of the aims of this thesis were to extend these investigations into a 
further model of resistance, to the endocrine agent fulvestrant, in order to determine 
whether CD44 upregulation represented a generic feature of acquired resistance. 
Furthermore, one aspect of CD44 which makes it difficult to study and undoubtedly 
contributes to variability between published studies is the extensive alternative 
splicing attributed to this molecule. Whilst CD44 is often found to become 
overexpressed in invasive breast cancer, CD44 isoforms have been shown to mediate 
both pro- and anti-tumoural signalling pathways in vitro (Cheng et al. 2006; Afify et 
al. 2008; Bourguignon et al. 2010; Babina et al. 2014) and have been correlated with 
both favourable and unfavourable patient outcome in clinical breast cancer (Morris 
et al. 2001; Rys et al. 2003; Ma et al. 2005; Lian et al. 2006; Afify et al. 2009). 
Therefore the main aims of this thesis were to explore CD44 isoform contribution to 
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tamoxifen- and fulvestrant- resistance and to investigate the hypothesis that specific 
CD44 isoforms promote an aggressive phenotype in these cells. 
The findings from this thesis confirmed results from Hiscox et al. 2012 and showed 
that total CD44 expression was upregulated in Tam-R cells compared to their 
parental endocrine sensitive MCF-7 cells. Importantly, this thesis reported the novel 
finding that CD44 expression also becomes upregulated in the model of fulvestrant-
resistance and further identified that a different expression profile of CD44 isoforms 
exists between resistant cell models thus suggesting that there is not a generic cohort 
of CD44 isoforms that become upregulated in resistance. Indeed, upregulation of 
CD44v3-containing proteins was specific to tamoxifen-resistance whilst CD44v10-
containing proteins were upregulated only in Fas-R cells. Although CD44v6 proteins 
were upregulated in both models of resistance, Western blotting analysis revealed a 
differential expression profile of CD44v6 splice isoforms between these cell models; 
however the composition of these isoforms was not determined.  
These findings may suggest that upregulation of particular CD44 isoforms may be 
specific to each resistant state. In support of this, Olsson et al. 2011 reported that 
individual CD44 isoform expression is associated with specific breast cancer 
characteristics and molecular subtypes and contributes to distinct oncogenic 
signalling pathways. For example, this study examined 187 primary breast tumours 
and 13 breast cancer cell lines and revealed that CD44v2-v10 and CD44v3-v10 
isoforms correlated with luminal A breast cancer, CD44v8-v10 isoforms were 
predominantly expressed in basal-like breast cancers, and CD44 Std was associated 
with HER2+ breast cancer. Furthermore, this group showed a correlation between 
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CD44 isoform expression and different clinical biomarkers in tumours. The 
CD44v2/v3-v10 isoforms correlated with positive steroid hormone receptor status, 
CD44v8-v10 was strongly correlated with EGFR positive/HER2 low/negative status 
and CD44 Std associated with HER2 expression. This study concluded that CD44 
isoforms may be part of a programme that drives development of distinct molecular 
subtypes in breast cancers or may be a consequence of this process.  
Given that only two models of acquired endocrine resistance were examined in this 
thesis, it is difficult to draw firm conclusions between the expression of individual 
CD44 isoforms and specific resistant states, however future studies using alternative 
models of acquired resistance may confirm these observations. Interestingly, the 
findings from Olsson et al. 2011 suggested that CD44 expression may be linked to the 
ER, with the greatest total level of CD44 isoform expression found in luminal A (ER+) 
breast cancers. Conversely, other groups have reported that CD44 expression is 
inversely proportional to ER expression and associated with the most aggressive 
triple negative subtype of breast cancer (Klingbeil et al. 2010; Montgomery et al. 
2012). In this thesis, the greatest level of total CD44 expression was shown in the ER- 
Fas-R cells, however CD44 was also elevated in ER+ Tam-R cells suggesting that an 
absolute relationship between CD44 and ER expression may not necessarily exist.  
To determine whether a relationship exists between CD44 and the ER in the resistant 
cell models, the effects of short term endocrine treatment upon CD44 expression 
was investigated (Appendix T). The data revealed that MCF-7 cells treated with the 
ER downregulator, fulvestrant, abrogated CD44 expression, whilst tamoxifen and 
oestradiol treatment (partial agonist and agonist of the ER respectively) enhanced 
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CD44 expression between 3 – 52 day treatments, compared to the untreated control 
cells. This data suggested a potential role for the ER within the regulation of CD44 
expression and further investigation by the Jason Carroll research group (Cancer 
Research UK, Cambridge Institute, personal communication) revealed that whilst the 
presence of an oestrogen receptor element (ERE) could not be found within the first 
500 bp of the CD44 gene promoter, sites for p300 and CPB binding proteins (known 
to bind and regulate ER activity) were located in this region. Therefore these data 
may infer a potential role for the indirect regulation of CD44 expression by the ER, 
which may provide an explanation for the modulation of CD44 expression shown 
within MCF-7 cells treated with endocrine agents that differentially alter ER 
expression. However, whilst the loss of ER expression that occurs upon fulvestrant 
treatment in MCF-7 cells abrogated CD44 expression in early endocrine treatment, 
CD44 becomes upregulated upon acquisition of fulvestrant-resistance, thus 
suggesting that alternative signalling pathways may be activated which upregulate 
CD44 isoform expression at a later stage of fulvestrant treatment in these cells.  
The data in this thesis showed that CD44 variant expression is upregulated in 
endocrine resistance, however the mechanisms which regulate CD44 alternative 
splicing are not yet fully understood. CD44 alternative splicing has been shown to 
occur in response to specific stimuli, such as oxidative stress (Takeo et al. 2009) and 
epigenetic changes on histones (Batsche et al. 2006; Ameyar-Zazou et al. 2012; 
Cappellari et al. 2013), however most often results from signalling transduction 
pathways, particularly MAPK activation (Matter et al. 2002; Cheng and Sharp 2006) 
and post-translational modifications that influence components of the alternative 
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splicing machinery, such as splicing factors (Weg-Remers et al. 2001; Cheng et al. 
2006). Ras/MAPK signalling has been shown to phosphorylate and subsequently 
activate the splicing factors, Sam68 and SRm160, which regulate the inclusion of 
CD44 variant exons into mRNA transcripts (Weg-Remers et al. 2001; Matter et al. 
2002; Cheng and Sharp 2006), however the signalling pathways between Ras/MAPK 
activation and stimulation of alternative splicing are not well defined. Cheng et al. 
2006 revealed a positive feedback loop in HeLa cells which coupled Ras/MAPK 
signalling and CD44 alternative splicing. This group revealed that RTK signalling 
stimulated CD44 splicing (by induction of Ras/MAPK signalling) and in turn, the 
specific upregulation of the CD44v6 isoform promoted further sustained Ras/MAPK 
activation leading to cell cycle progression. The inclusion of variant exons into the 
CD44 mRNA transcript has additionally been shown to be mediated by the epithelial 
cell type specific splicing regulator proteins (ESPR1 and ESRP2), which also connects 
growth factor signalling and CD44 splicing (Warzecha et al. 2009; Brown et al. 2011). 
Therefore it may be hypothesised that upregulation of specific growth factor 
receptor signalling pathways that activate these splicing factors and lead to the 
subsequent production of CD44 variant isoforms, may be an important factor in the 
acquisition of endocrine resistance. Whilst changes in the gene expression of splicing 
factors across the cell models was not investigated in this thesis, enhanced RTK 
signalling occurs in response to oestrogen withdrawal (endocrine treatment) 
(Normanno et al. 2005) and has been shown to be involved within the acquisition of 
endocrine resistance in breast cancer causing cells to change from an oestrogen-
dependent phenotype (endocrine responsive) to a non-responding phenotype and 
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eventually to oestrogen independence (Knowlden et al. 2003; Britton et al. 2006; 
Hiscox et al. 2006). Elevated ErbB receptor signalling has been shown to induce 
downstream signalling responses, including Ras/MAPK activation, which may lead to 
enhanced CD44 splicing in these cells (Kurokawa et al. 2000; Weigelt et al. 2010). 
Given that this thesis identified a role for CD44-mediated ErbB activation towards an 
aggressive phenotype, it may be postulated that this mechanism could lead to the 
enhanced aggressive phenotype in cells which accompanies endocrine resistance.  
Indeed, it has been reported that tumours expressing CD44 variant isoforms are 
more aggressive than tumours expressing the CD44 standard isoform only, and 
numerous reports document upregulation of CD44 splice variants in aggressive 
carcinoma tissues compared to their normal tissues (Lui et al. 2005; Lian et al. 2006; 
Wang et al. 2007; Ni et al. 2014).  Yae et al. 2012 showed that inoculation of the CD44 
variant (v8-v10) isoform-expressing subpopulation of mouse T41 breast cancer cells 
into severely immunocompromised mice conferred metastatic potential and led to 
the formation of lung metastases which was accompanied by an expansion of stem-
like cancer cells, an observation that was not seen in the CD44 variant-negative (CD44 
Std) subpopulation. Further, Banky et al. 2012 reported that CD44 proteins containing 
variant exons 3 and 6 showed dominant expression compared to other CD44 variants 
across colorectal cancer cell lines and suggested that in a minority of tumour 
subclones these variants may act as ‘metastasis genes’ and drivers of the metastatic 
phenotype in these cells. In accordance with these findings, data from this thesis 
showed that the upregulation of CD44 variant isoforms in resistant cell models 
associated with an increase in their endogenous aggressive cellular behaviours. For 
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example, endocrine resistant cells showed a significantly enhanced invasive (Tam-R 
and Fas-R cells) and migratory and proliferative (Fas-R cells) capacity compared to 
their endocrine sensitive MCF-7 counterpart. However, whilst CD44 expression was 
greatest in Fas-R cells, this study suggested an importance for CD44 proteins in both 
models of endocrine resistance as global knockdown of CD44 significantly reduced 
the migratory, invasive and proliferative capacity of Tam-R and Fas-R cells.  
As well as contributing to the endogenous aggressive phenotype of the resistant cell 
models, CD44 upregulation also led to the sensitisation of these cells to their 
principle ligand, hyaluronan (HA). The data revealed increased cellular migration 
(Tam-R and Fas-R cells), invasion and proliferation (Fas-R cells) in response to HA 
stimulation which was attenuated upon CD44 suppression. Interestingly, this thesis 
revealed that the mechanisms through which HA stimulation enhances the 
aggressive behaviour of Tam-R and Fas-R cells occurs through different pathways and 
thus may be dependent upon the composition of proteins in cells. For example, HA 
stimulation appeared to enhance cellular migration and invasion in Tam-R cells in an 
ErbB receptor dependent manner which corroborates from previous data from the 
BCMPG (Hiscox et al. 2012) and with other studies which have shown a role for CD44 
activation of ErbB receptors towards the induction of the metastatic cascade 
(Bourguignon et al. 1997; Kim et al. 2008; Palyi-Krekk et al. 2008; Bao et al. 2011). 
However, the mechanisms through which HA stimulated the CD44-mediated 
functions in Fas-R cells remains elusive but this thesis does not heavily implicate the 
RTKs EGFR, HER2 or c-Met in this process. These data suggest an importance for the 
bioavailability of co-receptor proteins in the determination of CD44-mediated 
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functions in cells and suggests that the presence of HA is likely to promote adverse 
behaviours in breast tumours which highly express CD44 proteins. These findings 
may have important implications with regards to the augmentation of breast tumour 
sensitivity to HA which is often found to be abundantly expressed in the 
microenvironment of breast carcinomas (Auvinen et al. 2000; Auvinen et al. 2014). 
Indeed, both HA and CD44 have been shown to be highly expressed within the 
peritumour stroma and tumour mass, respectively, in breast cancer where they are 
associated with tumour metastasis, increased relapse and poor patient prognosis 
(Udabage et al. 2005a; Auvinen et al. 2013).  
These data along with numerous other studies suggest that breast cancer cells which 
co-express high levels of HA and CD44 exhibit an enhanced susceptibility for 
metastasis and may predict tumour recurrence and therapeutic resistance. Whilst at 
present no current therapy is available which targets CD44 proteins in breast cancer, 
in recent years a large amount of interest has surrounded the exploitation of the HA-
binding properties of CD44 a mechanism for targetting drugs to tumour cells to 
reduce off-target effects of chemotherapeutic agents (Hyun-Jong et al. 2011; Lui et 
al. 2011; Young-II et al. 2012). Yang et al. 2013 revealed that treatment of the highly 
CD44-expressing breast cancer cell lines, BT549 and MDA-MB-231, with 
oligosaccharide HA nanoparticles conjugated with the chemotherapeutic drug, 
paclitaxel, diminished their endogenous protective HA coating, enhanced their 
sensitivity to paclitaxel and demonstrated growth inhibition in a breast cancer 
xenograft mouse model. Furthermore, Ganesh et al. 2013 revealed the use of HA as 
a vehicle for the delivery of RNA interference therapies into highly CD44-expressing 
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tumours. This group synthesised and evaluated a series of HA-based nanosystems to 
stably encapsulate and deliver siRNAs to a range of highly CD44-expressing human 
cancer cell lines, including the breast cancer cell line, MDA-MB-486. The results 
showed that several of the engineered HA-based nanosystems were effective in 
entering the cell lines leading to gene silencing activity, and also showed inhibition in 
models of in vivo lung cancer with and without resistance to chemotherapeutic 
drugs. Whilst these approaches may represent therapeutic value, a large amount of 
work is required before they can become a viable clinical treatment option. 
The overall aims of this thesis were to explore whether specific CD44 isoforms 
promote adverse cellular behaviours in endocrine resistance and the main findings 
of this study may go some way to explain the contradictory results found in CD44 
research. This thesis identified that CD44v3 overexpression in MCF-7 cells enhanced 
HA-induced invasion and suppressed cellular migration, however these results could 
not be validated in endocrine resistant models due to unavailability of CD44v3 siRNA 
and lack of clinical data. Whilst this thesis identified that CD44v6 was upregulated in 
both endocrine resistant cell models, no consistent relationship was observed 
between CD44v6 expression and increased aggressive cell behaviour. Indeed, despite 
Fas-R cells exhibiting the highest level of CD44v6 expression compared to Tam-R 
cells, CD44v6 siRNA knockdown modulated the activity of Tam-R cells but did not 
significantly alter Fas-R cell behaviour. These data suggest that it is likely that the 
contribution of CD44v6 to resistance occurs amongst other contextual factors and 
microenvironmental cues which may be specific to each resistant state. For example, 
CD44v6 enhanced invasion in Tam-R cells in an EGFR-dependent manner, however 
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did not significantly alter the behaviour of Fas-R cells which exhibit endogenously low 
levels of EGFR. This may infer a reliance on specific CD44 isoforms for the expression 
of alternative co-receptors, e.g. EGFR, to mediate an aggressive phenotype in these 
cells. Indeed, this is further observed in the exploratory immunohistochemical study 
shown in this thesis, where high CD44v6 expression associated with a trend for better 
outcome in ER+ breast cancer patients treated with tamoxifen which may relate to 
its role in the suppression of cellular migration as observed in the experimental data. 
However, this clinical series showed a trend for worsened outcome in patients whose 
tumours co-express high levels of CD44v6 and EGFR compared to the CD44v6+/EGFR- 
sub-cohort of tumours. These preliminary findings require further exploration 
however may implicate CD44v6 as a marker for better outcome in ER+ patients on 
tamoxifen treatment, whilst co-expression of CD44v6 and EGFR may represent a sub-
cohort of patients which may respond worse to this treatment.  
Whilst this thesis is the first to investigate CD44 isoform expression in ER+ breast 
cancer endocrine resistance, other studies have revealed a role for CD44v6 and EGFR, 
along with a panel of several other proteins including c-Met, as markers of highly 
invasive breast carcinomas where their expression has been shown to predict poor 
clinical outcome and may identify patient cohorts that require more aggressive 
treatment strategies (Charpin et al. 2009a; Charpin et al. 2009b). Furthermore, 
Vermeulen et al. 2012 screened tissue microarrays containing 483 cases of highly 
invasive breast carcinomas to identify the minimal number of targetted antibody 
probes required for the highest possible detection rate. This group revealed that 
whilst no single membrane marker is likely to detect all breast cancers, 80 % of 
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samples expressed at least one of a panel of 5 markers including CD44v6, EGFR, HER2, 
IGFR1 and GLUT1; thus concluding that at least 5 probes may be required for a high 
detection rate of breast cancers in vivo by molecular imaging. These studies along 
with others have revealed that CD44v6 and EGFR (along with several other receptors) 
are established markers of highly invasive/basal breast carcinomas that may be used 
to enhance detection rates and better predict disease outcome in patients. 
Additional studies have also identified these receptors as prognostic markers in 
alternative carcinomas, particularly colorectal cancer (Elliot et al. 2014; Zhao et al. 
2015). For example, Garouniatis et al. 2013 revealed that CD44v6, EGFR, c-Met and 
FAK were expressed in 183 cases of colorectal carcinoma and all correlated with 
cancer invasiveness and progression. Specifically, CD44v6 and FAK were 
demonstrated to be independent predictors of poor survival. This group further 
showed that aberrant co-expression of all receptor combinations remained 
significant thus also suggesting the occurrence of receptor cross-talk action. 
Collectively, these data revealed a predictive role for these receptors in colorectal 
carcinoma and highlighted their use as biomarkers for determining cohorts of 
patients which may respond worse to treatment and require more aggressive 
strategies. 
7.1 Future Work 
Given that global CD44 siRNA knockdown studies in this thesis reduced the 
migratory, invasive and proliferative capacity of Tam-R and Fas-R cells, these data 
may implicate additional CD44 isoforms within specific roles in endocrine resistance. 
Therefore, future work to explore alternative isoforms e.g. CD44 Std and CD44v10 
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proteins, and validate the role of CD44v3 in endocrine resistance, could be 
considered in these MCF-7 derived acquired resistant cell models.  
Whilst this study revealed that CD44 variant isoform expression becomes 
upregulated in acquired endocrine resistant cell models which associated with an 
increase in their aggressive phenotype, this thesis focused upon early resistance (1.5 
– 2 years) in MCF-7 derived tamoxifen- and fulvestrant- resistant cell models. To 
further explore the contribution of CD44 proteins to endocrine resistance, evaluation 
in the long term setting is required. During this thesis, the BCMPG developed MCF-7 
cell-derived models of late (3 years) tamoxifen- and fulvestrant- resistance. Whilst 
time did not allow for the study of CD44 isoform expression and function in these cell 
models in this thesis, unpublished and ongoing work by the BCMPG has shown that 
although CD44 isoform expression (including CD44 Std, CD44v3 and CD44v6) is 
elevated in the models of late tamoxifen- and fulvestrant- resistant cells compared 
to their endocrine sensitive counterpart, this level of expression is lower than that 
found in early resistance. These studies further revealed that despite a reduction in 
CD44 expression, these models of late resistance still show a high level of basal 
migration (no other function was tested), particularly revealing an increase in 
migration in late tamoxifen resistance. Therefore future work is required to further 
investigate the roles of CD44 isoforms in late endocrine resistance in MCF-7 cells 
including the analysis of additional functional roles (invasion, proliferation) and 
interactions with RTKs and HA in these cells MCF-7 derived cell models to determine 
their roles in early versus late endocrine resistance.  
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In this thesis the MCF-7 cell line was used as the only model of acquired endocrine 
resistance in ER+ (HER2-) breast cancer as, at the beginning of the project, this was 
the only available cell model for which to study acquired endocrine resistance and 
MCF-7 cells are used as a ‘standard’ for ER+ breast cancer research ubiquitously 
around the world. Since the start of this project, the BCMPG have subsequently 
developed several other models of acquired tamoxifen- and fulvestrant- resistance 
in the ER+/HER2- breast cancer cell line, T47D, and in the ER+/HER2+ cell lines, BT474 
and MDA-MB-361. The duration of this thesis did not allow time to study these 
additional cell models, therefore future work to investigate CD44 isoform expression, 
in particular the exploration of CD44v6 and EGFR and their contribution to the 
aggressive phenotype, in these models may validate the findings of this thesis.  
Given that RTK signalling is heavily implicated in the acquisition of endocrine 
resistance, and is known to activate Ras/MAPK signalling which may influence 
alternative splicing of CD44 isoforms. Future work to investigate the mechanisms 
which regulate the splicing of CD44 variant isoforms leading to their upregulated 
expression in endocrine resistance may offer therapeutic value. 
7.2 Conclusions 
This thesis revealed upregulated CD44 expression in models of endocrine resistance 
which associated with an increase in their aggressive phenotype and suggested that 
CD44 variant isoforms may associate with specific resistant states. The main aims of 
this thesis were to explore the hypothesis that specific CD44 variant isoforms 
promote an aggressive phenotype in endocrine resistance. The experimental and 
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clinical data in this thesis points to the importance of cellular context for CD44 
function. Whilst CD44v6 expression correlates with a better clinical outcome in ER+ 
breast cancer patients treated with tamoxifen, co-expression of CD44v6 and EGFR 
may provide a context where CD44v6 functions to enhance cellular invasion/growth 
leading to a worsened patient outcome. Whilst this finding requires validation from 
future work in a larger clinical series, CD44v6 and EGFR may have potential 
therapeutic value to predict a cohort of patients in ER+ breast cancer which relapse 
earlier on tamoxifen and may thus require more aggressive treatment strategies. 
Taken together, this thesis highlights that a clear understanding of the composition 
of CD44 splice variants and bioavailability of specific co-receptor proteins/ligands is 
of crucial importance towards understanding the role of CD44 in endocrine 
resistance and correlating this with clinical outcome. Whilst a predictive role for CD44 
proteins may be given to specific CD44 isoforms alone or in combinations with other 
proteins, the complex dual nature of these proteins as shown in this thesis may go 
some way to explain the contradictory results surrounding CD44 research and 
provide an explanation as to why at present there are no definitive correlations 
between CD44 expression and clinical parameters in breast cancer. 
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9. Appendices 
Appendix A. Charcoal-stripping procedure for 100 ml FCS 
Charcoal-stripped FCS (SFCS) was added to the culture media in replacement of FCS 
to mimic oestrogen deprivation conditions through the removal of non-polar 
materials including steroid hormones. A charcoal solution (2 g activated charcoal, 
0.01 g dextran T70 diluted in 18 ml distilled water) was stirred for one hour at room 
temperature. A solution of FCS used in routine culture media was adjusted to pH 4.2 
with HCI (5M) and equilibrated at 4 ˚C for 30 minutes. To 100 ml of adjusted FCS 
solution was added 5 ml charcoal solution and stirred gently for 16 hours at 4 ˚C. The 
charcoal contained within this solution was then removed by centrifugation at room 
temperature for 40 minutes, 12, 000 rpm (Labofuge 400R centrifuge, Heraeus, 
Germany). The resultant supernatant was coarse-filtered through Whatman filter 
paper NO.4 to ensure complete charcoal removal. The remaining solution was then 
readjusted to pH 7 using NaOH (5 M) and filter sterilised with a 2 μM Super Vacucap 
membrane (Gellman Laboratory Pall, Ann Arbor, USA). The resultant charcoal-
stripped FCS was aliquotted into sterile universal tubes and stored at - 20 ˚C. This 
procedure was performed by research technician staff in the Breast Cancer 
Molecular Pharmacology Group (BCMPG), Cardiff University. 
Appendix B. Jetset gene probes 
The affymetrix microarray platform contains multiple gene probe sets for each target 
gene which differ slightly in sequence. These differences in gene probe set sequences 
may lead to inconsistent or contradictory measurements dependent upon their 
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performance on the microarray platform which may ultimately result in difficulties 
determining the expression of the target gene. To assess the efficacy of each probe 
set sequence, Li et al. 2011 developed a method to score their performance based 
on 3 determinants which assessed overall specificity, coverage and degradation 
resistance (reviewed in Li et al. 2011). All probes sets achieve a score ranging from 0 
– 1 and the probe with the highest performance score (closer to 1) is determined as 
the Jetset probe.  
Appendix C. CD44 gene sequence and primer sequences 
The human gene sequence encoding CD44 mRNA obtained from the NCBI database 
(http://www.ncbi.nlm.nih.gov/) (Figure 9.1) with each variant exon depicted and 
described in Table 9.1 below. This sequence was utilised to (i) design primers for RT-
PCR analysis that bound to specific regions of DNA encoding the desired target exon 
corresponding to a specific CD44 isoform, (ii) design siRNA molecules which bound 
specifically to a sequence within the CD44v6 exon and (iii) confirm the specificity of 
the global CD44 siRNA molecules (purchased by Thermo Scientific, Dharmacon, UK) 
to the gene sequence. The primers that were designed and utilised for CD44 
detection in this project are highlighted in the gene sequence below and described 
in Table 9.2. The DNA sequences to which each siRNA target molecule used within 
this project bound to the CD44 gene are highlighted in the sequence below and 
described in the Table 9.3. 
 
 
  
 
 
 
287 
 
 
gagaagaaagccagtgcgtctctgggcgcaggggccagtggggctcggaggcacaggcaccccgcgac
actccaggttccccgacccacgtccctggcagccccgattatttacagcctcagcagagcacggggcg
ggggcagaggggcccgcccgggagggctgctacttcttaaaacctctgcgggctgcttagtcacagcc
ccccttgcttgggtgtgtccttcgctcgctccctccctccgtcttaggtcactgttttcaacctcgaa
taaaaactgcagccaacttccgaggcagcctcattgcccagcggaccccagcctctgccaggttcggt
ccgccatcctcgtcccgtcctccgccggcccctgccccgcgcccagggatcctccagctcctttcgcc
cgcgccctccgttcgctccggacaccatggacaagttttggtggcacgcagcctggggactctgcctc
gtgccgctgagcctggcgcagatcgatttgaatataacctgccgctttgcaggtgtattccacgtgga
gaaaaatggtcgctacagcatctctcggacggaggccgctgacctctgcaaggctttcaatagcacct
tgcccacaatggcccagatggagaaagctctgagcatcggatttgagacctgcaggtatgggttcata
gaagggcacgtggtgattccccggatccaccccaactccatctgtgcagcaaacaacacaggggtgta
catcctcacatccaacacctcccagtatgacacatattgcttcaatgcttcagctccacctgaagaag
attgtacatcagtcacagacctgcccaatgcctttgatggaccaattaccataactattgttaaccgt
gatggcacccgctatgtccagaaaggagaatacagaacgaatcctgaagacatctaccccagcaaccc
tactgatgatgacgtgagcagcggctcctccagtgaaaggagcagcacttcaggaggttacatctttt
acaccttttctactgtacaccccatcccagacgaagacagtccctggatcaccgacagcacagacaga
atccctgctaccactttgatgagcactagtgctacagcaactgagacagcaaccaagaggcaagaaac
ctgggattggttttcatggttgtttctaccatcagagtcaaagaatcatcttcacacaacaacacaaa
tggctggtacgtcttcaaataccatctcagcaggctgggagccaaatgaagaaaatgaagatgaaaga
gacagacacctcagtttttctggatcaggcattgatgatgatgaagattttatctccagcaccatttc
aaccacaccacgggcttttgaccacacaaaacagaaccaggactggacccagtggaacccaagccatt
caaatccggaagtgctacttcagacaaccacaaggatgactgatgtagacagaaatggcaccactgct
tatgaaggaaactggaacccagaagcacaccctcccctcattcaccatgagcatcatgaggaagaaga
gaccccacattctacaagcacaatccaggcaactcctagtagtacaacggaagaaacagctacccaga
aggaacagtggtttggcaacagatggcatgagggatatcgccaaacacccaaagaagactcccattcg
acaacagggacagctgcagcctcagctcataccagccatccaatgcaaggaaggacaacaccaagccc
agaggacagttcctggactgatttcttcaacccaatctcacaccccatgggacgaggtcatcaagcag
gaagaaggatggatatggactccagtcatagtataacgcttcagcctactgcaaatccaaacacaggt
ttggtggaagatttggacaggacaggacctctttcaatgacaacgcagcagagtaattctcagagctt
ctctacatcacatgaaggcttggaagaagataaagaccatccaacaacttctactctgacatcaagca
ataggaatgatgtcacaggtggaagaagagacccaaatcattctgaaggctcaactactttactggaa
ggttatacctctcattacccacacacgaaggaaagcaggaccttcatcccagtgacctcagctaagac
tgggtcctttggagttactgcagttactgttggagattccaactctaatgtcaatcgttccttatcag
gagaccaagacacattccaccccagtggggggtcccataccactcatggatctgaatcagatggacac
tcacatgggagtcaagaaggtggagcaaacacaacctctggtcctataaggacaccccaaattccaga
atggctgatcatcttggcatccctcttggccttggctttgattcttgcagtttgcattgcagtcaaca
gtcgaagaaggtgtgggcagaagaaaaagctagtgatcaacagtggcaatggagctgtggaggacaga
aagccaagtggactcaacggagaggccagcaagtctcaggaaatggtgcatttggtgaacaaggagtc
gtcagaaactccagaccagtttatgacagctgatgagacaaggaacctgcagaatgtggacatgaaga
ttggggtgtaacacctacaccattatcttggaaagaaacaaccgttggaaacataaccattacaggga
gctgggacacttaacagatgcaatgtgctactgattgtttcattgcgaatcttttttagcataaaatt
ttctactctttttgttttttgtgttttgttctttaaagtcaggtccaatttgtaaaaacagcattgct
ttctgaaattagggcccaattaataatcagcaagaatttgatcgttccagttcccacttggaggcctt
tcatccctcgggtgtgctatggatggcttctaacaaaaactacacatatgtattcctgatcgccaacc
tttcccccaccagctaaggacatttcccagggttaatagggcctggtccctgggaggaaatttgaatg
ggtccattttgcccttccatagcctaatccctgggcattgctttccactgaggttgggggttggggtg
tactagttacacatcttcaacagaccccctctagaaatttttcagatgcttctgggagacacccaaag
ggtgaagctatttatctgtagtaaactatttatctgtgtttttgaaatattaaaccctggatcagtcc
tttgatcagtataattttttaaagttactttgtcagaggcacaaaagggtttaaactgattcataata
aatatctgtacttcttcgatcttcaccttttgtgctgtgattcttcagtttctaaaccagcactgtct
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gggtccctacaatgtatcaggaagagctgagaatggtaaggagactcttctaagtcttcatctcagag
accctgagttcccactcagacccactcagccaaatctcatggaagaccaaggagggcagcactgtttt
tgttttttgttttttgtttttttttttgacactgtccaaaggttttccatcctgtcctggaatcagag
ttggaagctgaggagcttcagcctcttttatggtttaatggccacctgttctctcctgtgaaaggctt
tgcaaagtcacattaagtttgcatgacctgttatccctggggccctatttcatagaggctggccctat
tagtgatttccaaaaacaatatggaagtgccttttgatgtcttacaataagagaagaagccaatggaa
atgaaagagattggcaaaggggaaggatgatgccatgtagatcctgtttgacatttttatggctgtat
ttgtaaacttaaacacaccagtgtctgttcttgatgcagttgctatttaggatgagttaagtgcctgg
ggagtccctcaaaaggttaaagggattcccatcattggaatcttatcaccagataggcaagtttatga
ccaaacaagagagtactggctttatcctctaacctcatattttctcccacttggcaagtcctttgtgg
catttattcatcagtcagggtgtccgattggtcctagaacttccaaaggctgcttgtcatagaagcca
ttgcatctataaagcaacggctcctgttaaatggtatctcctttctgaggctcctactaaaagtcatt
tgttacctaaacttatgtgcttaacaggcaatgcttctcagaccacaaagcagaaagaagaagaaaag
ctcctgactaaatcagggctgggcttagacagagttgatctgtagaatatctttaaaggagagatgtc
aactttctgcactattcccagcctctgctcctccctgtctaccctctcccctccctctctccctccac
ttcaccccacaatcttgaaaacttcctttctcttctgtgaacatcattggccagatccattttcagtg
gtctggatttctttttattttcttttcaacttgaaagaaactggacattaggccactatgtgttgtta
ctgccactagtgttcaagtgcctcttgttttcccagagatttcctgggtctgccagaggcccagacag
gctcactcaagctctttaactgaaaagcaacaagccactccaggacaaggttcaaaatggttacaaca
gcctctacctgtcgccccagggagaaaggggtagtgatacaagtctcatagccagagatggttttcca
ctccttctagatattcccaaaaagaggctgagacaggaggttattttcaattttattttggaattaaa
tacttttttccctttattactgttgtagtccctcacttggatatacctctgttttcacgatagaaata
agggaggtctagagcttctattccttggccattgtcaacggagagctggccaagtcttcacaaaccct
tgcaacattgcctgaagtttatggaataagatgtattctcactcccttgatctcaagggcgtaactct
ggaagcacagcttgactacacgtcatttttaccaatgattttcaggtgacctgggctaagtcatttaa
actgggtctttataaaagtaaaaggccaacatttaattattttgcaaagcaacctaagagctaaagat
gtaatttttcttgcaattgtaaatcttttgtgtctcctgaagacttcccttaaaattagctctgagtg
aaaaatcaaaagagacaaaagacatcttcgaatccatatttcaagcctggtagaattggcttttctag
cagaacctttccaaaagttttatattgagattcataacaacaccaagaattgattttgtagccaacat
tcattcaatactgttatatcagaggagtaggagagaggaaacatttgacttatctggaaaagcaaaat
gtacttaagaataagaataacatggtccattcacctttatgttatagatatgtctttgtgtaaatcat
ttgttttgagttttcaaagaatagcccattgttcattcttgtgctgtacaatgaccactgttattgtt
actttgacttttcagagcacacccttcctctggtttttgtatatttattgatggatcaataataatga
ggaaagcatgatatgtatattgctgagttgaaagcacttattggaaaatattaaaaggctaacattaa
aagactaaaggaaacagaaaaaaaaaaaaaaaaa 
Figure 9.1. The human CD44 mRNA sequence obtained by NCBI. Base pairs shown in dark yellow 
depict the non-coding sequence and base pairs shown in black depict the coding sequence. Base 
pair letters highlighted in bold and underlined represent the first base pair of each exon. The 
sequence highlighted in red shows the start codon found in exon 1. The sequence highlighted in 
green shows the polyA site found in exon 20. CD44 variant exons are depicted by a different colour 
(described in Table 9.1) and the base pair sequences targetted by primers or siRNA molecules are 
highlighted (described in Table 9.2 and 9.3 respectively). 
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Table 9.1. A list of the exon number, corresponding standard/variant exon number and their depicted 
colour and base pair size (as shown in Figure 9.1) for each exon in the human CD44 mRNA sequence 
obtained from the NCBI. It is important to note that exon 6 (variant 1) is not translated into mRNA in 
the human genome due to the position of a stop codon in exon 6 (Screaton et al. 1992). Exon 19 
(standard 9) is usually absent from most CD44 proteins as inclusion of this exon results in the 
formation of a short-tail CD44 isoform due to the presence of an alternative translation stop codon 
(Goldstein and Butcher 1990).  
 
 
 
 
 
 
Exon number Standard/Variant number Colour Base pair size 
1 Standard 1  501 
2 Standard 2  166 
3 Standard 3  134 
4 Standard 4  69 
5 Standard 5  231 
6 Variant 1  Not translated to mRNA - 
7 Variant 2 Red 129 
8 Variant 3 Purple 126 
9 Variant 4 Green 114 
10 Variant 5 Dark Blue 117 
11 Variant 6 Orange 129 
12 Variant 7 Dark Green 132 
13 Variant 8 Dark red 102 
14 Variant 9 Dark Yellow 90 
15 Variant 10 Light Blue 204 
16 Standard 6  63 
17 Standard 7  73 
18 Standard 8  79 
19 Standard 9 Not translated to mRNA - 
20 Standard 10  3271 
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Table 9.2. A list of the CD44 primers used in this project with their corresponding forward and reverse 
sequences and colour in which they are shown in the above human CD44 mRNA sequence (Figure 
9.1).  
 
Target 
siRNA 
RNA sequence DNA sequence 
 
NT-siRNA 
(control) 
UGGUUUACAUGUCGACUAA 
UGGUUUACAUGUUGUGUGA 
UGGUUUACAUGUUUUCUGA 
UGGUUUACAUGUUUUCCUA 
TGGTTTACATGTCGACTAA 
TGGTTTACATGTTGTGTGA 
TGGTTTACATGTTTTCTGA 
TGGTTTACATGTTTTCCTA 
 
CD44 
(total) 
GAAUAUAACCUGCCGCUU 
CAAGUGGACUCAACGGAGA 
CGAAGAAGGUGUGGGCAGA 
GAUCAACAGUGGCAAUGGA 
GAATATAACCTGCCGCTT 
CAAGTGGACTCAACGGAGA 
CGAAGAAGGTGTGGGCAGA 
GATCAACAGTGGCAATGGA 
CD44v6  CAGAUGGCAUGAGGGAUUCGCCAA CAGATGGCATGAGGGATATCG
CCAA 
Table 9.3. A list of the target siRNAs and their corresponding RNA and DNA sequences for each siRNA 
used in this project. The colour of each target siRNA DNA sequence identifies their location in the 
above human CD44 mRNA sequence (Figure 9.1).  
 
 
 
 
 
Gene Forward Sequence Reverse Sequence 
CD44 Std 
5’-GACACATATTGC 
TTCAATGCTTCAGC-3’ 
5’-GATGCCAAGATGAT 
CAGCCATTCTGGAAT-3’ 
CD44v3 
5’-CGTCTTCAAAT  
ACCATCTCAGC-3’ 
5’ TCATCATCAA 
TGCCTGATCC-3’ 
CD44v6 
5’-CAACGGAAGA 
AACAGCTACCC-3’ 
5’ CCTGTTGTCG 
AATGGGAGTC-3’ 
CD44v10 
5’-GGAATGATGTCA 
CAGGTGGA-3’ 
5’-AAGGTCCTGCT 
TTCCTTCGT-3’ 
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Appendix D. HMMR gene sequence and primer sequences 
The human gene sequence encoding HMMR (RHAMM) mRNA obtained from the 
NCBI database (http://www.ncbi.nlm.nih.gov/) (Figure 9.2) with each exon depicted 
and described in Table 9.4. This gene sequence was utilised to design primers for RT-
PCR analysis that bound to DNA sequences common to all RHAMM isoforms (shown 
in Table 9.4) 
attctttcttcgtgttcctgtgcgggattggtgtgcccaggggtttggctttccaattggctaacgcc 
ggggtgggtggggaatgtggggagatttgaatttgaaaccggtagggagtgataatccgcattcagtt 
gtcgaggagtgccagtcaccttcagtttctggagctggccgtcaacatgtcctttcctaaggcgccct 
tgaaacgattcaatgacccttctggttgtgcaccatctccaggtgcttatgatgttaaaactttagaa 
gtattgaaaggaccagtatcctttcagaaatcacaaagatttaaacaacaaaaagaatctaaacaaaa 
tcttaatgttgacaaagatactaccttgcctgcttcagctagaaaagttaagtcttcggaatcaaaga 
aggaatctcaaaagaatgataaagatttgaagatattagagaaagagattcgtgttcttctacaggaa 
cgtggtgcccaggacaggcggatccaggatctggaaactgagttggaaaagatggaagcaaggctaaa 
tgctgcactaagggaaaaaacatctctctctgcaaataatgctacactggaaaaacaacttattgaat 
tgaccaggactaatgaactactaaaatctaagttttctgaaaatggtaaccagaagaatttgagaatt 
ctaagcttggagttgatgaaacttagaaacaaaagagaaacaaagatgaggggtatgatggctaagca 
agaaggcatggagatgaagctgcaggtcacccaaaggagtctcgaagagtctcaagggaaaatagccc 
aactggagggaaaacttgtttcaatagagaaagaaaagattgatgaaaaatctgaaacagaaaaactc 
ttggaatacatcgaagaaattagttgtgcttcagatcaagtggaaaaatacaagctagatattgccca 
gttagaagaaaatttgaaagagaagaatgatgaaattttaagccttaagcagtctcttgaggagaata 
ttgttatattatctaaacaagtagaagatctaaatgtgaaatgtcagctgcttgaaaaagaaaaagaa 
gaccatgtcaacaggaatagagaacacaacgaaaatctaaatgcagagatgcaaaacttaaaacagaa 
gtttattcttgaacaacaggaacgtgaaaagcttcaacaaaaagaattacaaattgattcacttctgc 
aacaagagaaagaattatcttcgagtcttcatcagaagctctgttcttttcaagaggaaatggttaaa 
gagaagaatctgtttgaggaagaattaaagcaaacactggatgagcttgataaattacagcaaaagga 
ggaacaagctgaaaggctggtcaagcaattggaagaggaagcaaaatctagagctgaagaattaaaac 
tcctagaagaaaagctgaaagggaaggaggctgaactggagaaaagtagtgctgctcatacccaggcc 
accctgcttttgcaggaaaagtatgacagtatggtgcaaagccttgaagatgttactgctcaatttga 
aagctataaagcgttaacagccagtgagatagaagatcttaagctggagaactcatcattacaggaaa 
aagcggccaaggctgggaaaaatgcagaggatgttcagcatcagattttggcaactgagagctcaaat 
caagaatatgtaaggatgcttctagatctgcagaccaagtcagcactaaaggaaacagaaattaaaga 
aatcacagtttcttttcttcaaaaaataactgatttgcagaaccaactcaagcaacaggaggaagact 
ttagaaaacagctggaagatgaagaaggaagaaaagctgaaaaagaaaatacaacagcagaattaact 
gaagaaattaacaagtggcgtctcctctatgaagaactatataataaaacaaaaccttttcagctaca 
actagatgcttttgaagtagaaaaacaggcattgttgaatgaacatggtgcagctcaggaacagctaa 
ataaaataagagattcatatgctaaattattgggtcatcagaatttgaaacaaaaaatcaagcatgtt 
gtgaagttgaaagatgaaaatagccaactcaaatcggaagtatcaaaactccgctgtcagcttgctaa 
aaaaaaacaaagtgagacaaaacttcaagaggaattgaataaagttctaggtatcaaacactttgatc 
cttcaaaggcttttcatcatgaaagtaaagaaaattttgccctgaagaccccattaaaagaaggcaat 
acaaactgttaccgagctcctatggagtgtcaagaatcatggaagtaaacatctgagaaacctgttga 
agattatttcattcgtcttgttgttattgatgttgctgttattatatttgacatgggtattttataat 
gttgtatttaattttaactgccaatccttaaatatgtgaaaggaacattttttaccaaagtgtctttt 
gacattttattttttcttgcaaatacctcctccctaatgctcacctttatcacctcattctgaaccct 
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ttcgctggctttccagcttagaatgcatctcatcaacttaaaagtcagtatcatattattatcctcct 
gttctgaaaccttagtttcaagagtctaaaccccagattcttcagcttgatcctggaggtcttttcta 
gtctgagcttctttagctaggctaaaacaccttggcttgttattgcctctactttgattctgataatg 
ctcacttggtcctacctattatccttctacttgtccagttcaaataagaaataaggacaagcctaact 
tcatagaaacctctctatttttaatcagttgtttaataatttacaggttcttaggctccatcctgttt 
gtatgaaattataatctgtggattggcctttaagcctgcattcttaacaaactcttcagttaattctt 
agatacataaaaatctgagaaactctacatgtaactatttcttcagagtttgtcatatactgcttgtc 
atctgcatgtctactcagcatttgattaacatttgtgtaatatgaaataaaattacacagtaagtcat 
ttaaccaattaaaaa 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.2. The human HMMR (RHAMM) mRNA sequence obtained by NCBI. Base pairs shown in 
dark yellow depict the non-coding sequence and base pairs shown in black depict the coding 
sequence. Base pair letters highlighted in bold and underlined represent the first base pair of each 
exon. The sequence highlighted in red shows the start codon found in exon 1. The sequence 
highlighted in green shows the polyA site found in exon 18. HMMR (RHAMM) base pair sizes and 
position of primer pairs (highlighted in grey) are described in Tables 9.4 and 9.5 respectively. The 
existence of several HMMR (RHAMM) isoforms have so far been characterised which contain N-
terminal truncations of i) exon 4, ii) exon 5, iii) exon 13, iv) exons 1 – 5 and v) exons. 1 – 9. 
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Table 9.4. A list of the exon number and corresponding base pair size for each exon in the human 
HMMR (RHAMM) gene.  
 
Table 9.5. The HMMR primer used in this project with its corresponding forward and reverse sequence 
and colour in which it is highlighted in the mRNA sequence (Figure 9.2). 
 
 
 
 
Exon Base pair size 
1 228 
2 99 
3 80 
4 48 
5 189 
6 87 
7 101 
8 75 
9 179 
10 149 
11 215 
12 117 
13 147 
14 153 
15 100 
16 177 
17 163 
18 836 
Gene Forward Sequence Reverse Sequence 
HMMR 5’-TGCAGCTCAGGAACAGCTAA-3’ 5’-GCTGACAGCGGAGTTTTGAT-3’ 
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Appendix E. Densitometry analysis using ImageJ software 
Band intensities obtained from Western blotting detection were quantified using the 
ImageJ software programme (http://imagej.nih.gov/ij/download.html) for analysis 
of protein expression levels. Each image analysed was scanned and uploaded into the 
software programme and converted to grayscale by using the Image>Type>8-bit 
command. Using the rectangle icon on the ImageJ selection toolbar a tall narrow 
rectangle was drawn around the first band representing the expression level of a 
protein of interest.  It was important to draw the box as close to the protein band as 
possible whilst containing all of the band in the box. Using the tool bar, the 
Analyse>Gels>Select First Lane command was then used to highlight the box and 
identify it as lane ‘1’. The box in lane 1 was then copied and pasted (to ensure all 
boxes were the same size for comparison) and moved to the protein band situated 
in lane 2. Using the tool bar, the Analyse>Gels>Select Next Lane command was then 
used to highlight the box and identify it as lane ‘2’. This was then repeated for each 
band in the image. Once all bands contained a rectangle around their perimeter 
including the number corresponding to their lane position, profile plots were then 
drawn for each band using the Analyse>Gel>Plot Lanes command. The resulting plots 
showed the relative density within each of the highlighted lanes. The width of the 
peaks represented the size/area of the bands and the peak height represented the 
shade/darkness of the bands. The straight line tool situated on the ImageJ selection 
toolbar was then used to draw a line across the base of each peak to enclose it so 
that the area could be measured with little/no background noise. This required 
subjective judgement as to where each peak ended and the background began. After 
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each peak was enclosed the wand tool from the ImageJ selection toolbar was used 
to measure and highlight each peak. Measurements for each peak appeared in a 
results pop-up window. When all peaks were highlighted using the wand tool, the 
peaks were then labelled using the Analyse>Gels>Label Peaks command on the 
toolbar. This labelled each peak with its size, expressed as a percentage of the total 
size of all the highlighted peaks. The values were then exported to an Excel 
spreadsheet to calculate the relative density of each peak. This process was repeated 
for bands representing housekeeping/loading control proteins. To determine the 
relative density of a protein normalised to the loading control the following formula 
was calculated. The relative densitometry value (RDV) for each loading standard 
band was calculated by dividing the percentage value for each lane by the percentage 
value in the control lane. The RDV for each sample band was then calculated by 
dividing the percentage value for each lane by the percentage value in the control 
lane. The total RDV for each protein was then calculated by dividing the RDV for each 
sample lane by the RDV of the loading control. 
Appendix F. (3-Aminopropyl)triethoxysilane-coating of coverslips 
Glass coverslips were cleaned with 100 % ethanol and allowed to air dry. Once fully 
dried, coverslips were incubated with 2 % (3-Aminopropyl)triethozysilane (Tespa) in 
acetone for 5 seconds. The coverslips were then placed into 100 % acetone for 2 
minutes before undergoing 2 x 1 minute washes in distilled water. Coated-coverslips 
were air-dried and sterilised before use. This procedure was performed by research 
technician staff in the BCMPG, Cardiff University. 
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Appendix G. Total cell fluorescence analysis using ImageJ software 
The total level of cell fluorescence was quantified for each image taken by 
immunofluorescence analysis using the ImageJ software analysis programme 
(http://imagej.nih.gov/ij/download.html). Each image was uploaded into the 
programme and each channel was measured separately and converted to 8-bit by 
using the Image>Colour>Split Channels command on the toolbar. Using the 
Analyse>Set Measurements command on the toolbar the following parameters alone 
were selected: area, integrated density and grey value. Each cell in the image was 
then outlined using the freehand tool on the ImageJ selection toolbar which allowed 
the user to precisely draw around the perimeter of the cells. The images were then 
measured using the Analyse>Measure command on the toolbar and the values for 
each parameter appeared in a results pop-up window. To obtain a background 
reading, a region with no fluorescence was selected and measured using the 
Analyse>Set Measurements command. To gain an accurate reading of the 
background fluorescence, 3 measurements of no fluorescence were taken. The data 
in the pop-up window was then imported into an Excel spreadsheet and total cell 
fluorescence for each cell was calculated using the following formula: integrated 
density – (area of selected cell x mean of fluorescence of background readings). The 
mean total cell fluorescence for all cells in the image was then calculated and 3 
independent experiments were repeated.  
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Appendix H. CD44 plasmid construct map 
The plasmid construct map common to each CD44 plasmid used in this project. 
Plasmid DNA constructs containing sequences encoding CD44v3, CD44v6 and their 
cytoplasmic tail truncation mutants (denoted as CD44v3∆cyt and CD44v6∆cyt) fused 
with an EGFP-tag in a p-PGKT-T7/2 vector were a kind gift from Dr Ursula Gunthert 
(Basel University, Switzerland).  
 
Figure 9.3. The plasmid construct map for the CD44v3, CD44v3∆cyt, CD44v6 and CD44v6∆cyt 
constructs obtained from Dr Ursula Gunthert, Basal University, Switzerland. This p-PGK-T7/2 
vector map shows the T7 promoter region, multiple cloning site (MCS) containing the CD44 gene 
insertion flanked by restriction enzymes EcoRI and BglII/BamHI and the Ampicillin resistance 
(AmpR) conferred within this vector.  
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Appendix I. CD44 Sequencing Results 
The sequencing results for each DNA plasmid construct used in this project, 
sequenced by the CBS and analysed using the Chromas Lite software programme 
(http://technelysium.com.au/). Each DNA sequence was translated into its protein 
sequence using the Expasy (http://web.expasy.org/translate/) online analysis 
software tool.  
CD44v3 plasmid DNA sequence 
Original sequence 
Plasmid sequence 
Promoter sequence 
EGFP tag 
 
gcggttacccgac 
 
atggacaagttttggtggcacgcagcctggggactctgcctcgtgccgctgagcctggcgcagatcgatttgaat 
atggacaagttttggtggcacgcagcctggggactctgcctcgtgccgctgagcctggcgcagatcgatttgaat 
 
ataacctgccgctttgcaggtgtattccacgtggagaaaaatggtcgctacagcatctctcggacggaggccgct 
ataacctgccgctttgcaggtgtattccacgtggagaaaaatggtcgctacagcatctctcggacggaggccgct 
 
gacctctgcaaggctttcaatagcaccttgcccacaatggcccagatggagaaagctctgagcatcggatttgag 
gacctctgcaaggctttcaatagcaccttgcccacaatggcccagatggagaaagctctgagcatcggatttgag 
 
acctgcaggtatgggttcatagaagggcacgtggtgattccccggatccaccccaactccatctgtgcagcaaac 
acctgcaggtatgggttcatagaagggcacgtggtgattccccggatccaccccaactccatctgtgcagcaaac 
 
aacacaggggtgtacatcctcacatccaacacctcccagtatgacacatattgcttcaatgcttcagctccacct 
aacacaggggtgtacatcctcacatccaacacctcccagtatgacacatattgcttcaatgcttcagctccacct 
 
gaagaagattgtacatcagtcacagacctgcccaatgcctttgatggaccaattaccataactattgttaaccgt             
gaagaagattgtacatcagtcacagacctgcccaatgcctttgatggaccaattaccataactattgttaaccgt 
 
gatggcacccgctatgtccagaaaggagaatacagaacgaatcctgaagacatctaccccagcaaccctactgat 
gatggcacccgctatgtccagaaaggagaatacagaacgaatcctgaagacatctaccccagcaaccctactgat 
 
gatgacgtgagcagcggctcctccagtgaaaggagcagcacttcaggaggttacatcttttacaccttttctact 
gatgacgtgagcagcggctcctccagtgaaaggagcagcacttcaggaggttacatcttttacaccttttctact 
 
gtacaccccatcccagacgaagacagtccctggatcaccgacagcacagacagaatccctgctaccagtacgtct 
gtacaccccatcccagacgaagacagtccctggatcaccgacagcacagacagaatccctgctaccagtacgtct 
 
tcaaataccatctcagcaggctgggagccaaatgaagaaaatgaagatgaaagagacagacacctcagtttttct 
tcaaataccatctcagcaggctgggagccaaatgaagaaGatgaagatgaaagagacagacacctcagtttttct 
 
ggatcaggcattgatgatgatgaagattttatctccagcaccagagaccaagacacattccaccccagtgggggg 
ggatcaggcattgatgatgatgaagattttatctccagcaccagagaccaagacacattccaccccagtgggggg 
 
tcccataccactcatggatctgaatcagatggacactcacatgggagtcaagaaggtggagcaaacacaacctct 
tcccataccactcatggatctgaatcagatggacactcacatgggagtcaagaaggtggagcaaacacaacctct 
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ggtcctataaggacaccccaaattccagaatggctgatcatcttggcatccctcttggccttggctttgattctt 
ggtcctataaggacaccccaaattccagaatggctgatcatcttggcatccctcttggccttggctttgattctt 
 
gcagtttgcattgcagtcaacagtcgaagaaggtgtgggcagaagaaaaagctagtgatcaacagtggcaatgga 
gcagtttgcattgcagtcaacagtcgaagaaggtgtgggcagaagaaaaagctagtgatcaacagtggcaatgga 
 
gctgtggaggacagaaagccaagtggactcaacggagaggccagcaagtctcaggaaatggtgcatttggtgaac 
gctgtggaggacagaaagccaagtggactcaacggagaggccagcaagtctcaggaaatggtgcatttggtgaac 
 
aaggagtcgtcagaaactccagaccagtttatgacagctgatgagacaaggaacctgcagaatgtggacatgaag 
aaggagtcgtcagaaactccagaccagtttatgacagctgatgagacaaggaacctgcagaatgtggacatgaag 
 
attggggtgtaa 
attggggtagat 
 
agatccccgggccgggtcgccaccatggtgagcaagggcgagagctgttcaccggggtggtgccatcctgtcgac 
tggacgcgacgtaaacgacacagttcagcgtgtccggcgaggccgaagccgaatgcactaccgcaaggctgaacc 
cttgaagtttcaaattcttgtgca  
 
CD44v3 DNA to protein translation 
 
Original sequence 
Plasmid sequence 
 
MDKFWWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTL 
MDKFWWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTL 
 
PTMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFN 
PTMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFN 
 
ASAPPEEDCTSVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNPTDDDVSS 
ASAPPEEDCTSVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNPTDDDVSS 
 
GSSSERSSTSGGYIFYTFSTVHPIPDEDSPWITDSTDRIPATSTSSNTISAGWEPNEENE 
GSSSERSSTSGGYIFYTFSTVHPIPDEDSPWITDSTDRIPATSTSSNTISAGWEPNEEDE 
 
DERDRHLSFSGSGIDDDEDFISRDQDTFHPSGGSHTTHGSESDGHSHGSQEGGANTTSGP 
DERDRHLSFSGSGIDDDEDFISRDQDTFHPSGGSHTTHGSESDGHSHGSQEGGANTTSGP 
 
IRTPQIPEWLIILASLLALALILAVCIAVNSRRRCGQKKKLVINSGNGAVEDRKPSGLNG 
IRTPQIPEWLIILASLLALALILAVCIAVNSRRRCGQKKKLVINSGNGAVEDRKPSGLNG 
 
EASKSQEMVHLVNKESSETPDQFMTADETRNLQNVDMKIGV Stop 
EASKSQEMVHLVNKESSETPDQFMTADETRNLQNVDMKIGV Stop  
Figure 9.4. The DNA sequencing results performed by the CBS and analysed using the software 
programmes Chromas Lite and Expasy for the CD44v3 plasmid construct. The variant 3 exon is 
highlighted in bold and underlined. The plasmid DNA sequence revealed a substitution mutation 
from guanine to alanine in the variant 3 exon (highlighted in yellow). Protein analysis using the 
online protein translation tool Expasy revealed this base pair substitution converted the amino 
acid from an asparagine (N) to an aspartic acid (D). No other differences between the original 
and plasmid CD44v3 sequence were found.  
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CD44v3∆cyt plasmid DNA and protein sequence 
Original sequence 
Plasmid sequence 
Promoter sequence 
EGFP tag 
 
ccccttcccaccccgccc 
 
atggacaagttttggtggcacgcagcctggggactctgcctcgtgccgctgagcctggcgcagatcgatttgaat 
atggacaagttttggtggcacgcagcctggggactctgcctcgtgccgctgagcctggcgcagatcgatttgaat 
 
ataacctgccgctttgcaggtgtattccacgtggagaaaaatggtcgctacagcatctctcggacggaggccgct 
ataacctgccgctttgcaggtgtattccacgtggagaaaaatggtcgctacagcatctctcggacggaggccgct 
 
gacctctgcaaggctttcaatagcaccttgcccacaatggcccagatggagaaagctctgagcatcggatttgag 
gacctctgcaaggctttcaatagcaccttgcccacaatggcccagatggagaaagctctgagcatcggatttgag 
 
acctgcaggtatgggttcatagaagggcacgtggtgattccccggatccaccccaactccatctgtgcagcaaac 
acctgcaggtatgggttcatagaagggcacgtggtgattccccggatccaccccaactccatctgtgcagcaaac 
 
aacacaggggtgtacatcctcacatccaacacctcccagtatgacacatattgcttcaatgcttcagctccacct 
aacacaggggtgtacatcctcacatccaacacctcccagtatgacacatattgcttcaatgcttcagctccacct 
 
gaagaagattgtacatcagtcacagacctgcccaatgcctttgatggaccaattaccataactattgttaaccgt             
gaagaagattgtacatcagtcacagacctgcccaatgcctttgatggaccaattaccataactattgttaaccgt 
 
gatggcacccgctatgtccagaaaggagaatacagaacgaatcctgaagacatctaccccagcaaccctactgat 
gatggcacccgctatgtccagaaaggagaatacagaacgaatcctgaagacatctaccccagcaaccctactgat 
 
gatgacgtgagcagcggctcctccagtgaaaggagcagcacttcaggaggttacatcttttacaccttttctact 
gatgacgtgagcagcggctcctccagtgaaaggagcagcacttcaggaggttacatcttttacaccttttctact 
 
gtacaccccatcccagacgaagacagtccctggatcaccgacagcacagacagaatccctgctaccagtacgtct 
gtacaccccatcccagacgaagacagtccctggatcaccgacagcacagacagaatccctgctaccagtacgtct 
 
tcaaataccatctcagcaggctgggagccaaatgaagaaaatgaagatgaaagagacagacacctcagtttttct 
tcaaataccatctcagcaggctgggagccaaatgaagaaGatgaagatgaaagagacagacacctcagtttttct 
 
ggatcaggcattgatgatgatgaagattttatctccagcaccagagaccaagacacattccaccccagtgggggg 
ggatcaggcattgatgatgatgaagattttatctccagcaccagagaccaagacacattccaccccagtgggggg 
 
tcccataccactcatggatctgaatcagatggacactcacatgggagtcaagaaggtggagcaaacacaacctct 
tcccataccactcatggatctgaatcagatggacactcacatgggagtcaagaaggtggagcaaacacaacctct 
 
ggtcctataaggacaccccaaattccagaatggctgatcatcttggcatccctcttggccttggctttgattctt 
ggtcctataaggacaccccaaattccagaatggctgatcatcttggcatccctcttggccttggctttgattctt 
 
gcagtttgcattgcagtcaacagtcgaagaaggtgtgggcagaagaaaaagctagtgatcaacagtggcaatgga 
gcagtttgcattgcagtcaacag 
 
gctgtggaggacagaaagccaagtggactcaacggagaggccagcaagtctcaggaaatggtgcatttggtgaac 
 
 
aaggagtcgtcagaaactccagaccagtttatgacagctgatgagacaaggaacctgcagaatgtggacatgaag 
 
 
attggggtgtaa 
 
 
agatccccggccggtcgccaccatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcga
gctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagct
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gaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacgg
cggtgcagtgctttcagccgctaccccgaccacatgaagcagcacgacttcttcagtccgccatgcccgatgcta
cgttcagagcgcaacaatctctcagacgacggcaacctacaagaccgcgccgaggtgaaggttcgaaggggcgac
aac 
 
 
DNA to protein translation 
 
Original sequence 
Plasmid sequence 
 
MDKFWWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTL 
MDKFWWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTL 
 
PTMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFN 
PTMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFN 
 
ASAPPEEDCTSVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNPTDDDVSS 
ASAPPEEDCTSVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNPTDDDVSS 
 
GSSSERSSTSGGYIFYTFSTVHPIPDEDSPWITDSTDRIPATSTSSNTISAGWEPNEENE 
GSSSERSSTSGGYIFYTFSTVHPIPDEDSPWITDSTDRIPATSTSSNTISAGWEPNEEDE 
 
DERDRHLSFSGSGIDDDEDFISRDQDTFHPSGGSHTTHGSESDGHSHGSQEGGANTTSGP 
DERDRHLSFSGSGIDDDEDFISRDQDTFHPSGGSHTTHGSESDGHSHGSQEGGANTTSGP 
 
IRTPQIPEWLIILASLLALALILAVCIAVNSRRRCGQKKKLVINSGNGAVEDRKPSGLNG 
IRTPQIPEWLIILASLLALALILAVCIAVN 
 
EASKSQEMVHLVNKESSETPDQFMTADETRNLQNVDMKIGV Stop 
 
Figure 9.5. The DNA sequencing results as performed by the CBS and analysed using the software 
programmes Chromas Lite and Expasy for the CD44v3∆cyt plasmid construct. The variant 3 exon is 
highlighted in bold and underlined. The DNA and protein sequence show the loss of the cytoplasmic 
tail starting at amino acid position 330. The plasmid DNA sequence revealed a substitution mutation 
from guanine to alanine in the variant 3 exon (highlighted in yellow). Protein analysis using the 
online protein translation tool Expasy revealed this base pair substitution converted the amino acid 
from an asparagine (N) to an aspartic acid (D). No other differences between the original and 
plasmid CD44v3∆cyt sequence were found.  
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CD44v6 plasmid DNA and protein sequence 
Original sequence 
Plasmid sequence 
Promoter sequence 
EGFP tag 
 
acggatacacgtc 
 
atggacaagttttggtggcacgcagcctggggactctgcctcgtgccgctgagcctggcgcagatcgatttgaat 
atggacaagttttggtggcacgcagcctggggactctgcctcgtgccgctgagcctggcgcagatcgatttgaat 
 
ataacctgccgctttgcaggtgtattccacgtggagaaaaatggtcgctacagcatctctcggacggaggccgct 
ataacctgccgctttgcaggtgtattccacgtggagaaaaatggtcgctacagcatctctcggacggaggccgct 
 
gacctctgcaaggctttcaatagcaccttgcccacaatggcccagatggagaaagctctgagcatcggatttgag 
gacctctgcaaggctttcaatagcaccttgcccacaatggcccagatggagaaagctctgagcatcggatttgag 
 
acctgcaggtatgggttcatagaagggcacgtggtgattccccggatccaccccaactccatctgtgcagcaaac 
acctgcaggtatgggttcatagaagggcacgtggtgattccccggatccaccccaactccatctgtgcagcaaac 
 
aacacaggggtgtacatcctcacatccaacacctcccagtatgacacatattgcttcaatgcttcagctccacct 
aacacaggggtgtacatcctcacatccaacacctcccagtatgacacatattgcttcaatgcttcagctccacct 
 
gaagaagattgtacatcagtcacagacctgcccaatgcctttgatggaccaattaccataactattgttaaccgt             
gaagaagattgtacatcagtcacagacctgcccaatgcctttgatggaccaattaccataactattgttaaccgt 
 
gatggcacccgctatgtccagaaaggagaatacagaacgaatcctgaagacatctaccccagcaaccctactgat 
gatggcacccgctatgtccagaaaggagaatacagaacgaatcctgaagacatctaccccagcaaccctactgat 
 
gatgacgtgagcagcggctcctccagtgaaaggagcagcacttcaggaggttacatcttttacaccttttctact 
gatgacgtgagcagcggctcctccagtgaaaggagcagcacttcaggaggttacatcttttacaccttttctact 
 
gtacaccccatcccagacgaagacagtccctggatcaccgacagcacagacagaatccctgctaccatccaggca 
gtacaccccatcccagacgaagacagtccctggatcaccgacagcacagacagaatccctgctaccatccaggca 
 
actcctagtagtacaacggaagaaacagctacccagaaggaacagtggtttggcaacagatggcatgagggatat 
actcctagtagtacaacggaagaaacagctacccagaaggaacagtggtttggcaacagatggcatgagggatat 
 
cgccaaacacccaaagaagactcccattcgacaacagggacagctggagaccaagacacattccaccccagtggg 
cgccaaacacccaaagaagactcccattcgacaacagggacagctggagaccaagacacattccaccccagtggg 
 
gggtcccataccactcatggatctgaatcagatggacactcacatgggagtcaagaaggtggagcaaacacaacc 
gggtcccataccactcatggatctgaatcagatggacactcacatgggagtcaagaaggtggagcaaacacaacc 
 
tctggtcctataaggacaccccaaattccagaatggctgatcatcttggcatccctcttggccttggctttgatt 
tctggtcctataaggacaccccaaattccagaatggctgatcatcttggcatccctcttggccttggctttgatt 
 
cttgcagtttgcattgcagtcaacagtcgaagaaggtgtgggcagaagaaaaagctagtgatcaacagtggcaat 
cttgcagtttgcattgcagtcaacagtcgaagaaggtgtgggcagaagaaaaagctagtgatcaacagtggcaat 
 
ggagctgtggaggacagaaagccaagtggactcaacggagaggccagcaagtctcaggaaatggtgcatttggtg 
ggagctgtggaggacagaaagccaagtggactcaacggagaggccagcaagtctcaggaaatggtgcatttggtg 
 
aacaaggagtcgtcagaaactccagaccagtttatgacagctgatgagacaaggaacctgcagaatgtggacatg 
aacaaggagtcgtcagaaactccagaccagtttatgacagctgatgagacaaggaacctgcagaatgtggacatg 
 
 
aagattggggtgtaa 
aagattggggtagat 
 
agatccccgggccgggtcgccaccatggtgagcaaggacgaggagctgttcaccggggtggtgcccatcctggtc
gagctgggacggcgacgttaaacgtcacagtttcagcgtgtccgccaagtcgaagtcgatgccaccgtaccggca
gcttgaaccctgaaggttcat 
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DNA to protein translation 
 
Original sequence 
Plasmid sequence 
 
MDKFWWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTL 
MDKFWWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTL 
 
PTMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFN 
PTMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFN 
 
ASAPPEEDCTSVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNPTDDDVSS 
ASAPPEEDCTSVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNPTDDDVSS 
 
GSSSERSSTSGGYIFYTFSTVHPIPDEDSPWITDSTDRIPATIQATPSSTEETATQKEQW 
GSSSERSSTSGGYIFYTFSTVHPIPDEDSPWITDSTDRIPATIQATPSSTEETATQKEQW 
 
FGNRWHEGYRQTPKEDSHSTTGTAGDQDTFHPSGGSTTHGSESDGHSHGSQEGGANTTSG 
FGNRWHEGYRQTPKEDSHSTTGTAGDQDTFHPSGGSTTHGSESDGHSHGSQEGGANTTSG 
 
PIRTPQIPEWLIILASLLALALILAVCIAVNSRRRCGQKKKLVINSGNGAVEDRKPSGLN 
PIRTPQIPEWLIILASLLALALILAVCIAVNSRRRCGQKKKLVINSGNGAVEDRKPSGLN 
 
GEASKSQEMVHLVNKESSETPDQFMTADETRNLQNVDMKIGV Stop 
GEASKSQEMVHLVNKESSETPDQFMTADETRNLQNVDMKIGV Stop 
 
Figure 9.6. The DNA sequencing results as performed by the CBS and analysed using the software 
programmes Chromas Lite and Expasy for the CD44v6 plasmid construct. The variant 6 exon is 
highlighted in bold and underlined. No differences between the original and plasmid CD44v6 DNA and 
protein sequence were found.   
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CD44v6∆cyt plasmid DNA and protein sequence 
 
Original sequence 
Plasmid sequence 
Promoter sequence 
EGFP tag 
 
acacttcacgac 
 
atggacaagttttggtggcacgcagcctggggactctgcctcgtgccgctgagcctggcgcagatcgatttgaat 
atggacaagttttggtggcacgcagcctggggactctgcctcgtgccgctgagcctggcgcagatcgatttgaat 
 
ataacctgccgctttgcaggtgtattccacgtggagaaaaatggtcgctacagcatctctcggacggaggccgct 
ataacctgccgctttgcaggtgtattccacgtggagaaaaatggtcgctacagcatctctcggacggaggccgct 
 
gacctctgcaaggctttcaatagcaccttgcccacaatggcccagatggagaaagctctgagcatcggatttgag 
gacctctgcaaggctttcaatagcaccttgcccacaatggcccagatggagaaagctctgagcatcggatttgag 
 
acctgcaggtatgggttcatagaagggcacgtggtgattccccggatccaccccaactccatctgtgcagcaaac 
acctgcaggtatgggttcatagaagggcacgtggtgattccccggatccaccccaactccatctgtgcagcaaac 
 
aacacaggggtgtacatcctcacatccaacacctcccagtatgacacatattgcttcaatgcttcagctccacct 
aacacaggggtgtacatcctcacatccaacacctcccagtatgacacatattgcttcaatgcttcagctccacct 
 
gaagaagattgtacatcagtcacagacctgcccaatgcctttgatggaccaattaccataactattgttaaccgt 
gaagaagattgtacatcagtcacagacctgcccaatgcctttgatggaccaattaccataactattgttaaccgt 
 
gatggcacccgctatgtccagaaaggagaatacagaacgaatcctgaagacatctaccccagcaaccctactgat 
gatggcacccgctatgtccagaaaggagaatacagaacgaatcctgaagacatctaccccagcaaccctactgat 
 
gatgacgtgagcagcggctcctccagtgaaaggagcagcacttcaggaggttacatcttttacaccttttctact 
gatgacgtgagcagcggctcctccagtgaaaggagcagcacttcaggaggttacatcttttacaccttttctact 
 
gtacaccccatcccagacgaagacagtccctggatcaccgacagcacagacagaatccctgctaccatccaggca 
gtacaccccatcccagacgaagacagtccctggatcaccgacagcacagacagaatccctgctaccatccaggca 
 
actcctagtagtacaacggaagaaacagctacccagaaggaacagtggtttggcaacagatggcatgagggatat 
actcctagtagtacaacggaagaaacagctacccagaaggaacagtggtttggcaacagatggcatgagggatat 
 
cgccaaacacccaaagaagactcccattcgacaacagggacagctggagaccaagacacattccaccccagtggg 
cgccaaacacccaaagaagactcccattcgacaacagggacagctggagaccaagacacattccaccccagtggg 
 
gggtcccataccactcatggatctgaatcagatggacactcacatgggagtcaagaaggtggagcaaacacaacc 
gggtcccataccactcatggatctgaatcagatggacactcacatgggagtcaagaaggtggagcaaacacaacc 
 
tctggtcctataaggacaccccaaattccagaatggctgatcatcttggcatccctcttggccttggctttgatt 
tctggtcctataaggacaccccaaattccagaatggctgatcatcttggcatccctcttggccttggctttgatt 
 
cttgcagtttgcattgcagtcaacagtcgaagaaggtgtgggcagaagaaaaagctagtgatcaacagtggcaat 
cttgcagtttgcattgcagtcaacag 
 
ggagctgtggaggacagaaagccaagtggactcaacggagaggccagcaagtctcaggaaatggtgcatttggtg 
 
 
aacaaggagtcgtcagaaactccagaccagtttatgacagctgatgagacaaggaacctgcagaatgtggacatg 
 
 
aagattggggtgtaa 
 
 
agatccccggccggtcgccaccatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcga
gctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagct
gaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacgg
cgtgcagtgcttcagccgctaccccgaccacatggagcagcacgacttcttcagtccgccatgccgatgcctacg
tcagagcgcacatctctcaagacgaccgcacctacaagaccggcgcccggaggggtgaagtcg 
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DNA to protein translation 
 
Original sequence 
Plasmid sequence 
 
MDKFWWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTL 
MDKFWWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTL 
 
PTMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFN 
PTMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFN 
 
ASAPPEEDCTSVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNPTDDDVSS 
ASAPPEEDCTSVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNPTDDDVSS 
 
GSSSERSSTSGGYIFYTFSTVHPIPDEDSPWITDSTDRIPATIQATPSSTEETATQKEQW 
GSSSERSSTSGGYIFYTFSTVHPIPDEDSPWITDSTDRIPATIQATPSSTEETATQKEQW 
 
FGNRWHEGYRQTPKEDSHSTTGTAGDQDTFHPSGGSTTHGSESDGHSHGSQEGGANTTSG 
FGNRWHEGYRQTPKEDSHSTTGTAGDQDTFHPSGGSTTHGSESDGHSHGSQEGGANTTSG 
 
PIRTPQIPEWLIILASLLALALILAVCIAVNSRRRCGQKKKLVINSGNGAVEDRKPSGLN 
PIRTPQIPEWLIILASLLALALILAVCIAVN 
 
GEASKSQEMVHLVNKESSETPDQFMTADETRNLQNVDMKIGV Stop 
 
Figure 9.7. The DNA sequencing results as performed by the CBS and analysed using the software 
programmes Chromas Lite and Expasy for the CD44v6∆cyt plasmid construct. The variant 6 exon is 
highlighted in bold and underlined. The DNA and protein sequence show the loss of the cytoplasmic 
tail starting at amino acid position 330. No other differences between the original and plasmid 
CD44v6∆cyt sequence were found.  
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Appendix J. Optimisation of HA stimulation across MCF-7, Tam-R and Fas-R cells 
The effect of high molecular weight HA upon the induction of growth factor signalling 
across the cell models. The cell lines were treated with high molecular weight HA 
(>500 kDa, R&D Systems, UK) for 10 minutes before cell lysis and investigation of 
protein activation by Western blotting. The results revealed that high molecular 
weight HA stimulated less of a signalling response to HER2, EGFR and ERK1/2 across 
the cell models compared to stimulation with medium molecular weight HA (215 
kDa) (shown in Figure 4.3). Therefore medium molecular weight HA was used for 
subsequent exogenous HA stimulation in this project.  
 
 
 
 
 
Figure 9.8. Representative Western blot images from 3 independent experiments showing HER2, 
EGFR and ERK1/2 activation in MCF-7, Tam-R and Fas-R cells in response to dose-dependent high 
molecular HA stimulation (>500 kDa, 0 – 400 µg/ml) for 10 minutes with ß actin as a loading 
control.  
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Appendix K. Densitometry analysis for CD44 isoform and RHAMM expression in 
Tam-R and Fas-R cells treated with global CD44 siRNA 
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Figure 9.10. Densitometry graphs showing CD44v3, CD44v6, CD44v10 and RHAMM expression in 
Tam-R and Fas-R cells after 24 – 144 hour treatment with global CD44 siRNA before cell lysis and 
detection by Western blotting analysis. The data shows the total protein levels in the cell lines 
normalised to GAPDH. Error bars represent the average normalised data ±SEM from 3 
independent experiments and the data is presented as the percentage of the untreated control. 
Statistical analysis was performed using a one-way ANOVA with Tukey post-hoc testing and all 
values were compared to the NT-siRNA control to identify any significant changes across all 3 cell 
models. Significance was set at p < 0.05. 
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Appendix L. Densitometry analysis for CD44 isoform expression in Tam-R and Fas-
R cells treated with global RHAMM siRNA 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.11. Densitometry graphs showing CD44 Std, CD44v3, CD44v6 and CD44v10 expression in 
Tam-R and Fas-R cells after 24 – 144 hour treatment with global RHAMM siRNA before cell lysis 
and detection by Western blotting analysis. The data shows the total protein levels in the cell lines 
normalised to GAPDH. Error bars represent the average normalised data ±SEM from 3 
independent experiments and the data is presented as the percentage of the untreated control. 
Statistical analysis was performed using a one-way ANOVA with Tukey post-hoc testing and all 
values were compared to the NT-siRNA control to identify any significant changes across all 3 cell 
models. Significance was set at p < 0.05. 
 
 
Tam-R CD44 Std
C
on
tr
ol
N
T-
si
R
N
A
24
 h
ou
r
48
 h
ou
r
72
 h
ou
r
14
4 
ho
ur
0
50
100
150
%
 C
o
n
tr
o
l
Tam-R CD44v3
C
on
tr
ol
N
T-
si
R
N
A
24
 h
ou
r
48
 h
ou
r
72
 h
ou
r
14
4 
ho
ur
0
50
100
150
200
%
 C
o
n
tr
o
l
Tam-R CD44v10
C
on
tr
ol
N
T-
si
R
N
A
24
 h
ou
r
48
 h
ou
r
72
 h
ou
r
14
4 
ho
ur
0
50
100
150
%
 C
o
n
tr
o
l
Tam-R CD44v6
C
on
tr
ol
N
T-
si
R
N
A
24
 h
ou
r
48
 h
ou
r
72
 h
ou
r
14
4 
ho
ur
0
50
100
150
%
 C
o
n
tr
o
l
           Fas-R CD44 Std
C
on
tr
ol
N
T-
si
R
N
A
24
 h
ou
r
48
 h
ou
r
72
 h
ou
r
14
4 
ho
ur
0
50
100
150
%
 C
o
n
tr
o
l
           Fas-R CD44v3
C
on
tr
ol
N
T-
si
R
N
A
24
 h
ou
r
48
 h
ou
r
72
 h
ou
r
14
4 
ho
ur
0
50
100
150
%
 C
o
n
tr
o
l
           Fas-R CD44v6
C
on
tr
ol
N
T-
si
R
N
A
24
 h
ou
r
48
 h
ou
r
72
 h
ou
r
14
4 
ho
ur
0
50
100
150
%
 C
o
n
tr
o
l
           Fas-R CD44v10
C
on
tr
ol
N
T-
si
R
N
A
24
 h
ou
r
48
 h
ou
r
72
 h
ou
r
14
4 
ho
ur
0
50
100
150
%
 C
o
n
tr
o
l
  
 
 
 
309 
 
Appendix M. Predicting the effect of amino acid substitutions on protein function  
To predict whether the N239D amino acid substitution (arginine to aspartic acid) 
detected by sequencing analysis in the variant 3 exon of the CD44v3/CD44v3∆cyt 
plasmid constructs may alter its protein function, several online publically available 
software programmes were utilised.  
PROVEAN 
The Protein Variation Effect Analyser (PROVEAN) online software tool 
(http://provean.jcvi.org/index.php) was utilised to predict whether the amino acid 
substitution (N239D) in the variant 3 econ may alter its protein function (Choi et al. 
2012). The results revealed a PROVEAN score of -1.436 which scored above the -2.5 
threshold thus suggesting that this substitution was ‘neutral’ and did not have a 
deleterious effect upon protein function.  
PROVEAN Prediction - Job ID: 012466680014698 
 Query sequence (fasta) 
 Supporting sequence set used for prediction 
Number of sequences: 163 (fasta, E-values) 
Number of clusters: 30 
 Score thresholds for prediction 
(1) Default threshold is -2.5, that is: 
-Variants with a score equal to or below -2.5 are considered "deleterious," 
-Variants with a score above -2.5 are considered "neutral." 
(2) How to use a more stringent threshold. 
Variant PROVEAN score Prediction (cutoff= -2.5)  
N239D -1.436 Neutral  
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PANTHER 
The online Protein ANalysis Through Evolutionary Relationships (PANTHER) 
classification System tool (www.pantherdb.org/) (Mi et al. 2013a; Mi et al. 2013b) 
was used as an additional means to investigate the effect of the N239D amino acid 
substitution in the CD44v3 exon. The results confirmed those gathered from the 
PROVEAN tool and the subPSEC score was -1.83966 which was above the threshold 
of -3 suggesting that this substitution does not have a deleterious effect upon protein 
function.  
 
SIFT 
The Sorting Intolerant From Tolerant (SIFT) sequence online tool 
(http://sift.jcvi.org/www/SIFT_seq_submit2.html) provides predictions for a given 
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FASTA sequence whether an amino acid substitution may alter protein function (Ng 
and Henikoff 2006; Kumar et al. 2009). SIFT scores of <0.05 were predicted to be 
deleterious. The results of this analysis revealed a score of 0.74 with the amino acid 
substitution at this position predicted to be tolerated. The web page below shows 
the list of tolerated amino acids sequences in the CD44v3 exon. At position 239 the 
amino acid asparagine (N) is predicted to tolerate the substitution to an aspartic acid 
(D).  
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Appendix N. Conserved domains in the CD44v3 sequence 
To determine whether any conserved domains in the CD44v3 sequence existed which 
may become altered upon amino acid substitution, the online Conserved Domains 
and Protein Classification tool was utilised 
(http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi) (Marcherl-Bauer et al. 
2015). This tool revealed that the only conserved sequence found in the CD44v3 
protein sequence was the link module (HA binding domain) found in the extracellular 
domain of CD44 and not within the variant 3 exon.  
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Appendix O. Densitometry analysis for CD44 isoform expression and RHAMM in 
MCF-7 cells treated with CD44v3 and CD44v3Δcyt plasmid DNA 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.12. Densitometry graphs showing CD44v6, CD44v10 and RHAMM expression in MCF-7 
cells after 24 – 144 hour treatment with CD44v3 (left) or CD44v3Δcyt (right) plasmid DNA, before 
cell lysis and detection by Western blotting analysis. The data shows the total protein levels in the 
cell lines normalised to GAPDH. Error bars represent the average normalised data ±SEM from 3 
independent experiments and the data is presented as the percentage of the untreated control. 
Statistical analysis was performed using a one-way ANOVA with Tukey post-hoc testing and all 
values were compared to the lipid-only control to identify any significant changes across all 3 cell 
models. Significance was set at p < 0.05. 
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Appendix P. Densitometry analysis for CD44 isoform expression and RHAMM in 
MCF-7 cells treated with CD44v6 and CD44v6Δcyt plasmid DNA 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.13. Densitometry graphs showing CD44v3, CD44v10 and RHAMM expression in MCF-7 
cells after 24 – 144 hour treatment with CD44v6 (left) or CD44v6Δcyt (right) plasmid DNA, before 
cell lysis and detection by Western blotting analysis. The data shows the total protein levels in the 
cell lines normalised to GAPDH. Error bars represent the average normalised data ±SEM from 3 
independent experiments and the data is presented as the percentage of the untreated control. 
Statistical analysis was performed using a one-way ANOVA with Tukey post-hoc testing and all 
values were compared to the lipid-only control to identify any significant changes across all 3 cell 
models. Significance was set at p < 0.05. 
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Appendix Q. Densitometry analysis for CD44 isoform expression and RHAMM in 
Tam-R and Fas-R cells treated with CD44v6 siRNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.14. Densitometry graphs showing CD44v3, CD44v6, CD44v10 and RHAMM expression in 
Tam-R and Fas-R cells after 24 – 144 hour treatment with CD44v6 siRNA, before cell lysis and 
detection by Western blotting analysis. The data shows the total protein levels in the cell lines 
normalised to GAPDH. Error bars represent the average normalised data ±SEM from 3 
independent experiments and the data is presented as the percentage of the untreated control. 
Statistical analysis was performed using a one-way ANOVA with Tukey post-hoc testing and all 
values were compared to the NT-siRNA control to identify any significant changes across all 3 cell 
models. Significance was set at p < 0.05. 
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Appendix R. Immunohistochemical analysis of CD44v6 expression in clinical breast 
cancer 
This technique and quantitation analysis was performed by the BCMPG research 
technician, Sue Kyme. Formalin-fixed paraffin-embedded tissue microarray sections 
(TMAs) (provided by Andrew Green, Nottingham University) were studied comprising 
140 breast cancers from ER+ adjuvant tamoxifen patients with 20 year follow up. The 
study population was derived from the Nottingham Tenovus Primary Breast Cancer 
series of women aged 70 or less who presented with primary operable invasive 
breast carcinoma (with tumours less than 5 cm diameter on clinical/pre-operative 
measurement stage I and II) between 1986 – 1998 (Rec: C2020313) (Abd El-Rehim et 
al. 2005; Habashy et al. 2009). For immunohistochemical analysis, the TMA’s were 
sectioned on a Microtome (3 – 5 microns) and dried at 37 °C overnight before being 
incubated at 60 °C for 20 minutes and allowed to cool. TMA’s were dewaxed and 
rehydrated by the following incubation steps: xylene (2 x 7 minutes), 100 % ethanol 
(2 x 2 minutes), 90 % ethanol (2 x 2 minutes), 70 % ethanol (2 x 2 minutes) and 
distilled water (1 x 5 minutes).  A 3 % aqueous solution of hydrogen peroxide was 
then applied to the sections for 5 minutes to eliminate endogenous peroxidases 
before being washed in distilled water for 5 minutes. For antigen retrieval, TMA’s 
were microwaved in 1 L 0.01 M Sodium Citrate buffer pH 6 for 30 minutes at Power 
level 6 (560 W) and cooled in running tap water for 5 minutes. TMA’s were then 
blocked in 10 % normal human serum diluted in PBS for 10 minutes. Excess blocking 
reagent was then removed before the addition of the primary antibody CD44v6 (1/40 
dilution in PBS, R&D Systems, UK)) for 2 hours at room temperature. Following 
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incubation TMA’s were washed for 3 minutes in PBS and 2 x 5 minutes in 0.02 % 
PBS/Tween. Dako EnVision seconday antibody (Dako Envision+ system-HRP labelled 
polymer anti-mouse) was then applied to the TMA’s for 90 minutes at room 
temperature. Following incubation TMA’s underwent a 2 x 1 minute wash in PBS and 
2 x 5 minute washes in 0.02 % PBS/Tween. Dako 2,3-diaminobenzidine 
(DAB)/substrate chromogen system solution was then applied to the TMA’s for 10 
minutes at room temperature and after incubation underwent 2 x 5 minute washes 
in distilled water. Counterstaining was performed by the addition of 1 % methyl 
green (diluted in distilled water) to the TMA’s for 15 minutes followed by 3 x 2 minute 
washes in distilled water. TMA’s were air dried before being mounted with coverslips 
using di-butylpthalatexylene (DPX) mountant (a mixture of Distyrene, a plasticizer, 
and xylene). The tumour epithelial cells in sections were assessed for staining level 
and localisation simultaneously by 2 observers blinded to the clinical data using a 
dual-viewing light microscope (Olympus BH-2) at x40 magnification. Plasma 
membrane percentage positivity and intensity were then assessed to derive a 
CD44v6 membrane H-score value for each TMA core (described in Materials and 
Methods section 2.7.1). Along with pathological parameters, EGFR and disease-free 
interval (DFI) and breast cancer-specific survival (OS) were available for analysis 
versus CD44v6 membrane expression in this endocrine treated series. The web-
based algorithm X-tile was used to define optimal CD44v3/CD44v6 membrane cut 
point versus patient outcome. Mantel-cox (Log Rank) statistical analysis was 
employed using SPSS96.0 and performed by BCMPG statistician Lynne Farrow. 
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Appendix S. Construction of alternative transfection controls 
In order to create an alternative transfection control to confirm that the effects 
observed by CD44 transfection into MCF-7 cells were due to the presence of the CD44 
variant isoforms and not the transfection method, experiments at the end of this 
project were undertaken in an attempt to create an empty vector plasmid DNA 
backbone construct (without the inserted CD44 gene sequence). However, the DNA 
sequence of the plasmid vector was not provided by Dr Gunthert therefore the 
plasmid map alone (Appendix H) was utilised for this investigation. The map revealed 
that the inserted full length CD44 sequences into the vector backbone are flanked by 
the restriction enzymes EcoRI and BamHI, however, these restriction enzymes were 
not compatible to create sticky ends for re-ligation after restriction digest. Using the 
vector map alone, no compatible restriction enzymes for vector re-ligation could be 
identified and the plasmid vector was not commercially available. Therefore, due to 
time limitations, a BamHI restriction enzyme was used to cut the CD44v6 plasmid 
vector at two sites: (i) at the end of the multiple cloning site and (ii) at the beginning 
of the CD44 sequence (Appendix H). This led to the creation of a plasmid vector which 
contained the backbone and the first 273 bp’s of the CD44 sequence, referred to as 
‘empty vector’ (EV). Given that the CD44 constructs contained a GFP-tag fused to 
their carboxy-terminus end, it was also investigated whether the presence of the GFP 
protein altered cellular behaviours through transfection of MCF-7 cells with a pEGFP-
N1 plasmid vector containing the GFP-tag construct only (referred to as GFP). The 
below sections show the methodology and results from these experiments. 
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DNA restriction endonuclease digest and electrophoresis detection 
To create an empty vector for use as an alternative control for the plasmid DNA 
constructs, the plasmid containing the CD44v6 DNA sequence was digested using a 
BamHI restriction enzyme to cut the plasmid vector at two sites: (i) at the end of the 
MCS and (ii) at the beginning of the CD44 sequence. For a 2 µl double DNA digest 
reaction, to a sterile eppendorf was added: 5 µl 10X NEBuffer 3, 4 µl plasmid DNA 
(diluted in RNase–free water), 2 µl BamHI restriction enzyme and 39 µl sterile RNase-
free water. The reaction was gently mixed by pipetting and allowed to incubate at 37 
°C for 1.5 hours. To visualise the results of the DNA double digest reaction, the 
samples were electrophoresed on a 0.7 % agar gel (0.7 g agar, 100 ml 1X TAE buffer 
(20 ml 50X TAE buffer (242g Tris, 57.1 ml glacial acetic acid, 100 ml 0.5 EDTA, 1 L 
distilled water, pH 8.3) diluted in 1 L distilled water), 2 mg/ml crystal violet solution 
(diluted in sterile water)). The set agar gels were placed into a Mini-Sub Cell GT 
electrophoretic tank (Bio-Rad Laboratories Ltd, Hertfordshire, UK) filled with 1 X TAE 
buffer (ensuring no contamination with ethidium bromide). 5 µl hyperladder I was 
used as a marker. To 9 µl DNA digest reaction was added 5 µl loading buffer (4 g 
sucrose, crystal violet, 10 ml distilled water) and pipetted into the wells of the agar 
gel. The electrophoresis reaction was allowed to run for 4 hours at 75 volts constant 
to ensure complete separation of differential sized digested DNA bands. The agar gel 
was then removed from the tank and transferred onto a light box where DNA bands 
intercalated with crystal violet could be viewed. The desired DNA fragment 
(containing the vector DNA backbone) was excised from the agarose gel using a 
sterile razor blade (ensuring as little agarose gel transfer as possible) and placed into 
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a sterile microfuge tube. The microfuge tube was weighed before and after the 
addition of the DNA/agarose fragment to determine its weight.  
Gel extraction and purification 
The excised DNA/agarose sample then underwent gel extraction and purification 
using a QIAquick Gel Extraction Kit (QIAGEN Ltd, Manchester, UK), all equipment and 
reagents used for this process were contained within the kit upon purchase. Table 
3.12 lists all reagents used with their corresponding composition, storage 
temperature and function. Once the weight of the DNA/agarose fragment was 
determined, 3 volumes of Buffer QG was added to 1 volume of gel fragment (100 mg 
= 100 µl) and incubated in a hot plate (Techne DRI-Block DB.2, Bibby Scientific 
Limited, Staffordshire, UK) at 50 °C for 10 minutes. During this incubation period, the 
sample was removed from the hot plate every 2 minutes and briefly vortexed to 
ensure the agarose gel was completely dissolved into the solution. After incubation, 
1 gel volume of isopropanol was added to the sample (100 mg = 100 µl) and mixed. 
A QIAquick spin column was then placed into a 2 ml collection tube and the sample 
was applied to the column and spun in a centrifuge (Labofuge 400R centrifuge, 
Heraeus, Germany) for 1 minute (room temperature, 13,000 rpm). The flow-through 
was then discarded and 0.5 ml Buffer QG was added to the column and centrifuged 
again for 1 minute (room temperature, 13,000 rpm). The column was then washed 
by addition of 0.75 ml Buffer PE and centrifuged for 1 minute (room temperature, 
13,000 rpm). The flow-through was discarded and the centrifugation step was 
repeated (1 minute, room temperature, 13,000 rpm). For DNA elution, the column 
was then placed into a sterile 1.5 ml microcentrifuge tube and 30 ml Buffer EB was 
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added to the centre of the column (directly applied to the membrane) and incubated 
at room temperature for 1 minute. The column was then centrifuged for 1 minute 
(room temperature, 13,000 rpm). DNA concentration was determined using a 
NanodropTM 2000/2000c spectrophotometer (Thermo Scientific, UK). The DNA 
programme was selected on the spectrophotometer and 2 µl TE buffer was measured 
twice as a blank. 2 µl of DNA sample was added to the spectrophotometer and 
measured in ng/µl, the spectrophotomer was then cleaned and the process was 
repeated for each sample.  DNA samples were stored at - 20 °C. 
Component Composition Storage °C Function 
Buffer QC 
5 mM guanide 
thiocyanate (GuSCN) 
20 mM Tris HCI pH 6.6 
15 – 25 
Solubilisation of 
agarose gel 
pH indicator 
Buffer PE 
10 mM Tris-HCI pH 7.5 
80 % ethanol 
15 – 25 
Washing agent 
(removes excess salt 
from the membrane) 
Buffer EB 10 mM Tris CI, pH 8.5 15 – 25 Elution buffer 
Isopropanol 100 % 15 – 25 DNA precipitation 
Table 9.6. A list of the components purchased with the QIAquick Gel Extraction kit (QIAGEN, 
Manchester, UK) detailing their composition, storage temperature and function.  
Vector DNA ligation 
For a 20 µl DNA ligation reaction, a sterile microcentrifuge tube was placed on ice 
and to this was added: 2 µl 10X T4 DNA ligase buffer (thawed and resuspended at 
room temperature), 50 ng vector DNA, 1 µl T4 DNA ligase (added last to the reaction) 
and made up to a volume of 20 µl by addition of sterile RNase free water. The 
reaction was gently mixed by pipetting, briefly microfuged and incubated at room 
temperature for 10 minutes. The samples were then heat inactivated at 65 °C for 10 
minutes in a hot plate (Techne DRI-Block DB.2, Bibby Scientific Limited, Staffordshire, 
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UK) before being chilled on ice and stored at -20 °C. To visualise the results and 
determine the success of the DNA ligation reaction, the samples were 
electrophoresed on a 1.2 % agar gel (1.2 g agar, 100 ml 1X TAE buffer, 1 µl ethidium 
bromide) as previously described. The samples were then stored at -20 °C.  
Transformation of plasmid constructs and transfection into MCF-7 cells 
The transformation of the plasmids were carried out following the protocol described 
in Materials and Methods 12.3.2. The EV was then sent to the CBS for sequencing 
using the T7 promoter (see Material and Methods 2.12.4) and analysed using the 
online Chromas Lite DNA sequencing software programme and Expasy protein 
translation tool and the results are shown below. The transfection procedure was 
undertaken as described in Materials and Methods 2.12.5 using 100 ng of EV and GFP 
plasmid DNA. 
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Empty vector plasmid DNA gene sequence 
Vector 
CD44 plasmid sequence 
CD44 original sequence 
 
               atggacaagttttggtggcacgcagcctggggactctgcctcgtgccgctgagcctggcg               
gggtgtcccccgtccatggtcaagttttggtggcacgcagcctggggactctgcctcgtgccgctgagcctggcg 
 
cagatcgatttgaatataacctgccgctttgcaggtgtattccacgtggagaaaaatggtcgctacagcatctct 
cagatcgatttgaatataacctgccgctttgcaggtgtattccacgtggagaaaaatggtcgctacagcatctct 
 
cggacggaggccgctgacctctgcaaggctttcaatagcaccttgcccacaatggcccagatggagaaagctctg 
cggacggaggccgctgacctctgcaaggctttcaatagcaccttgcccacaatggcccagatggagaaagctctg 
 
agcatcggatttgagacctgcaggtatgggttcatagaagggcacgtggtgattccccggatcttattaaagcag 
agcatcggatttgagacctgcaggtatgggttcatagaagggcacgtggtgattccccggatc 
 
gaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcattttt
ttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtcgagcaggtggcactt
ttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagac
aataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgccctta
ttcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaag
atcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccg
aagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggc
aagagcaactcggtcgccgcatacactattctcagaatgacttggtttgagtactcaccagtcacagaaaagcat
cttacggatgggcatgacagtaaggagattatgcagtgctgcccataaccatgatgatacactgcgtcaacctaa
ctttctgacacggatcgggagggaaccgaaaaag 
 
 
 
DNA to protein translation 
 
MDKFWWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTL 
MDKFWWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTL 
       
PTMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFN 
PTMAQMEKALSIGFETCRYGFIEGHVVIPRI 
 
ASAPPEEDCTSVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNPTDDDVSS 
 
GSSSERSSTSGGYIFYTFSTVHPIPDEDSPWITDSTDRIPATIQATPSSTEETATQKEQW 
 
FGNRWHEGYRQTPKEDSHSTTGTAGDQDTFHPSGGSTTHGSESDGHSHGSQEGGANTTSG 
 
PIRTPQIPEWLIILASLLALALILAVCIAVNSRRRCGQKKKLVINSGNGAVEDRKPSGLN 
 
GEASKSQEMVHLVNKESSETPDQFMTADETRNLQNVDMKIGV Stop 
 
Figure 9.15. The DNA sequencing results as performed by the CBS and analysed using the software 
programmes Chromas Lite and Expasy for the Empty Vector plasmid construct. The CD44 DNA 
sequence (1 – 273 bp) and protein (1 – 91 amino acids) expressed in this vector are highlighted in red 
(plasmid DNA sequence) and black (original DNA sequence).  
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Plasmid map for the pEGFP-N1 vector 
 
Figure 9.16. A map of the pEGFP-N1 vector used for transfection of MCF-7 cells in this project.  
Transfection of MCF-7 cells with EV and GFP plasmid constructs 
Western blotting analysis revealed that transfection of EV or GFP constructs into 
MCF-7 cells did not alter CD44 isoform or RHAMM expression between 24 – 72 hours 
post-transfection compared to lipid-treated control cells, however a modest 
reduction in CD44v10 expression was observed (Figure 9.11). Immunofluorescence 
analysis was further used to determine transfection efficiency and analyse CD44 
expression and localisation in MCF-7 cells transfected with the EV or GFP constructs; 
with CD44v6 used as a positive transfection control. Results revealed that GFP 
constructs were transfected into MCF-7 cells at a similar efficiency to the CD44v6 
constructs and did not alter total CD44 expression level or localisation in these cells 
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compared to the lipid-treated control (Figure 9.12). However transfection of the EV 
construct appeared to modestly enhance total CD44 expression at the cell surface 
compared to the untreated and lipid-treated control cells (Figure 9.12).   
To investigate whether transfection of these constructs altered cellular signalling 
activities in MCF-7 cells, EGFR and ERK1/2 activity was assessed, as these signalling 
components were modulated upon transfection of these cells with the CD44v3 and 
CD44v6 plasmid constructs. The results revealed that transfection of the GFP plasmid 
into MCF-7 cells did not alter EGFR activity, however transfection of the EV plasmid 
reduced EGFR activity, compared to the lipid-treated cells (Figure 9.13) and CD44v6 
enhanced EGFR expression as previously observed in Chapter 6. Transfection of both 
EV and GFP constructs led to a modest increase in ERK1/2 activity compared to the 
lipid-treated control cells, however this was less than compared to cells transfected 
with CD44v6 (Figure 9.13).  
To analyse the effect of these constructs upon MCF-7 cell function, endogenous and 
HA-stimulated (100 µg/ml) cellular migration was assessed. The results revealed that 
transfection of MCF-7 cells with EV and GFP constructs led to a small reduction in 
endogenous and HA-stimulated migration compared to the lipid-only treated control 
cells, however this effect was not significant (Figure 9.14). Whilst these preliminary 
data require further validation, these experiments suggest that transfection of the 
vector backbone and GFP-tag into MCF-7 cells does not significantly alter cell 
function, thus supporting that the effects observed from CD44v3/CD44v6 
transfection arise from the activities of these proteins alone. Future experimentation 
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is required to create a plasmid vector backbone without the CD44 sequence to 
confirm these observations. 
 
 
Figure 9.17. Western blot images showing CD44 isoform and RHAMM expression in MCF-7 cells 
after 24 - 72 hour transfection with the EV or GFP plasmid DNA compared to the untreated and 
lipid-only treated control (n=1). GAPDH was used as a loading control. 
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Figure 9.18. Immunofluorescence images showing CD44 Std expression in MCF-7 cells after 72 hour 
transfection with the EV, GFP or CD44v6 plasmid DNA compared to the untreated and lipid-only 
treated control (x63 magnification) (n=1).  
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Figure 9.19. Western blotting images showing CD44 Std expression and EGFR and ERK1/2 
activation in MCF-7 cells after 72 hour transfection with the EV, GFP or CD44v6 plasmid DNA 
compared to the untreated and lipid-only treated control. Total protein level was unaltered and 
GAPDH was used as a loading control (n=1).  
 
Figure 9.20. Measurement of endogenous and HA-stimulated cellular migration in MCF-7 cells 
transfected with EV, GFP or CD44v6 plasmid DNA. MCF-7 cells were transfected with the EV, GFP 
and CD44v6 plasmid DNA for 48 hours prior to the assessment of cellular migration (Boyden 
Chamber assay) in the presence (100 µg/ml) and absence of HA (n = 3). Error bars represent 
standard error of the means and statistical testing was performed using a one-way ANOVA and 
significance was set at p <0.05. 
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Appendix T. The effect of endocrine treatment upon CD44 expression in MCF-7 
cells 
To investigate whether a relationship exists between CD44 and ER, MCF-7 cells were 
treated with endocrine agents and the effect upon CD44 expression was 
investigated. Heatmap analysis (generated by Affymetrix analysis, see Materials and 
methods 2.3) revealed that the majority of gene probes corresponding to CD44 
showed enhanced gene expression in MCF-7 cells treated with oestradiol and 
tamoxifen for 10 days, however 10 day fulvestrant treatment reduced CD44 gene 
expression compared to the untreated control cells. Furthermore, Western blotting 
analysis revealed that CD44 Std expression became enhanced in MCF-7 cells upon 3 
– 52 day tamoxifen and oestradiol treatment, whilst fulvestrant treatment abrogated 
CD44 expression during this exposure time, compared to the untreated control cells.  
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Figure 9.21. Effect of short-term endocrine treatment upon CD44 expression in MCF-7 cells. A 
heatmap profile was generated by AffymetrixU-133A gene microarray analysis from 3 independent 
experiments to show CD44 gene expression after 10 day exposure to tamoxifen (100 nM), 
fulvestrant (100 nM) and oestradiol (1 nM) in MCF-7 cells compared to the untreated control cells. 
Representative Western blotting images from 3 independent experiments showing CD44 Std 
expression in MCF-7 cells after exposure to tamoxifen (100 nM), fulvestrant (100 nM) and 
oestradiol (1 n M) between 3 – 52 days. β-actin was used as a loading control.  
.  
